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Integration of viral DNA into the host genome is the hallmark of human 
immunodeficiency virus 1 (HIV-1) infections. However, in early infection, the most 
abundant viral DNA species are extrachromosomal unintegrated viral genomes, which 
despite being competent for gene expression, are poorly expressed in the host cell. 
This suggests the existence of a restriction mechanism acting selectively on 
extrachromosomal DNA species. Importantly, restriction of gene expression is relieved 
upon delivery of the HIV-1 accessory protein Vpr, which degrades host target proteins 
via the host CRL4DCAF1 cullin-RING ubiquitin ligase complex. 
To identify the responsible Vpr target, I performed a CRISPR-Cas9 forward genetic 
screen using a custom designed Vpr target sgRNA library. The screen identified SLF2, 
a poorly characterised protein which recruits the SMC5/6 complex to sites of DNA 
damage. I confirmed that SLF2 binds the SMC5/6 complex, and gene knockouts 
validated a functional role for SLF2 and all core SMC5/6 complex components for 
restriction of gene expression from unintegrated virus. This was independent of the 
SLF1-mediated DNA damage recruitment pathway. HIV-1 Vpr therefore selectively 
degrades SLF2 by exploiting CRL4DCAF1 activity to antagonise restriction.  
Unintegrated viral genomes are rapidly chromatinised by the host cell, forming the 
basis for epigenetic regulation. I showed that the SMC5/6 complex binds unintegrated 
viral genomes in an SLF2-dependent manner, suggesting that the complex acts 
directly on viral chromatin. Concomitantly, I showed that SLF2 induces a loss of 
activating histone marks on unintegrated virus. The SMC5/6 complex belongs to the 
structural maintenance of chromosomes (SMC) family of proteins that share the ability 
to topologically entrap and translocate DNA, which can lead to chromatin compaction. 
Using ATAC-seq, I showed that delivery of Vpr protein or loss of SLF2 increased 
chromatin accessibility suggesting a loss of compaction. I propose a model in which 
the SMC5/6 complex is recruited via SLF2 to unintegrated viral genomes, causing 
chromatin compaction with ensuing silencing of gene expression.  Expression of 
hepatitis B virus, another extrachromosomal DNA virus, is also restricted by the 
SMC5/6 complex. This suggests that the SMC5/6-mediated pathway of 
extrachromosomal DNA silencing may have wide-ranging importance for 
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1.1: HIV-1: From the molecular to the global health level 
1.1.1: HIV-1: A global health threat 
Human immunodeficiency virus 1 (HIV-1) is one of the major global health challenges 
of our time with 38 million people infected world-wide (UNAIDS, 2019). HIV-1 is the 
cause of Acquired Immune Deficiency Syndrome (AIDS); a disease characterised by 
immune exhaustion, which was first described in 1981 as a result of an uncommonly 
high occurrence of rare malignancies (e.g. Kaposi’s Sarcoma) and opportunistic 
infections (e.g. Pneumocystis pneumonia) among homosexual men in New York City 
(CDC, 1981). In the early years of the epidemic, AIDS was essentially a death sentence 
with a median survival of 1 year after diagnosis (Rothenberg et al., 1987). With the 
advent of antiretroviral therapy (ART), HIV positive individuals in the United States with 
access to appropriate healthcare now have a median further life expectancy of 
54.5 years at age 20, leaving only an 8 year survival gap compared to HIV negative 
individuals (Marcus et al., 2016). However, access to care and the cost of treatment 
remains a major obstacle for fully controlling the HIV-1 pandemic (Bekker et al., 2018), 
and last year saw an estimated 770,000 AIDS-related fatalities, predominantly in Sub-
Saharan Africa (UNAIDS, 2019). 
HIV-1 is an RNA virus belonging to the genus of Retroviridae, which replicates via 
integration of a DNA intermediate into the host cell genome, thus providing a 
transcriptional template for production of progeny virions. HIV-1 was first isolated in 
1983 from lymphocytes from patients with AIDS (Barré-Sinoussi et al., 1983; Gallo et 
al., 1983), just a few years after the isolation of the first described human retrovirus 
HTLV-1 (Poiesz et al., 1981). A closely related virus, HIV-2, was later isolated from a 
different group of AIDS patients in West Africa (Clavel et al., 1986). Both HIV-1 and 
HIV-2 are zoonotic in origin, resulting from cross-species transmission of simian 
immunodeficiency viruses (SIVs), which are predominantly asymptomatic in their 
natural hosts (Chahroudi et al., 2012). Four separate cross-species transmission 
events of SIVcpz from chimpanzees and SIVgor from gorillas, respectively, have given 
rise to the M, N, O and P lineages of HIV-1: SIVcpz (M, main pandemic group), SIVcpz 
(N), SIVgor (O), and SIVgor (P) (Sharp and Hahn, 2011). Similarly, eight cross-species 
transmission events of SIVsmm from sooty mangabey monkeys have given rise to the 
HIV-2 lineages (A-H) (Sharp and Hahn, 2011).  
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The main contribution to HIV-1 spread is sexual transmission through the lower genital 
and rectal mucosa, although the virus is also transmitted via the blood stream (e.g. 
sharing of contaminated sharps) or by maternal transmission in the placenta or breast 
milk (Hladik and McElrath, 2008). The integration of proviral DNA into the host genome 
forms the basis for a life-long persistent infection. To date, no effective HIV vaccine 
has been developed, reflecting multitudinous challenges including viral clade diversity, 
a high rate of viral mutagenesis, viral immune evasion, and a failure to elicit broadly 
neutralising antibodies (Barouch, 2008). Whilst ART efficiently limits active replication 
of the virus, a latent reservoir persists and poses a key barrier to a HIV cure (Deeks et 
al., 2016). HIV latency is defined as the persistence of integrated proviral DNA, which 
is transcriptionally silent but remains replication competent and thus has the potential 
to reactivate (Margolis et al., 2016). If treatment is stopped, reactivation of the latent 
reservoir usually leads to rebound viraemia, and thus life-long ART treatment is 
required (Van Lint et al., 2013). Consequently, furthering our understanding of the viral 
life cycle is crucial to ensuring continued control of the HIV-1 pandemic in the face of 
viral resistance to existing therapies. 
 
1.1.2: When one virion becomes many: The life cycle of HIV-1 
Like all viruses, HIV-1 is an obligate intracellular parasite, which is entirely dependent 
on host factors for replication. This host dependency is further increased by the limited 
size of its RNA genome. In its integrated proviral form, the genome is flanked by 
two long terminal repeats (LTRs) and encodes 9 partially overlapping open reading 
frames (ORFs) (Figure 1.1A), which produce 15 proteins (Frankel and Young, 1998). 
Each LTR region is composed of a U3, an R, and a U5 region. The 5′-LTR acts as the 
promoter for transcription of the viral genes, driven by the viral transactivator Tat 
(Frankel, 1992). Each virion contains two copies of the viral RNA genome associated 
with nucleocapsid protein (NC), which are contained in a cone-shaped capsid made of 
capsid protein (CA). The virion is enveloped by a host-cell derived membrane lined by 
the viral matrix protein (MA). The envelope contains trimeric spikes of viral 
glycoproteins gp120 and gp41, which are produced by proteolytic cleavage of the 
gp160 polyprotein encoded by env (Frankel and Young, 1998). 
To enter the host cell, the virion glycoprotein gp120 engages the cell surface receptor 
CD4 and either the CXCR4 or CCR5 co-receptor, thus mediating entry by fusion  
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Figure 1.1: HIV-1 genome organisation and life cycle
A, HIV-1 genome structure. The ~9.5 kB genome is represented here in its integrated 
proviral DNA form. It is flanked by two long-terminal repeats (LTRs) and encodes 9 
ORFs. gag, pol, and env encode structural proteins (light blue), which are produced as 
polyproteins and are proteolytically cleaved during viral maturation. tat and rev encode 
regulatory proteins (petrol blue), and vif, vpr, vpu, and nef encode accessory proteins 
(dark blue). B, The HIV-1 life cycle. (i) Virion gp120 binds to the CD4 cell surface 
receptor, engages the CXCR4 co-receptor and together with gp41 mediates fusion. (ii) 
Reverse transcription takes place within the intact capsid, which traffics to the nucleus. 
(iii) Viral cDNA is integrated into the host DNA and acts as template for viral RNA 
(vRNA) transcription (iv). (v) vRNA is exported from the nucleus, and viral proteins are 
produced. (vi) Gag and Gag-Pol proteins self-associate at the cell membrane, driving 
viral assembly. The new virion buds from the cell via host ESCRT proteins, and viral 
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(Chen, 2019); see illustration of viral life cycle (Figure 1.1B). The primary host target 
cells for HIV-1 are CD4+ T cells, although infection of macrophages also contributes to 
viral pathogenesis (Sattentau and Stevenson, 2016). Once inside the cell, the viral 
capsid traffics towards the nucleus along host microtubules in a dynein-dependent 
manner, and reverse transcription of the viral genome is concomitantly initiated inside 
the intact capsid leading to production of a double stranded DNA (dsDNA) copy of the 
viral genome (James, 2019). The capsid docks at a nuclear pore complex (NPC), and 
the pre-integration complex (PIC) containing the viral dsDNA and integrase is released 
into the nucleus (Ambrose and Aiken, 2014). Integrase catalyses 3’ processing of the 
viral dsDNA creating reactive groups, which attack the host DNA and allows integrase 
to catalyse DNA strand transfer thus joining the viral DNA to the host DNA (Engelman 
and Singh, 2018). The DNA recombination intermediate is resolved by host DNA 
repair, thus completing integration of the provirus into host chromatin. In addition to the 
integrated provirus, linear viral DNA also gives rise to abundant unintegrated viral DNA 
species, which will be discussed in detail in section 1.4. In the late phase of the viral 
life cycle, the provirus acts as the template for production of spliced and unspliced viral 
mRNAs leading to the production of viral proteins (De Marco et al., 2013). Nuclear 
export of single spliced and full-length genomic viral RNA is mediated by the Rev 
protein (Fischer et al., 1995). Virion assembly is mediated by self-association of Gag 
proteins at the host cell membrane followed by budding catalysed by host ESCRT 
machinery (Weiss and Göttlinger, 2011). Concomitant with virus release, the viral 
protease catalyses cleavage of Gag-Pol and Gag, thus triggering maturation of the 
virion, which can then infect a new target cell (Freed, 2015). 
Our knowledge of the HIV-1 biology has informed the development of different classes 
of ART compounds targeting various aspects of the viral life cycle, predominantly by 
targeting unique viral enzymatic activities. Two classes of drugs target reverse 
transcriptase: Nucleoside reverse transcriptase inhibitors (NRTI, e.g. Tenofovir) and 
non-nucleoside reverse transcriptase inhibitors (NNRTI, e.g. Efavirenz) (Das and 
Arnold, 2013). Other inhibitors target the viral integrase (INI, e.g. Raltegravir) or 
protease (PI, e.g. Lopinavir) enzymes (Wensing et al., 2010). Finally, entry inhibitors 
target receptor binding (e.g. Maraviroc) or conformational changes in viral 
glycoproteins (e.g. Enfuvirtide) (Haqqani and Tilton, 2013). To limit viral resistance, 
treatment is administered as combination ART (cART) regimes. The current WHO 
recommendation for first-line ART is two NRTIs plus one INI, and inclusion of a PI is 
recommended for second-line regimens (WHO, 2019).  
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1.2: Viral accessory proteins: When the host is not hospitable 
1.2.1: Host cell restriction and HIV-1 accessory proteins 
Whilst HIV-1 is entirely dependent on host factors and cellular pathways for replication, 
the host cell does not willingly compromise its functions to support viral replication. 
Rather, viral replication takes place in the face of a hostile host cell environment, in 
which host proteins collectively termed ‘restriction factors’ specifically limit viral 
replication, thus providing cell intrinsic immunity as a first line of defence against 
pathogen invasion (Bieniasz, 2004). Initial insights into the existence of restriction 
factors was based on heterokaryon studies, in which permissive and non-permissive 
host cells were fused in vitro, thus allowing examination of the ability of the hybrid cells 
to support HIV-1 infection (Cowan et al., 2002; Münk et al., 2002; Simon et al., 1998a). 
The outcome was clear: Non-permissive cell types conferred a dominant restrictive 
phenotype to the heterokaryons, and their non-permissivity did not reflect lack of a host 
dependency factor, but rather the presence of an intrinsic resistance factor or 
‘restriction factor’. Since, numerous restriction factors limiting replication of HIV-1 have 
been identified including APOBEC3G (Sheehy et al., 2002), TRIM5α (Stremlau et al., 
2004), tetherin (Van Damme et al., 2008; Neil et al., 2008), SAMHD1 (Hrecka et al., 
2011; Laguette et al., 2011), IFITM1/2/3 (Lu et al., 2011), SLFN11 (Li et al., 2012), 
MX2 (Goujon et al., 2013), REAF (Marno et al., 2014), the HUSH complex 
(Tchasovnikarova et al., 2015), SERINC3/5 (Rosa et al., 2015; Usami et al., 2015), 
and MARCH2/8 (Tada et al., 2015; Zhang et al., 2018), illustrated in (Figure 1.2A). 
Whilst targeting widely different aspects of viral replication, most identified restriction 
factors share a number of characteristic features (Doyle et al., 2015; Malim and 
Bieniasz, 2012). Firstly, they are germline encoded and, although often interferon (IFN) 
inducible, constitutively expressed in most cell types. Secondly, they act in a cell-
autonomous manner meaning that a restriction factor is capable of limiting viral 
replication independent of communication with or recruitment of other cells. They 
display hallmarks of positive genetic selection, reflecting an evolutionary pressure 
imposed by the invading pathogen. Lastly, and most importantly for this thesis, they 
are targeted by active viral antagonism. Whilst they constitute a significant barrier to 
cross-species transmission of viruses to an unnatural host, most restriction factors are 
essentially inactive against wild-type viruses replicating in their natural host, as the 
viruses have developed means of antagonism. This forms the basis for an evolutionary  
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Figure 1.2: Host cell restriction and antagonism by HIV-1 accessory proteins
A, Restriction factors target different aspects of the HIV-1 life cycle. The IFITM/SERINC 
proteins inhibit viral fusion. SAMHD1 limits dNTP levels, and like REAF, restricts reverse 
transcription. TRIM5α reduces capsid stability. MX2 prevents nuclear import and 
integration of viral DNA. The HUSH complex orchestrates position-dependent silencing 
of integrated proviruses. SLFN11 inhibits translation of viral proteins. MARCH2/8 limits 
incorporation of viral glycoproteins. Tetherin prevents release of the budding virions. 
APOBEC3G is incorporated into new virions and catalyses cytidine deamination leading 
to viral hypermutation upon infection of a new host cell. B, HIV-1 accessory proteins 
hijack cellular cullin-RING E3 ubiquitin ligases. 3 of the HIV-1 accessory proteins (Vpu, 
Vif, and Vpr) target host proteins for proteasomal degradation by recruiting them to 
cellular cullin-RING E3 ligase complexes. The viral accessory protein binds the host 
target as well as a cullin ligase adaptor, which, in turn, recruits its cognate cullin-RING 
E3 ligase complex, bringing the target in proximity of the complex E2 and leading to 
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arms race as described by the Red Queen hypothesis (Van Valen, 1973). The 
evolutionary pressure posed by host antiviral restriction forces the virus to adapt by 
developing a means of antagonism, which again puts the host under an evolutionary 
pressure to restore the ability to restrict. In the words of Lewis Caroll’s Red Queen: “It 
takes all the running you can do, to keep in the same place”.  
In the case of HIV-1, viral antagonism is the role of the accessory proteins Nef, Vif, 
Vpu, and Vpr. The vif gene was acquired early in lentiviral evolution and is also found 
in ovine-caprine, bovine, and feline lentiviruses, whilst the vpr and nef genes are 
characteristic of primate lentiviruses (Kirchhoff, 2010). The additional vpu gene was 
acquired by the SIVcpz ancestor of HIV-1, whereas the SIVsmm ancestor of HIV-2 
acquired the gene vpx, potentially originating from an ancestral vpr gene either by gene 
duplication or non-homologous recombination with another virus strain (Sharp and 
Hahn, 2011). The term ‘accessory proteins’ reflects that these proteins are generally 
dispensable for viral replication in in vitro culture systems, although they are essential 
for viral replication and pathogenesis in vivo (Malim and Emerman, 2008). The 
accessory proteins have no enzymatic activity but instead exploit cellular machinery to 
deplete host factors either by targeting them to a different subcellular localisation (e.g. 
Nef-mediated depletion of cell surface CD4; (Chaudhuri et al., 2007)) or by directly 
inducing their degradation (e.g. Vpu-induced degradation of tetherin; (Van Damme et 
al., 2008)). Specifically, viral hijacking of host cullin-RING finger ubiquitin ligases is a 
common strategy utilised by both Vif (Yu et al., 2003), Vpu (Margottin et al., 1998), and 
Vpr (Hrecka et al., 2007) for degradation of cellular targets to antagonise host 
restriction. The HIV accessory protein (e.g. Vpu) interacts with a ubiquitin ligase 
receptor protein (e.g. β-TrCP) which is in turn bound by another adaptor protein (e.g. 
Skp1) enabling recruitment of the cullin-RING E3 ubiquitin ligase complex (e.g. the 
cullin1/RBX ligase). This brings the host factor bound by the HIV accessory protein 
(e.g. tetherin/BST-2) intro proximity of the ubiquitin-conjugating enzyme (E2) of the 
ubiquitin ligase complex, leading to ubiquitination and consequent targeting of the host 
factor for proteasomal degradation, illustrated in (Figure 1.2B). The HIV-1 accessory 
protein therefore alters the normal substrate specificity of the host cullin-RING ligase 
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1.2.2: HIV-1 Vpr: A multi-tool shaping the host cell 
Whilst the roles of the other HIV-1 accessory proteins in antagonism were quickly 
uncovered in the early 2000s, pinpointing the function of Vpr provided more of a 
challenge, in hindsight reflecting its unparalleled multifunctionality. HIV-1 viral protein 
R (Vpr) is a 14 kDa protein of 96 amino acids expressed as a late gene product from 
the vpr gene  (Wong-Staal et al., 1987). Whilst deletion of vpr has modest effects on 
viral replication in most experimental tissue culture systems (including CEM and Jurkat 
T cells) (Cohen et al., 1990; Ogawa et al., 1989), the in vivo importance of Vpr for viral 
replication and pathogenicity is clear, as seen by highly reduced disease progression 
for vpr-deletion mutant SIV in rhesus macaques (Lang et al., 1993). Importantly, Vpr 
is the only HIV-1 accessory protein found at high levels inside the virion resulting from 
active incorporation of Vpr into the virion via interaction with the p6 region of Gag 
(Paxton et al., 1993). Based on a 1:7 stoichiometry for the incorporation of Vpr relative 
to Gag, each HIV-1 virion is estimated to contain 275-700 Vpr molecules of Vpr (Briggs 
et al., 2004; Müller et al., 2000). Whilst other accessory proteins can also be detected 
in the virion (e.g. Vif; 1-150 molecules/virion), these are not actively packaged and their 
presence likely reflects viral protein levels in the producer cell (Simon et al., 1998b). 
The delivery of large amounts of Vpr protein into the host cell via the virion means that 
Vpr is present and is likely to be of maximal importance in the earliest stages of viral 
infection, prior to the production of de novo viral proteins. 
Whilst recent research from our laboratory sheds new light on the multifunctional 
nature of Vpr (Greenwood et al., 2019), research into Vpr has long been characterised 
by an attempt to define a single central function for the accessory protein (Guenzel et 
al., 2014). The first proposed function of Vpr was the ability to cause cell cycle arrest 
in G2/M (Rogel et al., 1995), which can be abrogated by the S79A point mutation of 
Vpr (Zhou and Ratner, 2000). Whilst this function of Vpr can be robustly replicated and 
is evolutionarily conserved, the molecular basis is a point of debate, and it remains 
unclear how induction of cell cycle arrest would be beneficial for HIV-1 replication 
(Fabryova and Strebel, 2019). Yet, it was in the context of the cell cycle arrest 
phenotype that Vpr was first shown to usurp cullin-RING ubiquitin ligase activity to elicit 
its function (Hrecka et al., 2007), as had previously been shown for Vif and Vpu. Vpr 
binds the substrate adaptor protein DCAF1 (DDB1- and CUL4-associated factor 1; 
previously called Vpr binding protein, VprBP) and in turn recruits the DDB1-CUL4A-
RBX ubiquitin ligase, composed of the adaptor ‘DNA damage-binding protein’ (DDB1), 
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Cullin-4A (CUL4A), and the E3 ligase ‘RING-box protein 1’ (RBX1), collectively called 
CRL4DCAF1 (Hrecka et al., 2007) (Figure 1.2B). This leads to protein target 
ubiquitination and proteasomal degradation. The interaction with DCAF1 involves the 
leucine-rich domain of Vpr (amino acids 60-81) and is abrogated by the Q65R point 
mutation of Vpr. The Q65R point mutation concomitantly abrogates Vpr function, thus 
showing the dependency of Vpr on CRL4DCAF1 activity (Le Rouzic et al., 2007). 
Numerous Vpr target proteins have since been identified including UNG2/SMUG1 
(Schrofelbauer et al., 2005), ZIP/sZIP (Maudet et al., 2013), SLX4 (Laguette et al., 
2014), MCM10 (Romani et al., 2015), HLTF (Hrecka et al., 2016; Lahouassa et al., 
2016), MUS81/EME1 (Zhou et al., 2016), TET2 (Lv et al., 2018), EXO1 (Yan et al., 
2018), MR (Lubow et al., 2020), and REAF (Gibbons et al., 2020), and degradation of 
these targets has been linked to various proposed functions of Vpr, summarised in 
(Figure 1.3A). 
Recently, unbiased proteomics analyses performed in our lab have revealed a global 
remodelling of the cellular proteome orchestrated by Vpr (Greenwood et al., 2019), 
which was also recapitulated in primary T cells (Naamati et al., 2019). When comparing 
infection with pseudotyped wild-type or Vpr deletion viruses or upon delivery of Vpr 
protein alone in Vpr-containing virus-like particles, we observed significant depletion 
of >1,000 host proteins (Greenwood et al., 2019). Whilst some of these changes are 
likely to be indirect, it was also clear that the number of direct Vpr targets is much larger 
than anticipated. Based on our most stringent inclusion criteria, we identified at least 
38 direct Vpr targets (not included in Figure 1.3A), which is certainly an underestimate 
of the true number of direct Vpr targets. Rather than attempting to pinpoint a single 
important function for Vpr, it is thus much more relevant to characterise how the 
multitude of functions contributes to remodelling the host cell to allow viral replication. 
A global remodelling of the cellular proteome requires a broad substrate specificity for 
Vpr. Noticeably, the majority of identified Vpr targets are nucleic acid binding proteins 
(>70% of identified Vpr-depleted proteins in our proteomics datasets based on GO 
term annotation) (Greenwood et al., 2019). This is likely mediated by DNA molecular 
mimicry, which was revealed by solving the structure of Vpr in complex with UNG2 and 
DCAF1-DDB1 (Wu et al., 2016). Here, the substrate binding surface on Vpr interacts 
with the loop of UNG2 which normally binds DNA. Vpr forms a binding cleft which 
mimics the minor groove of DNA, thus allowing binding to UNG2. This provides a model 
for how Vpr can have such a wide array of direct targets. Based on our proteomics 
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Figure 1.3: Host targets of HIV-1 Vpr
A, Table summarising published host protein targets of the HIV-1 accessory protein Vpr, 
excluding the novel Vpr targets identified as part of the global proteome remodelling in 
Greenwood et al. (2019)
Vpr target Cellular function
UNG2/
SMUG1
DNA repair (base excision
repair)
Enhances viral replication (Restricted in cell
types with high dUTP levels)





SLX4 G2/M cell cycle arrestDNA repair (structure-
specic endonuclease)
Laguette (2014)









G2/M cell cycle arrest Zhou (2016)





EXO1 DNA repair (nucleotide
excision repair)
Unidentied Yan (2018)
MR Innate immunity (mannose
receptor)
Increases Env expression in macrophages Lubow (2020)
REAF Enhances viral replication (restricted at the
point of reverse transcription)
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analysis, we propose that Vpr, rather than performing an isolated function in depleting 
a single important restriction factor, orchestrates a global remodelling of the cellular 
proteome to create a cellular environment which is permissive for viral replication 
(Greenwood et al., 2019). By increasing our understanding of the individual cellular 
changes induced by Vpr, we can thus obtain novel insight in yet uncharacterised 
mechanisms of HIV-1 restriction.   
 
1.2.3: Where did Vpr come from? 
Whilst the presence of a vpr gene is characteristic for all primate lentiviruses, the 
evolutionary origin of vpr is unclear. The acquisition of vpr  in primate lentiviruses 
coincides with an absence of the deoxyuridine 5′-triphosphate nucleotidohydrolase 
(dUTPase) encoded within the pol gene of non-primate lentiviruses (Gifford, 2012). 
The UTPase catalyses conversion of dUTP to dTTP, thus lowering the cellular dUTP 
levels, which is thought to be particularly important for infection of non-dividing cell 
types (Hizi and Herzig, 2015). Given the limited genome size of all retroviruses, the 
function of the UTPase is likely essential to viral replication and may enable escape 
from a host restriction mechanism. It is thus tempting to hypothesise that the vpr gene 
has replaced the essential function of the dUTPase. This may be linked to the ability 
of Vpr to degrade UNG2, which has been shown to restrict HIV-1 replication specifically 
in cells with high dUTP levels (Weil et al., 2013). One possibility is that acquisition of 
the vpr gene with an ability to degrade UNG2 in the ancestral non-primate lentivirus 
made the UTPase activity redundant, such that only the vpr gene was kept in the 
primate lentiviral lineage. Concordantly, small ruminant lentiviruses (e.g. Maedi-Visna 
virus) encode a dUTPase but also have a vpr-like gene (Villet et al., 2003), which is 
phylogenitically similar to primate lentiviral vpr, yet does not have Vpr functions, 
perhaps reflecting a transition state. Alternatively, the UTPase gene may have first 
been lost in the primate lentivirus ancestor with subsequent acquisition of the vpr gene. 
It has been suggested that the acquisition of vpr was a prerequisite for the cross-
species transmission to primates, however, DNA fossils of endogenous lentiviruses 
that encode a UTPase but no vpr gene have been found in lemuriform primates (Gifford 
et al., 2008). It remains possible that this reflects a separate cross-species 
transmission event from the one that gave rise to primate lentiviruses. Further studies 
of primate and non-primate endogenous lentiviruses may inform the origin of vpr. 
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Whilst the DNA mimic domain of Vpr at first may have only enabled the UNG2 
degradation necessary to replace the function of dUTPase, the subsequently acquired 
ability of Vpr to recruit a multitude of host proteins for proteasomal degradation 
represents a clear evolutionary advantage over a unifunctional dUTPase gene. In 
agreement with this, our proteomics study showed that although degradation of some 
proteins was evolutionarily conserved across Vpr proteins from various primate 
lentiviruses, fewer Vpr-dependent changes were seen in more divergent Vpr proteins 
(e.g. SIVagm, SIVsmm, and SIVrcm), and the global proteome remodelling was unique 
to the SIVcpz and HIV-1 lineages (Greenwood et al., 2019). This observation supports 
a gradual acquisition of Vpr targets during the course of evolution, allowing Vpr to 
become a multifunctional player in the HIV life cycle which is instrumental for the 
remodelling of the host cell to support viral replication. 
 
1.3: Hit-and-run or persistence: A vital viral choice 
1.3.1: The different strategies of HIV-1, HCMV, and SARS-CoV-2 
Although they have all adapted to life in the same human host, different viruses use 
very different strategies for ensuring successful replication within the host and as a 
result have very different life cycles. A key “choice” for any virus is whether to establish 
a persistent infection in the host or use a “hit-and-run” strategy that uniquely focuses 
on lytic replication in one host cell to quickly move on to the next host cell. Hit-and-run 
virus strategies are often associated with higher levels of immunopathology and 
cytopathic effect (Heaton, 2017). If the viral strategy does not require persistence in 
the host, the virus modulation of the host cell only needs to be sufficient to ensure 
efficient replication. A topical example is Severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) which is the source of the current pandemic and the 
etiological agent of the acute respiratory disease Coronavirus disease 2019 (COVID-
19) (Zhou et al., 2020). Here, viral antagonism leads to low levels of interferon (IFN) 
production with ensuing reduced innate antiviral defences alongside induction of 
exuberant inflammatory cytokine production, which drives the development of COVID-
19 (Blanco-Melo et al., 2020). However, the higher immunopathology likely not only 
reflects a hit-and-run viral strategy but rather results from poor host adaptation due to 
the recent zoonotic transmission of SARS-CoV-2 from its presumed natural bat 
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reservoir (Ji et al., 2020) in which coronavirus infections are largely asymptomatic 
(Bean et al., 2013). 
At the other extreme, herpesviruses such as human cytomegalovirus (HCMV) have 
co-evolved with their human host for millions of years and are completely 
asymptomatic in immunocompetent individuals (Griffiths et al., 2015). Like HIV-1, 
HCMV establishes a life-long infection of the host, however, the two viruses employ 
very different strategies for persistence. Whilst HIV-1 integrates into the host genome, 
HCMV establishes a latent infection in myeloid progenitor cells where is exists as an 
extrachromosomal episome (Bolovan-Fritts et al., 1999; Sinclair and Reeves, 2014). 
HCMV reactivation from latency is intimately linked to differentiation of the host cell, 
meaning that whilst a persistent viral reservoir is maintained in the bone marrow, 
reactivating cells spread to the periphery where they enter the lytic life cycle and 
produce progeny virus (Dupont and Reeves, 2016). In non-myeloid cell types (e.g. 
fibroblasts and endothelial cells), HCMV directly establishes a lytic infection, and the 
choice between a latent and lytic infection is likely aided by differences in events during 
viral entry (Murray et al., 2018). In contrast to this, HIV-1 latency is not cell-type 
dependent but rather reflects the host chromatin context in which the virus has 
integrated, leading to a transcriptionally silent state. HIV latency is thus not an actively 
regulated process, whereas HCMV latency is modulated by expression of a few key 
viral proteins such as US28 (Krishna et al., 2017). This active modulation of the host 
may enable the virus to persist as a latent extrachromosomal episome, made possible 
in part by the large coding capacity of dsDNA viruses like HCMV. It is interesting to 
hypothesise that retroviruses like HIV-1 have evolved to integrate into the host genome 
to escape innate sensing and host restriction of extrachromosomal DNAs. By 
integrating into host chromatin, and essentially becoming host genes, retroviruses 
escape pathogen sensing mechanisms for the majority of their lifetime. Still, both HIV-
1 and HCMV face the challenge of navigating and modulating the hostile host cell 
environment prior to the establishment of a successful persistent infection, akin to the 
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1.4: Unintegrated HIV-1 DNA: An underrated team player? 
1.4.1: Unintegrated viral DNA species in HIV-1 infection 
Although integration into the host genome is a hallmark feature of HIV-1 infection, 
extrachromosomal viral DNA species, collectively described as unintegrated virus, 
accumulate and are widely reported to be the most abundant viral DNA species during 
natural infection (Sloan and Wainberg, 2011). Still, the role of unintegrated viral DNA 
species in the HIV-1 life cycle remains poorly researched. Unintegrated HIV-1 DNA 
exists in three different forms: Linear unintegrated DNA and circularised genomes 
harbouring one or two LTRs, termed 1-LTR circles and 2-LTR circles respectively 
(Figure 1.4A). Linear unintegrated DNA is identical to the reverse transcribed viral 
genome found in the pre-integration complex (PIC), and is the substrate for viral 
integration (Chun et al., 1997). Linear unintegrated DNA can be circularised by host 
factors either by homologous recombination (HR) between the two LTRs, leading to 
formation of 1-LTR circles, or by non-homologous end joining (NHEJ), leading to 
formation of 2-LTR circles (Farnet and Haseltine, 1991). The accumulation of 
unintegrated DNA is not unique to HIV-1 but observed across all retroviruses (Wu, 
2004), and circular retroviral DNA species were first observed in cells infected with 
avian sarcoma virus (ASV) (Guntaka et al., 1975) and Moloney leukemia virus (MLV) 
(Gianni et al., 1975). 
Early studies of resting CD4+ T cells from HIV-1 infected individuals suggested that the 
most abundant viral DNA species in a natural infection was linear unintegrated DNA, 
calculated by limiting dilution PCR assays for integrated viral DNA and linear 
unintegrated DNA via linker-ligation onto the blunt ended unintegrated DNA (Bukrinsky 
et al., 1991). Whilst 1-LTR and 2-LTR circles could also be detected, these made up 
less than 10% of the total detected unintegrated viral DNA in resting CD4+ T cells 
isolated from lymph nodes of HIV-1 positive individuals (Chun et al., 1997). 
Subsequent studies of experimental infection in immortalised T cell lines confirmed a 
high prevalence of unintegrated DNA species, yet suggested that although linear 
unintegrated DNA dominated in the first 8 hours of infection, 1-LTR circles 
subsequently became more prevalent along with a minor fraction of 2-LTR circles 
(Munir et al., 2013). This discrepancy in linear unintegrated DNA prevalence compared 
to the original studies may reflect improved PCR techniques, differences between 
natural and experimental infection, or cell type specific differences.  
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Figure 1.4: Unintegrated HIV-1 DNA species
A, Unintegrated viral DNA species are abundantly produced in HIV-1 infection. The viral 
cDNA produced by reverse transcription not only acts as template for integration into 
the host genome but also gives rise to abundant extrachromosomal viral DNA species, 
collectively termed unintegrated viral DNA. There are three types of unintegrated viral 
DNA: Linear unintegrated DNA, 1-LTR circles, and 2-LTR circles. Linear unintegrated 
DNA is identical to the viral cDNA that is found in the pre-integration complex (PIC) and 
is the precursor for production of the two other types of unintegrated viral DNA. 1-LTR 
circles contain only one LTR and are formed by homologous recombination between 
the two LTRs of the linear viral genome. 2-LTR circles contain two consecutive LTRs 
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Despite their abundance, unintegrated HIV-1 DNA species are generally thought to be 
replication incompetent, and production of progeny virions requires the presence of an 
integrated provirus (Hamid et al., 2017). Early studies of experimental HIV-1 infection 
revealed that unintegrated viral DNA species were labile in rapidly dividing 
immortalised T cell lines (Pauza et al., 1994), yet they were remarkably long-lived in 
slow dividing cells such as growth-arrested T cells (Sonza et al., 1994) and 
macrophages (Gillim-Ross et al., 2005). Consequently, it was suggested that the 
gradual loss of unintegrated DNA species largely reflected dilution by cell division 
(Butler et al., 2002; Pierson et al., 2002). Still, some controversial studies have 
reported replication of integrase-defective viruses (Nakajima et al., 2001) indicating 
that unintegrated virus can act as template for full-length viral genome production. This 
is theoretically conceivable given the presence of the full viral sequence on 2-LTR 
circles, which is equivalent to an integrated provirus. In agreement with this, another 
study reported reversal to productive infection upon termination of raltegravir treatment 
in experimental infection, suggesting that unintegrated viral DNA species had initiated 
de novo integration (Thierry et al., 2015). True or not, these observations highlight the 
importance of furthering our understanding of unintegrated viral DNA species both in 
the context of ART adherence and in defining the latent HIV reservoir. 
In the light of an inability to replicate, it is tempting to draw the conclusion that 
unintegrated virus represents an irrelevant dead-end by-product in the HIV-1 life cycle. 
Yet, in addition to their abundance, unintegrated viral DNA species exhibit another 
interesting characteristic: They are capable of expressing viral gene products. The 
early evidence for this was based on studies of integrase mutant viruses, where 
production of p24 (Stevenson et al., 1990a), multiply spliced nef and tat transcripts 
(Wu and Marsh, 2001), and in the last case all classes of viral transcripts (Wu and 
Marsh, 2003) were reported in the absence of integration. Additionally, in vitro p24 
expression was shown from synthetic circles HIV-1 DNA mimicking 1-LTR and 2-LTR 
circles (Cara et al., 1996). Subsequent studies showed expression of Nef from 
unintegrated viral genomes (Poon et al., 2007) which was also capable of modulating 
cell surface MHC class I expression (Sloan et al., 2011). This is perhaps not surprising, 
as unintegrated HIV-1 DNA species are derived from the viral cDNA and therefore 
contain the same genetic and regulatory elements as the integrated provirus, including 
the LTR, providing the full genetic basis for viral gene expression (Wu, 2004). 
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The evidence for gene expression from unintegrated virus lends support to the 
functional importance of unintegrated virus in the HIV-1 life cycle. It is interesting to 
hypothesise that the abundant unintegrated viral DNA species provides essential gene 
products to ensure the success of the integrated provirus. For example, expressing 
early HIV-1 genes from the unintegrated viral DNA could be instrumental for the initial 
establishment of a productive infection. Supporting this hypothesis, tat encoding HIV-
1 RNAs could be detected in infected cells at very early time points prior to detection 
of integrated provirus, suggesting that this viral gene expression originated from 
unintegrated viral DNA species (Stevenson et al., 1990b). Consequently, unintegrated 
virus may play an underestimated active role in HIV infection, and it is therefore 
important that we increase our understanding of the regulation of gene expression from 
unintegrated genomes. 
 
1.4.2: Vpr and gene expression from unintegrated HIV-1 
A noticeable feature in early studies reporting gene expression from integrase-deficient 
viruses was that the level of gene expression was much lower than the gene 
expression observed upon infection with wild-type integrase proficient viruses. This 
initially led to the conclusion that integration was a prerequisite for efficient gene 
expression from HIV-1 genomes (Sakai et al., 1993). The gene expression from 
unintegrated virus appeared markedly restricted by the host cell. Yet, there was 
another noticeable feature of these studies reporting poor gene expression from 
unintegrated virus: They utilised HIV-1 molecular clones lacking the vpr gene, such as 
the R7/3 strain derived from HXB2 (Wiskerchen and Muesing, 1995). Subsequent work 
from the Chen lab identified a role for the Vpr accessory protein in increasing gene 
expression from unintegrated HIV-1 genomes (Poon and Chen, 2003). Here, the 
authors employed a vesicular stomatitis virus G protein (VSV-G) pseudotyped NL4-3 
reporter virus, which expressed a luciferase reporter in place of Nef and carried a 
truncated vpr gene due to a frameshift mutation at codon 64 of the vpr open reading 
frame. Introduction of the D64E integrase mutation into this construct, preventing viral 
integration, led to a significant decrease in viral gene expression in HeLa cells, which 
could be rescued by trans-complementation with a Vpr overexpression construct. 
Similar increases were observed for packaging of Vpr protein along with the vpr 
deficient viral genomes or co-transduction with genome-less virus-like particles (VLPs) 
containing Vpr protein. In conclusion, Vpr protein alone was sufficient to increase gene 
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expression from unintegrated HIV-1 genomes. Similar results were obtained in a 
follow-up study using reporter viruses with a functional nef gene in SupT1 cells, where 
Vpr led to increased Nef protein levels and enhanced cell surface CD4 depletion (Poon 
et al., 2007). 
The mechanism for this Vpr-dependent increase in viral gene expression from 
unintegrated virus, however, remained unknown. It did not require the presence of the 
Tat transactivator, nor was it dependent on cell cycle arrest in G2/M (Poon and Chen, 
2003). Additionally, in HeLa cells, Vpr had no effect on gene expression from 
integrated virus nor from transfected reporters, which both exhibited high gene 
expression even in the absence of Vpr (Poon and Chen, 2003). The Vpr-dependent 
effect on gene expression was thus specific to unintegrated viral genomes. Importantly, 
these studies from the Chen lab predate the implication of CRL4DCAF1 activity in the 
function of Vpr (Hrecka et al., 2007) as well as the expansion of the concept of intrinsic 
antiviral restriction. With our current mechanistic insight into Vpr function, it seems 
likely that the increased gene expression from unintegrated virus by Vpr might reflect 
antagonism of host cell restriction of unintegrated viral genomes. Could Vpr hold the 
key to understanding cellular restriction of unintegrated HIV-1 genomes? 
 
1.4.3: Unintegrated virus chromatinisation 
As reverse transcription takes place within the lentiviral capsid, unintegrated HIV-1 
genomes enter the nucleus as naked DNA. This provides a template for de novo 
loading of histone complexes, which differs from the replication-coupled nucleosome 
assembly characteristic of eukaryotic DNA chromatinisation (Serra-Cardona and 
Zhang, 2018). Our understanding of unintegrated HIV-1 genome chromatinisation 
builds on work from the Goff laboratory focusing mainly on the retrovirus Moloney 
murine leukemia virus (MLV) but recently also HIV-1 genomes. First, the Goff lab 
showed that unintegrated retroviral genomes are rapidly chromatinised (Wang et al., 
2016). Twelve hours after infection with integrase-mutant VSV-G pseudotyped MLV 
reporters, core histone H3 could already be detected on unintegrated linear and 2-LTR 
circle MLV DNA by chromatin immunoprecipitation (ChIP). This required nuclear entry 
and was followed by gradual appearance of histone tail modifications including 
trimethylation of H3 lysine 9 (H3K9me3), indicative of epigenetic regulation. 
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Subsequently, a forward genetic screen implicated the ‘human silencing hub’ (HUSH) 
complex in H3K9me3 deposition and transcriptional silencing of unintegrated but not 
integrated MLV genomes (Zhu et al., 2018). The HUSH complex is an epigenetic 
silencing complex identified by the Lehner lab which forms the basis for position-effect 
variegation in human cells (Tchasovnikarova et al., 2015). The Goff lab showed 
recruitment of the HUSH complex to unintegrated MLV genomes via the DNA-binding 
protein NP220 leading to H3K9me3 deposition and reduced gene expression (Zhu et 
al., 2018). However, when examining the effect of this novel silencing pathway on 
unintegrated HIV-1 reporters, knockout of the HUSH complex had no effect on gene 
expression (Zhu et al., 2018), similar to observations which we had already made in 
our lab. Upon knockout of NP220, the Goff lab observed an increase in unintegrated 
HIV-1 gene expression, although to a lesser degree than for MLV reporters expression 
(Zhu et al., 2018). This indicates that the mechanistic basis of the observed restriction 
of unintegrated virus gene expression may differ between MLV and HIV-1 genomes. 
In their most recent study, the Goff lab showed that unintegrated HIV-1 genomes, like 
MLV, are rapidly chromatinised, associating with both core histones, variant histone 
H3.3 and linker histone H1 (Geis and Goff, 2019). H1 linker histones contribute to 
higher order chromatin structure in eukaryotes and have been implicated in 
heterochromatin formation in Drosophila melanogaster (Hergeth and Schneider, 
2015). It is thus possible that H1-dependent compaction of unintegrated HIV-1 
genomes could contribute to the hitherto unknown mechanism for silencing of 
unintegrated HIV-1 genomes. 
 
1.5: Cellular extrachromosomal DNA 
1.5.1: Extrachromosomal DNA: Cellular refuse that needs controlling? 
The tightly regulated chromatin structure of eukaryotic genomes is primed to ensure 
genomic integrity and stability. Still, a degree of genomic plasticity prevails, a 
component of which is the production of extrachromosomal DNA species (Ain et al., 
2020). Extrachromosomal DNA (ecDNA) is a collective term describing the highly 
heterogenous population of circular DNA species found outside the chromosomes in 
all cells. The existence of circular ecDNA in mammalian cells has long been recognised 
(Hotta and Bassel, 1965), and whereas early insight was based on differential 
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migration between linear chromosomal DNA and circular ecDNA in two-dimensional 
gel electrophoresis (Cohen and Lavi, 1996), advances in next-generation sequencing 
(NGS) have recently allowed more detailed characterisations of the “DNA circulome” 
in health and disease, e.g. Circle-Seq (Møller et al., 2015). 
ecDNA species display a wide heterogeneity in origin and size, ranging from a few 
hundred to several million base pairs (bp). Some ecDNA species are formed by natural 
genome rearrangement such as the excision of DNA fragments between V, D, and J 
segments of the T cell receptor during T cell differentiation, leading to the release of 
extrachromosomal T cell receptor excision circles (TRECs) (Somech, 2011). However, 
the majority of ecDNA formation is generally not thought to serve a purpose in the cell, 
but rather to be a product of genomic instability, particularly in the context of repetitive 
sequences such as ribosomal DNA (rDNA) and telomeres (Cohen and Segal, 2009). 
Despite tight regulation, these regions are recombination hotspots and are prone to 
formation of R-loops and T-loops respectively, both of which can lead to genomic 
instability and thus ecDNA formation (Cohen et al., 2010; Pickett et al., 2009). 
Additionally, short ecDNA species termed microDNA (100-400 bp) are abundantly 
produced from actively transcribed non-repetitive regions of chromatin (e.g. GC rich 
sequences or genomic regions flanked by microhomology), where their excision leads 
to microdeletions in the genome (Dillon et al., 2015; Shibata et al., 2012). Larger 
ecDNA species (>1 Mb) are particularly abundant in cancer cells, where they allow for 
oncogene duplication and have attracted much recent interest as they contribute to 
tumour evolution and oncogenesis (Turner et al., 2017; Wu et al., 2019). 
Despite their abundance, our knowledge of the turn-over and regulation of ecDNA is 
limited. Research into this matter has been hampered by the sequence equivalence 
between ecDNAs and the genomic loci from which they are derived. Consequently, 
exogenously derived extrachromosomal DNAs such as unintegrated viral genomes 
provide interesting model systems for uncovering regulatory mechanisms of more 
ubiquitous importance for the host cell. A role for genomic instability and ecDNA 
production in cellular senescence (Storci et al., 2020) and neurodegenerative 
disorders was recently proposed (Ain et al., 2020). The existence of extrachromosomal 
DNA in its own right might constitute a molecular damage-associated molecular pattern 
(DAMP), and thus the regulation of extrachromosomal viruses may reflect both a 
mechanism for intrinsic genome stability maintenance as well as a means of pathogen 
restriction.   
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1.6: Thesis aims 
Although integration of viral DNA into the host genome is a hallmark of HIV-1 infection, 
unintegrated viral DNA species accumulate in infected cells and may play an important 
role in the HIV-1 life cycle. Gene expression from unintegrated virus could contribute 
vital gene products to ensure productive infection, yet expression from unintegrated 
viral genomes appears markedly restricted by the host cell compared to integrated 
proviruses (Wiskerchen and Muesing, 1995). This indicates the existence of a hitherto 
unknown host restriction mechanism acting specifically on extrachromosomal viral 
DNA species. Consequently, the overall aim of this thesis was to uncover the molecular 
mechanism for restriction of gene expression from unintegrated HIV-1 genomes. 
In the light of the previous work from the Chen laboratory showing that HIV-1 Vpr can 
increase gene expression from unintegrated viral genomes (Poon and Chen, 2003; 
Poon et al., 2007), I hypothesised that Vpr might hold the key to understanding 
unintegrated virus restriction. My initial aim was to characterise the ability of HIV-1 Vpr 
to increase gene expression from unintegrated virus (Chapter 3). The data revealed 
the involvement of CRL4DCAF1 activity in this phenotype, indicating that HIV-1 Vpr 
induces the degradation of an elusive host target, which would normally restrict gene 
expression from unintegrated virus. By taking an innovative forward genetics approach 
to this question, I have identified a novel Vpr target and implicated it in restriction of 
gene expression from unintegrated viral genomes (Chapter 4). Through identification 
of protein interactors by mass spectrometry, I have identified the wider context for 
restriction (Chapter 5) and finally explored the molecular mechanism for silencing of 
unintegrated HIV-1 genomes (Chapter 6). This thesis thus describes a novel 
mechanism for HIV-1 restriction acting on unintegrated viral genomes, which not only 
furthers our understanding of the viral life cycle but may also have wider implications 
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Primary antibodies used were as follows, listed by manufacturer: Abcam: Rabbit α-
SLF2 (ab122480), rabbit α-Histone H3 (ab1791), rabbit α-H3K9me3 (ab8898). 
Biolegend: Mouse α-CD4-APC (317416), mouse α-LNGFR-PE (345106). Cell 
Signaling: Rabbit α-H3K4me3 (#9751), rabbit α-H3K27me3 (#9733), normal rabbit IgG 
(#2729). GeneTex: Rabbit α-SMC6 (GTX116832), rabbit α-NSMCE1 (GTX107136). 
Roche: Rat α-HA (11867423001). Sigma-Aldrich: Mouse α-β-actin (A5316), rabbit α-
ANKRD32 (SAB2701555). Secondary antibodies used were as follows: Goat α-
mouse-HRP, goat α-rabbit-HRP, and goat-α-rat-HRP (Jackson ImmunoResearch). 
 
2.1.2: Chemical inhibitors 
Chemical inhibitors used were as follows: Raltegravir (Cayman Chemical; 1 µM), 
MLN4924 (Millipore; 1 µM), EDTA-free protease inhibitor tablets (cOmplete™, 
Roche; 1x). For use of MLN4924, cells were pre-treated with compound for 30 minutes 
prior to infection. No preincubation was used for treatment with raltegravir (RAL). 
Protease inhibitors were solely used for molecular biology purposes. 
 
2.1.3: Enzymes and general reagents 
All restriction enzymes for molecular cloning were purchased from New England 
Biolabs (NEB), as were DNA polymerases (Phusion, Q5) and DNA ligases (T4, T7). 
Nucleases were purchased from Sigma-Aldrich (Micrococcal nuclease (MNase), 
Benzonase), Qiagen (RNase A), or Promega (RQ1 RNase-Free DNase). PCR-grade 
nuclease-free water was purchased from Invitrogen. Phosphate-buffered saline (PBS) 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) and Tris-
buffered saline (TBS) (10 mM Tris, 150 mM NaCl, pH 7.4) were prepared in the 
department media kitchen. DNA isolation was performed using the appropriate Qiagen 
DNA isolation kits (Miniprep, Maxiprep, Puregene) unless otherwise stated. Method-
specific reagents are described in the appropriate sections.  
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2.1.4: Software 
Flow cytometry data was analysed in FlowJo (v 10.6.2). SnapGene Viewer (v 5.0.7) 
was used for visualisation of plasmid maps and Sanger sequencing data. Sanger 
sequencing data analysis and alignment was performed using the DNASTAR 
Lasergene suite (v 17). Genomics data were visualised in IGV (v 2.8.0). Graphing and 
associated statistical analyses were performed in GraphPad Prism (v 8.4.2). All final 
figures were prepared using the Adobe Creative Cloud software suite (2020 desktop 
apps). Graphic illustrations were drawn as vector graphics in Adobe Illustrator (v 
24.1.2), and composite figures were assembled in Adobe InDesign (v 15.0.2). All 
software was accessed on a MacBook Pro running MacOS Mojave (10.14.6). 
 
2.2: DNA cloning and constructs 
2.2.1: Polymerase chain reaction (PCR) 
PCR amplification of template DNA for general molecular cloning was performed using 
Phusion high-fidelity DNA polymerase (NEB) and custom DNA oligonucleotide primers 
(Sigma-Aldrich). Reactions were typically set up in 50 µL total volume containing 
0.5 µL Phusion DNA polymerase, 1x Phusion HF buffer, 0.2 mM dNTPs, 
0.5 µM forward and reverse primers, and 100 ng template DNA. Cycling conditions: 
1 x [98°C, 30 s], 20 x [(98°C,10 s), (56°C, 15 s), (72°C, 30 s)], 1 x [72°C, 5 min], hold 
at 10°C. For longer PCR products, the extension cycle was increased to 2 min, and 
the number of cycles was increased to 35 for amplification of low-copy templates. 
Gradient PCR was used to determine optimal annealing temperatures. 
 
2.2.2: Plasmid DNA cloning and propagation 
Cloning of constructs was achieved by restriction digest and ligation. Restriction digest 
reactions were typically set up in 20 µL total volume containing 1 µL of each restriction 
enzyme (NEB), 1x restriction enzyme buffer, and 2 µg template DNA. Reactions were 
incubated at 37°C for 1-4 h, and digested vectors were dephosphorylated using 
Antarctic phosphatase (NEB), 30 min, 37°C. Digested products were gel purified by 
agarose gel electrophoresis, band excision, and gel extraction (Qiagen). Ligation of 
the insert into the vector was performed using T4 DNA ligase (NEB). Reactions were 
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typically 25 µL total volume containing 0.2 µL T4 DNA ligase, 1x T4 DNA ligase buffer, 
0.4 mg/mL BSA, 1 mM DTT, 1 mM ATP, 1 µL digested vector backbone, and 0.5 µL 
digested insert DNA (incubated 1 h, RT). For cloning of sgRNA or shRNA expression 
constructs, inserts were ordered as pairs of staggered complementary 
oligonucleotides (Sigma-Aldrich) which were phosphorylated individually using T4 
PNK (NEB), annealed, and ligated into the pre-digested expression vector using T4 
DNA ligase. Ligations were transformed into Silver efficiency chemically competent 
cells (Bioline), spread on LB-agar plates containing 100 µg/mL Ampicillin (Amp), and 
incubated at 37°C overnight. Single colonies were picked into LB-Amp medium, grown 
for 16 h at 37°C in a shaking incubator, and plasmid DNA was isolated using a QIAprep 
spin Miniprep kit (Qiagen). Plasmid sequence was confirmed by Sanger sequencing 
(Source Bioscience). 
 
2.2.3: Expression constructs and lentiviral reporters 
This study predominantly used 2nd generation lentiviral systems based on the pHRSIN 
backbone (Demaison et al., 2002), which carried an inactivating U3 deletion in its LTR 
but contained an internal spleen focus-forming virus (SFFV) promoter driving 
expression of the gene of interest (GOI). Vesicular stomatitis virus G protein (VSV-G) 
pseudotyped lentiviral particles were produced by co-transfection of pHRSIN with the 
packaging vector pCMVΔR8.91 (expressing HIV-1 Gag and Pol) and pseudotyping 
vector pMD.G (expressing VSV-G). Fluorescent lentiviral reporters were 
pHRSIN.pSFFV-GFP, pLTR-Tat-IRES-GFP (pEV731, a gift from Eric Verdin), and 
pHRSIN.pSFFV-iRFP. Full-length and Vpr deletion NL4-3 reporters were pNL4-3-
ΔEnv-Nef-P2A-SBP-ΔLNGFR (NL4-3LNGFR) for immunostaining and flow cytometry 
(Naamati et al., 2019), and pNL4-3-ΔEnv-eGFP (NL4-3GFP) for viral RNA FISH 
(Greenwood et al., 2019; Zhang et al., 2004). Full-length SLF2 and NSMCE2 cDNA 
was isolated by PCR amplification of the respective CDS from HeLa cDNA and cloned 
into pHRSIN.pSFFV-GOI.pGK-PuroR or pHRSIN.pSFFV-3xHA-GOI.pGK-PuroR. For 
cloning of HA-tagged minimal SLF2, the 590-1173 amino acid region of SLF2 was 
amplified by PCR, appending an N-terminal SV40 NLS. Human and primate lentiviral 
Vpr constructs were expressed from pHRSIN.RSV-HA-Vpr.Ub-Emerald as previously 
described (Greenwood et al., 2019). 3xHA-HBx was cloned from a subtype A HBx 
construct obtained from Christine Neuveut and expressed either from a pHRSIN or an 
M5P MLV-based vector (a kind gift from Felix Randow). Non-lentiviral expression 
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constructs pCMV-SPORT6-mCherry and pCMV-SPORT6-Vpr were used for 
expression of protein for packaging into virus-like particles (VLP) in the absence of a 
viral genome. 
 
2.3: Cell culture and lentivirus production 
2.3.1: Cell culture 
CEM-T4 were acquired from the NIH AIDS Reagent Program (Cat. #117) and Jurkat 
T cells from ATCC (Clone E6-1, TIB-152). HEK293T cells were a generous gift from 
Dr Felix Randow. All cell lines were cultured at 37°C and 5% CO2 in Iscove's Modified 
Dulbecco's Medium (IMDM, Sigma-Aldrich) supplemented with 10% fetal calf serum 
(FCS, Gibco), 1x GlutaMAX (Gibco), and 100 U/mL penicillin/streptomycin (Gibco). 
 
2.3.2: Lentivirus production 
VSV-G pseudotyped lentivirus was produced by transfection of HEK293T cells with a 
lentiviral expression vector and packaging vectors pCMVΔR8.91 and pMD.G at a DNA 
ratio of 3:2:1 using TransIT-293 (Mirus) following the manufacturers recommendation. 
For small scale virus production, HEK293T cells were seeded at ~70% confluency in 
a 12-well plate and transfected with 0.75 µg lentiviral vector DNA, 0.5 µg pCMVΔR8.91, 
and 0.25 µg pMD.G using 3 µL TransIT-293. For large scale virus production, 
HEK293T cells were seeded in 15 cm dishes and transfected with 20 µg lentiviral 
vector DNA, 13 µg pCMVΔR8.91, and 7 µg pMD.G using 80 µL TransIT-293. For NL4-
3 reporters, transfections were performed using FuGENE 6 (Promega) and a pNL4-3 
to pMD.G DNA ratio of 9:1. 48 hours post transfection, supernatants were collected, 
filtered (0.45 μm pore size), and stored at -80°C. For sensitive applications, lentiviral 
supernatants were DNase treated (1 h, 37°C; RQ1, Promega) and purified (Lenti-X, 
Takara). Control VLPs and Vpr VLPs were produced by co-transfection of a non-
lentiviral pCMV-SPORT6-mCherry or -Vpr construct, respectively, with pCMVΔR8.91 
and pMD.G at a DNA ratio of 2:2:1. All infections were performed by spinoculation 
(750xg, 60 min, 37°C). 
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2.4: Cell biology methods 
2.4.1: Flow cytometry and immunostaining 
Flow cytometry data was collected on an LSR Fortessa (BD) and was analysed using 
FlowJo v.10.6.2. Geometric mean fluorescence intensities (MFI) were used for 
quantification. For NL4-3 flow cytometry, cells were first incubated with the indicated 
fluorochrome-conjugated antibodies (15 min, 4˚C) and then fixed in PBS with 
1% paraformaldehyde.  
 
2.4.2: Fluorescence-activated cell sorting (FACS) 
Prior to sorting, cells were resuspended in 10% FCS-PBS and filtered through a sterile 
50 µm cell strainer. Sorted cells were collected into complete IMDM media 
supplemented with 50% FCS and 200 U/mL penicillin/streptomycin. For single cell 
cloning, cells were sorted directly into round-bottom 96-well plates containing 50% 
conditioned media and 50 % fresh complete IMDM. Large scale sorting (i.e. for forward 
genetic screen) was performed by the department flow cytometry team on an Influx 
(BD). Small scale sorting was performed on a researcher-operated Melody (BD). 
 
2.4.3: Viral RNA fluorescence in situ hybridization (vRNA FISH) 
HIV-1 RNA detection was performed by branched DNA in situ hybridization (bDNA 
FISH) following a modified RNAscope protocol with RNAscope reagents from 
Advanced Cell Diagnostics (ACD) (Wang et al., 2012). Briefly, cells were seeded on 
poly-d-lysine coated coverslips 48 h post infection, fixed in 4% PFA (30 min, RT), 
washed three times in PBS, incubated 10 minutes in 0.1% Tween-20-PBS (PBS-T), 
and washed twice in PBS. Cells were incubated with manufacturers protease treatment 
(Pretreat 3; 1:5 dilution in PBS) in a humidified ACD HybEZ oven at 40°C, 15 min. 
Protease solution was decanted, and samples were washed twice in PBS. A probe 
that recognizes HIV-1 RNA (HIV-nongagpol-C3; ACD 317711-C) was applied following 
manufacturers recommendations and samples incubated at 40 °C for 2 h in the HybEZ 
oven. Remaining wash steps, hybridization of preamplifiers, amplifiers, and fluorescent 
label were performed as previously described (Puray-Chavez et al., 2017). Nuclei were 
counter-stained with 4’,6’-diamino-2-phenylinndole (DAPI) and mounted using Prolong 
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Gold Antifade (Invitrogen). Imaging was performed using a Nikon C2 confocal 
microscope using a 60x APO oil-immersion objective (numerical aperture 1.4). The 
excitation/emission bandpass wavelengths to detect DAPI (405 nm) and HIV-1 RNA 
(647 nm) were set to 420-480 nm and 655-705 nm, respectively. Images were 
quantified using Gen5 software (BioTek) to count individual cells and determine the 
integrated fluorescence intensity of HIV-1 RNA per cell. Background signal was 
determined using uninfected Jurkat T cells processed as described above. 
 
2.5: Forward genetic screening and gene knockout 
2.5.1: Custom Vpr target sgRNA library cloning 
Putative Vpr targets were identified based on host protein depletion in published and 
unpublished proteomics datasets as described in section 4.2.1. Targets were split into 
4 sub-libraries to reflect the target inclusion criteria (see Figure 4.1) and make library 
cloning more efficient. sgRNA sequences were derived from published genome-wide 
sgRNA libraries (Morgens et al., 2017a; Wang et al., 2014). The library cloning strategy 
was based on a previously published protocol (Doench et al., 2016). sgRNA 
sequences were synthesised as long adaptor-flanked oligos enabling sub-library 
amplification and restriction cloning into the U6 expression vector, which also encoded 
BFP and a puromycin resistance cassette (pKLV.pU6.sgRNA.pGK-PuroR-P2A-BFP). 
Each oligo was composed of a binding site for the sub-library forward primer, a BsmBI 
restriction site, the sgRNA sequence, another BsmBI site, and the binding site for the 
sub-library reverse primer (see Appendix 1). 
5′-(Forward Primer) CGTCTCACACC G(sgRNA) GTTTCGAGACG (Reverse Primer) 
Oligos were ordered as a pooled oligo array from CustomArray, which was used as 
template for PCR amplification of sub-libraries using Q5 DNA polymerase (NEB) 
followed by clean-up using a QIAquick nucleotide removal kit (Qiagen). Sub-library 
PCR products were BsmBI digested and ligated into the gel purified BsmBi digested 
expression vector using T7 DNA ligase (NEB). Ligation products were electroporated 
into Stbl4 competent cells (Invitrogen) which were grown in SOC (1 h, 37°C, shaking 
incubator), spread onto 2 x 14 cm LB-Amp plates, and incubated at 37°C for 19 h. 
Transformation efficiency was calculated based on serial dilutions (>50-fold coverage 
for each sub-library). Colonies were harvested and DNA was extracted using a plasmid 
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DNA maxiprep kit (Qiagen). Pooled Vpr library DNA was produced by mixing sub-
library DNA at the appropriate ratio, and library lentivirus was produced as described 
in section 2.3.2. 
 
2.5.2: CRISPR-Cas9 knockout screen  
A cell line stably expressing Cas9 (Cas9-CEM-T4) was established by transduction of 
CEM-T4 T cells with a lentiviral construct encoding Cas9 and a hygromycin resistance 
cassette allowing selection. Cas9 efficiency was confirmed by transduction with a 
pKLV lentiviral vector encoding a β2m sgRNA and puromycin selection of sgRNA-
expressing cells followed by cell surface staining for MHC class I and analysis by flow 
cytometry. The CRISPR-Cas9 knockout screen was commenced by transduction of 
48 x 106 Cas9-CEM-T4 cells with “Vpr target library” sgRNA lentivirus at MOI ~0.3 in 
6-well plates with 2 x 106 cells per well (spinoculation 1 h, 750xg, 37°C). 24 h post 
infection, cells were pooled in T175 flasks, and puromycin selection was applied 48 h 
post infection to enrich for sgRNA containing cells. Transduction efficiency was verified 
by flow cytometry (BFP+) 96 hpi, revealing 33.5% BFP+ cells equivalent to >1,000-fold 
coverage of the library: 
0.335 × 48×10
6
 sgRNA containing cells
12,510 sgRNAs in library
 = 1,285 fold coverage of sgRNA library 
An unselected pooled knockout library was maintained for the duration of the screen 
at >1,000-fold library coverage in parallel with the experimental population. On day 7, 
48 x 106 pooled knockout library cells were transduced at MOI ~1.5 with GFP and 
mCherry lentiviral reporters (pHRSIN.SFFV-GFP and pHRSIN.SFFV-mCherry) in the 
presence of 1 µM raltegravir with spinoculation as described for the library virus 
transduction. The experimental cell population was subsequently maintained in 1 µM 
raltegravir for the duration of the screen. 3 days after reporter virus transduction 
(screen day 10), the top 0.5% GFP+/mCherry+ cells were selected by FACS to enrich 
for rare cells carrying a knockout of a gene that is normally repressive to expression 
from unintegrated virus. 6 days after the 1st FACS sort, cells with stably integrated virus 
were removed by sorting the GFP-/mCherry- population. On day 18 and 21, 
respectively, reporter virus infection and sorting the top 0.5% GFP+/mCherry+ cells 
were repeated, and DNA was isolated immediately after sorting using a Quick-DNA 
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Microprep kit (Zymo). In parallel, DNA was isolated from 10 x 106 unsorted pooled 
knockout library using a Gentra Puregene kit (Qiagen). 
 
2.5.3: Preparation of screen samples for Illumina sequencing 
DNA was prepared for next-generation sequencing by amplification of sgRNA 
sequences in two sequential rounds of PCR using a Q5 high-fidelity DNA polymerase 
kit (NEB) supplemented with 0.2 mM dNTPs (see Appendix 1 for primer sequences). 
In the first round of PCR, 48 x 50 μL reactions (2 μg template DNA/reaction) were 
performed for the library DNA and 4 x 25 μL reactions (0.25 μg template DNA/reaction) 
for the sorted DNA sample. Cycle conditions: 1 x [98°C, 30 s], 18 x [(98°C,10 s), (64°C, 
20 s), (72°C, 20 s)], 1 x [72°C, 2 min], hold at 4°C; primers sgRNA_outer_f and 
sgRNA_outer_r. Samples were pooled and used as template in the second round of 
PCR, which served to append Illumina P5 and P7 sequencing adapters and index 
samples (7 bp TruSeq DNA LT index). 3 x 50 uL reactions for each sample (1 μL PCR1 
template), run for 10, 12, or 16 cycles. Cycle conditions: 1 x [98°C, 30 s], 10/12/16 x 
[(98°C,10 s), (64°C, 20 s), (72°C, 20 s)], 1 x [72°C, 2 min], hold at 4°C; primers P5-
sgRNA_inner_f and P7-sgRNA_inner_r. PCR purification was performed using 
AMPure XP beads (Beckman Coulter). Purified PCR samples were profiled and 
quantified using an Agilent DNA1000 kit on a Bioanalyzer 2100. Samples chosen for 
sequencing were in the 5-15 nM concentration range with the smallest possible 
number of second round PCR cycles. Sequencing was performed in house on an 
Illumina MiniSeq platform (35 bp single-end sequencing). 
 
2.5.4: CRISPR-Cas9 screen data analysis  
Sequencing data was analysed using a custom developed pipeline using tools installed 
in a Bioconda environment. First, raw FASTQ were processed using the fastX toolkit 
(Hannon Lab) to remove reads with low quality scores and trim off adaptor sequences 
leaving only the 19 bp long sgRNA sequences. This generated 11.5 x 106 reads for the 
unsorted library and 3.3 x106 reads for the sorted sample. Trimmed reads were aligned 
to an index of Vpr library sgRNA sequences using Bowtie2 (Langmead and Salzberg, 
2012), and alignment files were converted to the BAM format using SAMtools (Li et al., 
2009). Read count statistics were generated using the Model-based Analysis of 
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Genome-wide CRISPR/Cas9 Knockout (MAGeCK) algorithm (Li et al., 2014), thus 
achieving a gene-wise significance score for the enrichment of sgRNA sequences in 
the sorted cells compared to the unsorted library population. Detailed code can be 
accessed on https://github.com/LDUP92/hiv-compaction  
 
2.5.5: CRISPR-Cas9-mediated gene knockout 
CRISPR-Cas9 mediated genomic editing was performed by transduction of cell lines 
stably expressing Cas9 with sgRNA expression vectors encoding sgRNA sequences 
targeting the gene of interest as well as BFP and a puromycin resistance cassette. 
sgRNA sequences are listed in Appendix 2. sgRNA expressing cells were enriched 
by puromycin selection. Phenotypic experiments of resulting mixed knockout 
populations were performed immediately 7 days post sgRNA introduction to minimise 
lethality-based outgrowth effects. For unintegrated virus reporter assays in mixed and 
clonal knockout populations, BFP+ WT Jurkat cells were mixed 1:1 with BFP- knockout 
cells prior to reporter infection to rigorously control infection levels. For generation of 
clonal knockout cell lines, sgRNA transduction was performed in 1 µM raltegravir to 
prevent stable integration, and single cell clones were isolated in round-bottom 96-well 
plates on a BD FACSMelody. Clonal cell lines were expanded and screened for loss 
of protein expression by SDS-PAGE and western blotting. To confirm biallelic gene 
disruption for clonal knockout cell lines, genomic DNA was isolated from 1 x 106 cells 
using a QIAamp DNA Mini Kit (Qiagen), and the sgRNA target exons were amplified 
by PCR using nested primer sets (see Appendix 1). PCR products were resolved by 
gel electrophoresis, gel purified, and prepared for Sanger sequencing using a Zero 
Blunt TOPO PCR cloning kit (Invitrogen). 10 colonies were sequenced for each 
knockout clone to cover all alleles. 
 
2.6: Protein analysis techniques 
2.6.1: SDS-PAGE and western blotting 
Cells were lysed in Laemmli buffer supplemented with 100 mM dithiothreitol (DTT) and 
benzonase (1:100, Sigma-Aldrich). Following denaturation at 65°C, samples were 
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) 
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and transferred to PVDF-membranes (Millipore) by TransBlot semi-dry transfer. 
Membranes were blocked in 5% (w/v) milk – PBS-T (0.2% Tween-20) (1 h, RT, on 
rocker) and incubated with primary antibody in milk-PBS-T (4°C, overnight, on rocker) 
followed by 4 washes in PBS-T (5 min, RT, on rocker). Membranes were incubated 
with HRP-conjugated secondary antibodies (1 h, RT, on rocker), and washes in PBS-
T were repeated. Blots were developed using chemiluminescent substrates (Thermo 
Scientific) and were visualised using either X-ray film or an iBright CL1000 imaging 
system (Thermo Fisher Scientific). 
 
2.6.2: Immunoprecipitation (IP) 
15 x 106 cells were incubated in cell lysis buffer (0.1% IGEPAL, 85 mM KCl, 10 mM 
HEPES, 1x protease inhibitor), 5 min, 4°C, and spun at 800xg, 4°C, 5 min. The 
supernatant was discarded, and the pellet was resuspended in nuclei lysis buffer (1% 
IGEPAL, 1x TBS, 1:100 benzonase, 1x protease inhibitor) and incubated 15 min, 4°C, 
followed by mechanical sheering with a 0.45 mm needle. Lysates were clarified by 
centrifugation at 10,000xg, 10 min, 4°C, and diluted 1:2 in TBS, thus making the final 
IP buffer 0.5% IGEPAL, 1xTBS, 1x protease inhibitor. For endogenous SLF2 IP pre-
clearing of the lysates was performed by incubation with protein A and immunoglobulin 
G (IgG)-sepharose (1 h, 4°C, on rotor). Pre-cleared lysates were incubated with 1 µg 
primary antibody (3 h, 4°C, on rotor) followed by incubation with protein A-sepharose 
(1 h, 4°C, on rotor). For HA IP, lysates were pre-cleared with 25 µL protein A and 25 
µL protein G Pierce magnetic beads (1 h, 4°C, on rotor) followed by incubation with 
50 µL anti-HA magnetic beads (3 h, 4°C, on rotor). Following antibody/bead incubation, 
samples were washed 5 times in IP buffer (5 min, 4°C, on rotor), and bound proteins 
were eluted in 2% SDS, 50 mM Tris (pH 8) by incubation at 65°C, 10 min. 
 
2.6.3: Mass spectrometry 
Eluted proteins samples were brought to 5% SDS and reduced/alkylated with 10mM 
TCEP/40mM Iodoacetamide. Subsequently, samples were digested on a micro S-trap 
(Protifi), acidified with phosphoric acid, and precipitated with neutral buffered methanol 
(wash buffer) before loading onto an S-trap using a vacuum manifold. Traps were 
washed with wash buffer prior to digest with trypsin/lysC in HEPES pH8 (digestion 
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buffer) (37°C, 6 h). Peptides were eluted sequentially with digestion buffer, 0.2% formic 
acid and 0.2% formic acid + 50% Acetonitrile. Eluted samples were dried in a vacuum 
centrifuge and stored at -20°C prior to analysis. Mass spectrometry data acquisition 
and analysis were performed as previously described (Greenwood et al., 2019). Briefly, 
data were acquired on an Orbitrap Fusion (Thermo Fisher) operating a 1 h reversed 
phase gradient. The instrument obtained MS1 spectra in the Orbitrap and MS2 spectra 
in the ion trap. Data were searched using Mascot (Matrix Science) from within 
Proteome Discoverer (Thermo Fisher), and Percolator was used to determine PSM 
FDR which was controlled at 1%. Proteins were quantified using the Hi3 method. 
 
2.7: Chromatin analysis techniques 
2.7.1: Chromatin immunoprecipitation (ChIP) 
10 x 106 cell aliquots were crosslinked in 1% formaldehyde in complete IMDM (10 min, 
RT) and quenched with 0.125 M glycine (5 min, RT). Nuclei were isolated by lysis in 
2x 5 mL ChIP lysis buffer (10 mM HEPES, 85 mM KCl, 0.5% IGEPAL, protease 
inhibitor cocktail) at 4°C, 5 min, and nuclei pelleted (1,000xg, 5 min, 4°C). Nuclei were 
lysed in 200 µL MNase buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM MgCl2, 
1 mM CaCl2, 4% IGEPAL, protease inhibitor cocktail) supplemented with 1 µL MNase 
and 1 µg RNase A, incubated 10 min at 37°C, and the digest immediately quenched 
by addition of 100 µL MNase-STOP buffer (50 mM Tris-HCl pH 8.1, 10 mM EDTA, 10 
mM EGTA, 1% SDS, protease inhibitor cocktail) 5 min, 4°C. Digested chromatin was 
sonicated in 1.5 mL tubes in a Bioruptor Pico (Diagenode) for 5 cycles (10 s ON, 30 s 
OFF, 4°C) and clarified by centrifugation at 6,000xg, 10 min, 4°C. Lysates were diluted 
by adding 1 mL IP dilution buffer (20 mM Tris-HCl, 2 mM EDTA, 150 mM NaCl, 1% 
Triton X-100, 0.01% SDS, protease inhibitor cocktail) and pre-cleared by incubation 
with 12.5 µL Protein G magnetic beads (Pierce), 4°C, 2 h. 120 µL pre-cleared 
chromatin was kept as input, equivalent to 1 x 106 cells. Chromatin aliquots from 5 x 
106 cells for histone ChIP or 10 x 106 cells for 3xHA-NSMCE2 ChIP were 
immunoprecipitated with either 5 µg primary antibody and 12.5 µL Protein G magnetic 
beads (histone ChIP) or 30 µL anti-HA magnetic beads (3xHA-NSMCE2 ChIP), 4°C, 
overnight. Bead-bound chromatin was washed twice in low-salt buffer (20 mM Tris-HCl 
pH 8.1, 2 mM EDTA, 50 mM NaCl, 1% Triton X-100, 0.1% SDS), once in LiCl buffer 
(10 mM Tris-HCl pH 8.1, 1 mM EDTA, 250 mM LiCl, 1% IGEPAL, 1% sodium 
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deoxycholate monohydrate), and twice in TE buffer (10 mM Tris-HCl pH 8.1, 1 mM 
EDTA). Protein-DNA complexes were eluted from beads in 200 µL elution buffer (1% 
SDS, 100 mM NaHCO3) and de-crosslinked with 0.3 M NaCl (final) and 1 µg RNase A 
(65°C, overnight), followed by digestion with 3 µL proteinase K and PCR purification 
(Qiagen). Quantitative PCR (qPCR) was performed with SYBR green master mix 
(Applied Biosystems) and iRFP primers (see Appendix 1) on a QuantStudio7 Flex 
(Applied Biosystems). Serial dilutions were prepared for input samples (1:20, 1:200, 
1:2000), and IP samples were diluted 1:20. All reactions were set up in triplicate in 25 
µL total reaction volume containing 2 µL diluted sample and 0.2 µM forward and 
reverse primer. Cycle conditions: 1 x [(50°C, 2 min), (95°C, 5 min)], 40 x [(95°C,15 s), 
(62°C, 15 s)], 1 x [62°C, 1 min]. Data was analysed using the percent input method. 
 
2.7.2: ATAC-seq 
Chromatin accessibility was assessed by ATAC-seq following a published protocol 
(Buenrostro et al., 2015) with some modifications including omission of the nuclei 
isolation step, which has been previously shown to reduce mitochondrial DNA 
contamination in K562 cells (Karabacak Calviello et al., 2019). Briefly, 50,000 Jurkat T 
cells were resuspended in 50 µL 1x Illumina Tagment DNA with 2.5 µL TDE1 Tagment 
DNA Enzyme (Illumina). Transposition reactions were incubated in a thermomixer (1 h, 
37°C, 1,400 rpm), and chromatin fragments were purified using a MinElute PCR 
purification kit (Qiagen). Libraries of transposed DNA fragments were generated by 
minimal PCR amplification using custom Nextera single-indexed primers as previously 
described (Buenrostro et al., 2015). 50 µL PCR reactions were set up containing the 
entire transposed sample, NEBNext high-fidelity PCR master mix (NEB), and 1.25 µM 
forward (Ad1_noMx) and reverse (Ad_2.x,) primers (see Appendix 1). Cycle 
conditions: 1 x [(72°C, 5 min), (98°C, 30 s)], 5 x [(98°C,10 s), (63°C, 30 s), (72°C, 1 
min)], store at 4°C. In order to stop PCR amplification prior to saturation, the minimal 
number of additional cycles needed were determined by analysing 10% of this pre-
amplified reaction by qPCR through addition of SYBR Green I nucleic acid stain 
(Invitrogen). By determining the number of additional PCR cycles needed to obtain 1/3 
max fluorescence, GC and size bias of the PCR amplification is limited. Accordingly, 
the remaining 90% reactions were amplified for a further 4 or 5 cycles. A double-sided 
size selection (1.7x / 0.5x beads) followed by an additional clean-up (1.7x beads) was 
performed using AMPure XP magnetic beads (Beckman Coulter) to remove primers 
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and unwanted large DNA fragments. Samples were pooled in equimolar ratios and 
sequenced on a NovaSeq6000 platform (150 bp paired-end reads). 
 
2.7.3: ATAC-seq data analysis 
Paired-end reads (50-75 million per sample) were trimmed using cutadapt (Martin, 
2011) to remove adapters and low quality reads. A combined viral and human 
reference genome was created by appending the 3.5 kB 1-LTR GFP reporter virus 
sequence as an additional chromosome onto the human reference genome (hg38). 
Reference genome indexing was performed using the Burrows-Wheeler alignment 
package (BWA) (Li and Durbin, 2009). Reads were aligned using BWA-MEM, and 
alignment bam files were created using SAMtools (Li et al., 2009). Duplicate reads, 
reads aligning to mitochondrial DNA, and reads aligning to the ENCODE blacklist of 
problematics regions of the human genome (Amemiya et al., 2019) were removed. 
BigWig coverage tracks were created by normalising reads to counts per million (CPM) 
using bamCoverage from the deepTools suite (Ramírez et al., 2016). Tracks were 
visualised in Integrative Genomics Viewer (IGV) to generate figures. Fragment size 
distribution plots were generated using ATACseqQC (Ou et al., 2018). To allow 
differential analysis of read count densities for both the viral and human genome, 
100,000 virus-sized (3.8 kB) regions were randomly defined in the human genome. 
For each of these regions, read count statistics were generated and used for pairwise 
comparisons of experimental conditions, determining the fold change in read counts 
with an associated FDR-adjusted significance generated by Fisher’s test. Volcano 
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3.1: Introduction 
Whilst HIV-1 integration into the host genome is critical for the production of progeny 
virions, cDNA produced by reverse transcription of the viral genome not only provides 
a template for integration, but also gives rise to extrachromosomal viral DNA species. 
These include linear DNA, 1-LTR and 2-LTR circles and are collectively referred to as 
unintegrated virus (Hamid et al., 2017). At early time points of HIV-1 infection, 
unintegrated virus are the most abundant viral DNA species in infected cells (Munir et 
al., 2013) and they are therefore likely to play a crucial role in the viral life cycle. 
Despite their abundance, unintegrated viral DNA species have been the subject of 
limited research and remain poorly understood. Early studies reported that gene 
expression could be detected from integrase-defective viruses (Wiskerchen and 
Muesing, 1995), indicating that unintegrated virus was transcriptionally active, albeit at 
a very low level compared to what was observed for integrated virus. Their expression 
appeared markedly restricted by the host cell.  
Importantly, these early studies were carried out using HIV-1 molecular clones carrying 
mutations in the vpr gene. In two key publications, HIV-1 Vpr was later shown by the 
Chen laboratory to enhance gene expression from unintegrated HIV-1 DNA (Poon and 
Chen, 2003; Poon et al., 2007), indicating that Vpr plays a role in antagonising host 
restriction of unintegrated virus gene expression via an unknown mechanism. Vpr is 
an HIV-1 accessory protein with a plethora of proposed functions (Fabryova and 
Strebel, 2019). Vpr is actively packaged into the HIV-1 virion via an interaction with the 
Gag precursor protein (Lavallée et al., 1994) and elicits its function by recruiting host 
factors to a cellular E3 ligase complex containing CUL4, RBX1 and DDB1 (CRL4) via 
the adaptor protein DCAF1 (Hrecka et al., 2007), thereby targeting them for 
proteasomal degradation. 
Whilst the observation that HIV-1 Vpr can enhance gene expression from unintegrated 
virus is fascinating, it has not been independently reproduced outside the Chen lab, 
and the mechanism remains unclear. The aim of my initial work, described in this 
chapter, was therefore to characterise the ability of HIV-1 Vpr to increase expression 
from unintegrated virus using an independently developed reporter assay and 
subsequently to examine the involvement of CRL4DCAF1 activity in this phenotype. 
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3.2: Results 
3.2.1: HIV-1 Vpr increases gene expression from unintegrated lentivirus 
My first aim was to demonstrate that unintegrated viral genomes have reduced gene 
expression compared to integrated viral genomes and consequently characterise the 
effect of HIV-1 Vpr on gene expression in both cases. I therefore established a reporter 
assay using flow cytometry for evaluation of GFP fluorescence from a lentiviral reporter 
as a read-out for viral gene expression (Figure 3.1A). HIV-1 Vpr is normally packaged 
into the virion such that it is delivered as a protein into the host cell. To establish a 
representative but easily manipulated reporter assay, I decided to use virus-like 
particles (VLPs) for delivery of Vpr protein. These VLPs were produced by transfection 
of 293T cells with a non-lentiviral Vpr expression construct and lentiviral packaging 
plasmids, leading to the packaging of Vpr protein into VSV-G pseudotyped particles in 
the absence of a viral genome. Similarly, control VLPs were produced by replacing Vpr 
with a non-lentiviral mCherry expression construct. Control VLPs were included to 
mitigate any effect of VSV-G entry receptor competition between Vpr VLPs and 
reporter virus. 
For my main reporter, I selected a pHRSIN-based lentiviral vector expressing GFP 
from a spleen focus-forming virus (SFFV) promoter (Figure 3.1B), due to the well-
established high expression potential. To focus the assay on integrated or unintegrated 
virus, CEM-T4 T cells were co-transduced with the SFFV-GFP reporter and either Vpr 
or control VLPs in the absence or presence of the integrase inhibitor raltegravir (RAL). 
Evaluating GFP fluorescence by flow cytometry 72 h post infection, viral gene 
expression was clearly increased in the presence of Vpr compared to control VLPs, 
and this effect was most pronounced when integration was prevented using RAL. This 
finding was replicated using another lentiviral reporter expressing GFP from a Tat-
dependent wildtype HIV-1 LTR (Figure 3.1C), confirming that the phenotype was not 
unique to the SFFV promoter. Quantification of the fold change in GFP fluorescence 
upon addition of Vpr confirmed a significantly larger effect of Vpr on the viral gene 
expression when integration was inhibited with RAL (3.65 or 3.71 fold increase for 
SFFV-GFP or LTR-Tat-GFP, respectively) compared to infection in the absence of 
RAL (2.11 or 2.19 fold), indicating that Vpr increases gene expression more potently 
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Figure 3.1: HIV-1 Vpr delivered in VLPs increases gene expression from 
unintegrated lentiviral reporters
A, Unintegrated virus reporter assay with Vpr VLPs. CEM-T4 T cells were co-transduced 
with GFP expressing lentiviral reporters and control VLPs or HIV-1 Vpr containing VLPs, 
with or without 1 μM raltegravir (RAL) treatment. GFP fluorescence was evaluated by 
flow cytometry 72 h post infection. (B-D) VLP-delivered Vpr increases gene expression 
from unintegrated viral reporter. SFFV-GFP (B) or LTR-Tat-GFP (C) lentiviral reporters 
were used for unintegrated virus reporter assay in CEM-T4 T cells co-transduced with 
control VLPs (grey shaded) or Vpr VLPs (red/blue line). Histograms are representative 
examples of n = 3 independent experiments, quantified in (D) as the fold change in 
GFP mean fluorescence intensity (MFI) upon addition of Vpr VLPs compared to control 
VLPs. *, P < 0.05. Error bars denote standard deviation.
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To confirm the validity of my Vpr VLP reporter assay, I set up a parallel assay using 
virion-packaged Vpr (Figure 3.2A), which more closely resembles a wild-type 
infection. Here, the SFFV-GFP lentiviral reporter construct and packaging plasmids 
were transfected into 293Ts along with the non-lentiviral Vpr expression construct, 
leading to the production of virions containing both the GFP reporter construct and Vpr 
protein. Again, control virions were produced replacing the Vpr expression construct 
with an mCherry expression construct. As observed for the VLP reporter assay, the 
presence of Vpr packaged inside the virion lead to a clear increase in viral gene 
expression when integration was inhibited (Figure 3.2B), compared to a marginal 
increase in gene expression in the absence of RAL. To rule out that this was a side-
effect of using RAL, I repeated the reporter assay using a non-integrating reporter virus 
that carries an inactivating D64V point mutation in integrase (Wiskerchen and Muesing, 
1995). As for the RAL-based assay, virion-packaged Vpr significantly increased gene 




















































































Figure 3.2: Virion-packaged HIV-1 Vpr increases gene expression from 
unintegrated lentiviral reporters
A, Unintegrated virus reporter assay with virion-packaged Vpr. CEM-T4 T cells 
were transduced with SFFV-GFP lentiviral reporters with or without packaged Vpr 
protein contained in the reporter virion, in the absence or presence of 1 μM RAL. 
GFP fluorescence was evaluated by flow cytometry 72 h post infection, representative 
histogram seen in (B) (n = 2). C, Unintegrated virus reporter assay using D64V integrase 
mutant SFFV-GFP reporters with or without packaged Vpr. Flow cytometry 72 h post 
infection (n = 1)
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3.2.2: Vpr does not increase gene expression from stably integrated lentivirus 
Whilst my initial results suggested a role for Vpr in increasing gene expression from 
unintegrated virus, in agreement with previous reports from the literature, I was 
surprised to also see a small but reproducible Vpr-dependent increase in viral gene 
expression when integration was not inhibited (e.g. Figure 3.1B), suggesting a 
potential effect on integrated as well as unintegrated virus. To further examine this, I 
repeated my Vpr VLP reporter assay, this time including a condition in which CEM-T4 
cells had been infected with the SFFV-GFP reporter virus 3 days prior to addition of 
VLPs, allowing stable integration. 
Interestingly, under these conditions, Vpr had only a negligible effect on the stably 
integrated reporter compared to the more significant increase in gene expression 
observed for co-transduction of the reporter with Vpr VLPs (Figure 3.3A). By following 
the GFP fluorescence over time, I observed a gradual loss of the Vpr-dependent 
increase in viral gene expression for the infection in the absence of raltegravir (middle 
panels), mirroring the gradual loss of unintegrated virus expression (left panels) due to 
the dilution of unintegrated viral genomes through cell division. Based on this data, I 
find no convincing evidence for a significant effect of Vpr on gene expression from 
stably integrated reporters. I instead attribute the initial effect of Vpr observed in the 
absence of RAL (Figure 3.1B) to the presence of unintegrated viral genomes 









































































































































































































































Figure 3.3: Time course of co-transduction of Vpr VLPs with reporter virus and 
addition of Vpr VLPs post reporter virus integration
A, CEM-T4 T cells were transduced with SFFV-GFP lentiviral reporters either 3 days 
prior to or upon co-transduction with control VLP (grey shaded) or Vpr VLP (red/blue 
line) in presence or absence of RAL as indicated. GFP expression was analysed by 
flow cytometry 3, 5, 7, and 10 days post infection, respectively (n = 1). 
60
Chapter 3: HIV-1 Vpr increases unintegrated virus gene expression via CRL4DCAF1 
  
3.2.3: Vpr deletion decreases gene expression from unintegrated NL4-3 virus 
Next, I wanted to validate that the phenotypes I was observing for my simplified 
reporter system were also representative for full-length HIV-1 reporters. I therefore 
used an NL4-3 reporter virus previously established in the lab (Naamati et al., 2019) in 
which a truncated low-affinity nerve growth factor receptor (LNGFR) protein is 
expressed on a bicistronic transcript downstream of nef via a P2A peptide (Figure 
3.4A). Cell surface staining for LNGFR therefore provides a convenient readout for Nef 
expression alongside surface depletion of CD4 as a functional read-out for Nef and 
Vpu expression (Aiken et al., 1994; Willey et al., 1992). CEM-T4 T cells were infected 
with either full length or Vpr deletion VSV-G pseudotyped NL4-3LNGFR reporter virus at 
a low MOI in the presence or absence of RAL followed by immunostaining and flow 
cytometry 48 h post infection (kindly performed by Dr Adi Naamati). Vpr deletion lead 
to a marked decrease in LNGFR expression from unintegrated virus (Figure 3.4B), 
which correlated with a reduced ability to deplete cell surface CD4 (7.2% for ΔVpr NL4-
3LNGFR vs. 26.7% for WT NL4-3LNGFR). Again, only a marginal Vpr-dependent increase 
in LNGFR expression was observed for infection in the absence of raltegravir with no 
significant change in the ability to deplete CD4 (33.7% for ΔVpr NL4-3LNGFR vs 36.8% 
for WT NL4-3LNGFR). Vpr thus appears to play a key role in regulating gene expression 
from unintegrated full-length NL4-3 reporters. 
To further corroborate this finding, we initiated a collaboration with the Sarafianos lab 
at Emory University to use imaging techniques for quantifying viral RNA production 
from full-length virus. Here, Jurkat T cells were infected with another NL4-3 reporter 
previously established in the Lehner lab, which has a major env deletion and instead 
expresses a GFP reporter (Figure 3.5A). Of note, this NL4-3GFP reporter is 
unfortunately too weak to be detected from unintegrated virus early in infection and 
therefore could not be used in the above reporter assay. 48 h post infection in the 
presence of RAL, cells were fixed and viral RNA (vRNA) was visualised by 
fluorescence in situ hybridization (FISH) (kindly performed by Raven Shah - Sarafianos 
lab). vRNA was detected at higher levels in cells infected with wild type NL4-3GFP with 
readily observed transcriptional bursts (representative image, Figure 3.5B), whereas 
fewer cells infected with Vpr deletion NL4-3GFP reached the vRNA detection limit. 
To quantify this phenotype, slides were analysed by high-content imaging evaluating 
vRNA fluorescence from 500 random cells for each condition, revealing a highly 
significant increase in the amount of vRNA detected per infected cell for WT NL4-3GFP 
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compared to ΔVpr NL4-3GFP (Figure 3.5C). Although infection levels were comparable, 
and the same number of infected cells were analysed for both conditions, a smaller 
proportion of cells met the analysis threshold for vRNA fluorescence for ΔVpr NL4-
3GFP, explaining the discrepancy in visualised datapoints in the scatterplot and further 




Figure 3.4: Unintegrated Vpr deletion NL4-3 reporter viruses have lower gene 
expression and impeded CD4 downregulation
A, Schematic representation of the NL4-3-ΔEnv-Nef-P2A-SBP-ΔLNGFR lentiviral 
reporter (NL4-3LNGFR). B, Unintegrated Vpr deletion NL4-3LNGFR reporters have 
reduced gene expression and CD4 downregulation. CEM-T4 T cells were infected with 
WT or ΔVpr NL4-3LNGFR at equal MOI with or without 1 µM RAL. Cells were stained 
with anti-LNGFR and anti-CD4 antibodies 48 h post infection and analysed by flow 
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Figure 3.5: Unintegrated Vpr deletion NL4-3 reporter viruses give rise to lower 
viral RNA levels
A, Schematic representation of the NL4-3-ΔEnv-eGFP lentiviral reporter (NL4-3GFP). 
B-C, Unintegrated Vpr deletion NL4-3GFP reporters produce less vRNA. Jurkat T cells 
were infected with WT or ΔVpr NL4-3GFP lentiviral reporters in presence of 1 µM RAL. 
48 h post infection, viral RNA was detected by FISH and analysed by fluorescence 
microscopy. Representative images in (B). For quantification, 500 cells/condition were 
analysed by high-content imaging and automated image analysis. Scatter plot in (C) 
shows integrated vRNA fluorescence per infected cell, filtered for cells with signal 
intensity ≥2xSD above background. Data is representative example of n = 2. Error 
bars represent standard deviation. ***, P < 0.001.
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3.2.4: Pandemic clade Vpr shares ability to rescue unintegrated virus expression 
Having confirmed an effect of NL4-3 Vpr in the context of full-length virus infection, I 
lastly wanted to extend my characterisation to a wider panel of HIV-1 Vpr proteins. In 
addition to Vpr from NL4-3 as a model X4 tropic virus, I therefore selected Vpr from 
the primary clinical HIV-1 isolate YU-2 as a model R5 tropic virus, both representing 
the widely studied HIV-1 clade B, which is the main genetic form circulating in Europe 
and America (Buonaguro et al., 2007). On a world-wide level, the most prevalent 
genetic strains belong to the less studied pandemic HIV-1 clade C, which dominates 
in Southern and Eastern Africa as well as India. I therefore included a representative 
Clade C clinical isolate Vpr (98BR004) in my analysis. Repeating my Vpr VLP 
unintegrated virus reporter assay, Vpr protein from all three selected HIV-1 strains 
shared the ability to increase gene expression from unintegrated virus (Figure 3.6A), 
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Figure 3.6: The ability of HIV-1 Vpr to rescue unintegrated virus gene 
expression is consistent between multiple clade model strains
A, CEM-T4 T cells were co-transduced with SFFV-GFP lentiviral reporters and either 
control VLPs (grey shaded) or Vpr VLPs (red line), as indicated, in the presence of RAL. 
GFP fluorescence was analysed by flow cytometry 48 h post infection. Histograms are 
a representative example of n = 2. 
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3.2.5: Vpr VLPs added after infection still rescue unintegrated virus expression 
In the previous sections, I have described my characterisation of the ability of Vpr to 
increase gene expression from unintegrated virus in different scenarios, including a 
replication of previously published observations. The possibility, however, remained 
that Vpr could be affecting the very initial parts of the viral life cycle, prior to viral gene 
expression, which could present as a similar phenotype to the observed. To discount 
this hypothesis, I repeated my Vpr VLP unintegrated virus reporter assay, this time 
adding Vpr VLPs 24 h or 48 h post infection with reporter virus (Figure 3.7A). Based 
on GFP fluorescence 72 h post infection, Vpr VLPs added 24 h post infection with 
reporter virus were equally potent in rescuing gene expression from unintegrated virus 
as Vpr VLPs added at the time of infection. Only a marginal effect was observed when 
Vpr VLPs were added 48 h post infection. It can thus be deducted that the effect of Vpr 
on unintegrated virus is on a later event in the viral life cycle, as reverse transcription 
and unintegrated virus DNA species formation would already be completed prior to 
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Figure 3.7: Vpr VLPs added after unintegrated reporter virus infection can still 
rescue gene expression
A, CEM-T4 T cells were transduced with SFFV-GFP lentiviral reporters in the presence 
of 1 μM RAL. Control (grey shaded) or Vpr VLPs (red line) were added either at the time 
of infection, 24 h post infection or 48 h post infection, as indicated. GFP fluorescence 
was analysed by flow cytometry 72 h post infection. Histograms are a representative 
example of n = 2. 
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3.2.6: Vpr usurps CRL4DCAF1 E3 ligase to increase unintegrated virus expression  
My next aim was to understand how Vpr can increase gene expression from 
unintegrated virus. Whilst the ability of HIV-1 Vpr to directly transactivate the HIV-1 
LTR was reported in early studies (Cohen et al., 1990; Wang et al., 1995), the plethora 
of functions later attributed to Vpr almost all involve Vpr-induced protein degradation 
(Fabryova and Strebel, 2019). Vpr recruits host proteins to a cellular E3 ligase complex 
containing CUL4, RBX1 and DDB1 (CRL4) via the adaptor protein DCAF1 (Hrecka et 
al., 2007), thereby targeting them for proteasomal degradation. I therefore wanted to 
examine if the ability of Vpr to increase unintegrated virus gene expression was 
dependent on CRL4DCAF1 activity. 
First, I repeated my Vpr VLP unintegrated virus reporter assay using Vpr carrying a 
Q65R point mutation which abrogates the interaction with DCAF1 (Le Rouzic et al., 
2007). Unlike wild type Vpr, Q65R Vpr was completely unable to increase gene 
expression from unintegrated virus (Figure 3.8A) despite being present at higher 
levels in the VLP supernatant (Figure 3.8B). This therefore provided a first indication 
of a role for CRL4DCAF1 in the Vpr-dependent increase of gene expression from 
unintegrated virus. In parallel, I also examined VLPs containing an S79A Vpr point 
mutant, which no longer causes cell cycle arrest (Zhou and Ratner, 2000). In contrast 
to Q65R Vpr, S79A Vpr retained the ability to increase gene expression from 
unintegrated virus (Figure 3.8A). This is important as it separates this Vpr function 
from the induction of cell cycle arrest, which is perhaps the best recognised function of 
Vpr. 
In order to corroborate the finding that CRL4DCAF1 activity was required for my Vpr 
phenotype, I depleted cellular DCAF1 in CEM-T4 T cells using an shRNA targeting 
DCAF1 alongside a non-targeting control shRNA. Whilst the control shRNA had no 
effect, knockdown of DCAF1 prevented upregulation of unintegrated virus expression 
by wild type Vpr (Figure 3.8C). Similarly, chemical pan-cullin inhibition using the 
neddylation inhibitor MLN4924 (Soucy et al., 2009) completely abrogated Vpr-
dependent increase of unintegrated virus expression (Figure 3.8D). Together, these 
data show a clear dependency of Vpr on both DCAF1 and cullin E3 ligase activity for 








































































































































































Figure 3.8: HIV-1 Vpr increases gene expression from unintegrated lentiviral 
reporters in a cullin-RING E3 ligase dependent manner
A, Q65R Vpr does not increase unintegrated virus expression. Unintegrated virus 
reporter assay in CEM-T4 T cells co-transduced with SFFV-GFP lentiviral reporters 
and control VLP (grey shaded) or Vpr VLPs (red line) as indicated, evaluated by flow 
cytometry 48 h post infection, Representative histograms (n = 2). B, Western blot of 
VLP supernatants. C-D, Inhibition of CRL4DCAF1 activity abrogates Vpr phenotype. 
Unintegrated virus reporter assay with SFFV-GFP lentiviral reporters and control or 
Vpr VLPs upon shRNA knockdown of DCAF1 (C) or MLN4924 chemical pan-cullin 
inhibition (D) evaluated by flow cytometry 72 h or 48 h post infection, respectively. 
Representative histograms (n = 2).
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3.3: Discussion          
Previously published work had proposed an ability of HIV-1 Vpr to increase gene 
expression from unintegrated viral genomes. In this chapter, I have robustly replicated 
and further elaborated on this observation in a series of reporter assays focusing on 
both integrated and unintegrated virus. The mechanism for the Vpr-dependent 
increase in unintegrated virus gene expression has been hitherto unknown. Here, I 
implicate the cullin E3 ligase complex CRL4DCAF1 and propose a role for degradation 
of a repressive factor via Vpr. 
 
3.3.1: Unintegrated virus reporter assay robustly replicates Vpr-dependent 
increase in gene expression  
Gene expression from unintegrated virus is known to be markedly restricted compared 
to integrated virus and has previously been shown to be enhanced by the HIV-1 
accessory protein Vpr (Poon and Chen, 2003). By developing a GFP-based 
unintegrated virus reporter assay I could readily observe increased gene expression 
from unintegrated viral reporters as evidenced by higher GFP fluorescence in the 
presence of Vpr when integration was inhibited using the HIV-1 integrase inhibitor 
raltegravir (RAL). Vpr thus effectively antagonises restriction of unintegrated virus. 
I decided to focus my studies on incoming HIV-1 Vpr by using delivery of Vpr protein, 
either in VLPs or packaged inside reporter virions. Vpr is the only accessory protein 
which is actively packaged and thus present at substantial levels in the HIV-1 virion 
(Lavallée et al., 1994). Incoming Vpr protein can therefore act immediately on the 
infected cell and is likely to play a key role early in infection, that is independent of de 
novo expression of Vpr. Both my Vpr VLP and my virion packaged Vpr reporter assays 
showed that incoming Vpr is fully capable of increasing gene expression from 
unintegrated viral reporters, in agreement with the literature. The ability of incoming 
Vpr to increase unintegrated virus expression is interesting, as it enables gene 
expression specifically from unintegrated viral genomes, providing additional 
expression of essential gene products early in the viral life cycle. 
When designing my reporter assay, I made a number of changes compared to the 
studies by Poon et al. (Poon and Chen, 2003). Firstly, whilst Poon et al. had focused 
on genetic integrase-mutant viruses, I instead replicated their observations using the 
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chemical integrase inhibitor raltegravir. Both methods of studying unintegrated virus 
are well recognised in the field and produce similar results. Whilst  it is recognised that 
these assays exhibit an increased production of 1-LTR and 2-LTR circles compared to 
a wild type infection in dividing cell types (Munir et al., 2013), they both provide a useful 
system for understanding unintegrated virus gene expression without confounding 
gene expression from an integrated genome. Secondly, I decided to use a GFP 
reporter whereas Poon et al. predominantly used luciferase reporters, which are highly 
sensitive. This allows for larger amplification, and Poon et al. show a >40-fold Vpr-
dependent increase in unintegrated virus expression. My GFP reporter system shows 
smaller differences, but circumvents some limitations of luciferase reporters. Firstly, 
luciferase reporters only allow studies at a population level and more subtle differences 
for subpopulations are lost. This also means luciferase reporters are more sensitive to 
differences in infection level between conditions (e.g. different number of uninfected 
cells), which are easily misinterpreted as differences in gene expression. Lastly, unlike 
luciferase reporters, fluorescent reporters like GFP are compatible with phenotypic 
selection by fluorescence-activated cell sorting (FACS), which will become important 
for my mechanistic dissection in the following chapters.  
In addition to developing a GFP-based unintegrated reporter assay that robustly 
replicates previously published work, I have also made some novel observations. First, 
I have extended my studies beyond Vpr from the NL4-3 model strain and shown that 
Vpr proteins from two other HIV-1 strains, YU2 and 98BR004, are also able to increase 
unintegrated virus expression (Figure 3.6). 98BR004 Vpr in particular is interesting, as 
around 50% of all HIV-1 cases worldwide are caused by clade C strains of HIV-1 
compared to the 10% caused by the more studied clade B strains (Buonaguro et al., 
2007). The unintegrated virus phenotype is thus not NL4-3 specific. Second, I 
performed a time-of-addition analysis for Vpr VLPs, which showed that Vpr VLPs 
added 24 h post infection retained full ability to increase unintegrated virus expression 
(Figure 3.7A). This contrasts with the report from Poon et al. that Vpr added 24 h post 
infection had a 4-fold smaller effect on unintegrated virus expression than VLPs added 
at the time of infected. This could reflect the greater sensitivity of the luciferase reporter 
or it could reflect differences in assay design: Poon et al. assays gene expression 2 
days post Vpr addition (and therefore on separate days for their t=0 and t=24 h VLP 
addition), whereas I chose a constant assay time point 72 h post reporter infection. 
The amount of unintegrated viral genomes that Poon et al. are trying to assay may 
thus have decreased between the two assay time points, lessening the phenotype, in 
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agreement with my own observation of gradual loss of unintegrated reporter 
expression over time (Figure 3.3, left panel). A similar explanation can be applied to 
why I observed only a marginal effect of Vpr VLP addition 48 h post infection (Figure 
3.7A). Also, for this time point I evaluated unintegrated virus expression just 24 h after 
VLP addition, during which time the Vpr protein had to both enter the cell and reverse 
unintegrated virus restriction before increased GFP transcription and translation could 
ensue. 
 
3.3.2: Integrated virus gene expression is not increased by Vpr  
A key question arising from my data is whether the mechanism of Vpr-dependent 
increase of unintegrated virus expression also affects integrated viral genomes. Poon 
et al. reported no effect of Vpr on integrated virus expression, yet, at first glance, my 
data appears internally conflicting: Vpr delivered in VLPs had a small, but reproducible 
effect on gene expression from both SFFV-GFP and LTR-Tat-GFP lentiviral reporters 
upon co-transduction in the absence of RAL (Figure 3.1). However, virion-delivered 
Vpr (Figure 3.2B) and Vpr VLPs added 3 days post infection (Figure 3.3A, right panel) 
had only negligible effects. The effect of Vpr on integrated virus was thus not 
consistent. 
One explanation might be a titration dependent effect: Vpr might only increase gene 
expression from integrated virus when Vpr protein is provided in excess (i.e. a higher 
ratio of VLPs to reporter virions) but not when delivered at more physiological levels 
inside the reporter virion. This, however, does not explain the noticeable difference in 
the integrated virus phenotype, when Vpr VLPs were added at the time of infection or 
3 days post infection (Figure 3.3, top panel, middle and right), both in the absence of 
RAL. It remains possible that the stably integrated reporter had already been silenced 
in a way that cannot be reversed by Vpr, however, a comparison between the flow 
cytometry time courses in the figure provides an interesting alternative hypothesis: 
Could the increased gene expression observed for the addition of Vpr VLPs at the time 
of infection be a result of increased gene expression from unintegrated viral genomes 
present alongside the integrated viral genome? It is well-documented that unintegrated 
viral DNA species are produced alongside integrated genome copies in infection 
(Munir et al., 2013), and so any Vpr-dependent increase in unintegrated DNA species 
gene expression should still be detectable during infection in the absence of RAL. By 
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following the GFP fluorescence over time (Figure 3.3), I observed a gradual diminution 
of the Vpr VLP phenotype for infection in the absence of RAL (Figure 3.3, middle 
panel), which followed the profile of decreased GFP fluorescence for infection with 
RAL (Figure 3.3, left panel). This will of course be partially due to turn-over of the 
delivered Vpr protein, but also reflects the loss of non-replicating unintegrated viral 
DNA species with cell division. Further evidence supporting this is the gradual 
appearance of a minor uninfected population (Figure 3.3, middle panel), which 
suggests that these cells arose from cells that previously appeared infected but in fact 
only contained unintegrated copies of the reporter, which were subsequently lost. It is 
thus probable that these unintegrated genomes were also transiently present in and 
contributed gene expression to cells containing integrated genomes. This 
phenomenon may not have been observed by Poon et al. due to a cell type specific 
difference, as most of their experiments were performed in HeLa cells. In summary, I 
do not find supporting evidence for a direct effect of Vpr on expression of integrated 
virus, and I hypothesise that effects of Vpr on gene expression from integrated 
reporters at least partially reflect increased gene expression from concomitantly 
produced unintegrated viral DNA species.  
 
3.3.3: A CRL4DCAF1-dependent but cell cycle arrest independent mechanism for 
increased unintegrated virus expression by Vpr 
To commence my mechanistic studies, I focused on a key characteristic of Vpr: The 
ability to induce host target degradation via recruitment of the CRL4DCAF1 E3 ubiquitin 
ligase complex. I repeated my unintegrated virus reporter assays with concurrent 
inhibition of CRL4DCAF1 activity (Figure 3.8) and found that it was absolutely 
indispensable for the ability of Vpr to increase gene expression from unintegrated virus. 
This conclusion was made more powerful by the fact that involvement of CRL4DCAF1 
activity could be shown both via disruptions to the virus (Q65R Vpr mutation) and 
disruptions to the cell (DCAF1 knockdown or cullin inhibition). If studied in isolation, 
the DCAF1 knockdown and cullin inhibition results would be inconclusive, as it is 
possible that CRL4DCAF1 was needed for an early event in the HIV-1 life cycle, prior to 
gene expression from unintegrated genomes. By including the Q65R Vpr data, where 
all cells are clearly infected (as evidenced by GFP expression) yet Q65R Vpr fails to 
increase gene expression, I can discount this hypothesis and connect the DCAF1 
phenotype specifically to the effect of Vpr on unintegrated virus gene expression. 
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One of the earliest and most well-established functions of Vpr is the induction of cell 
cycle arrest in G2 (Rogel et al., 1995), which was also the first function to be linked to 
recruitment of CRL4DCAF1 (Le Rouzic et al., 2007). It was therefore important to 
establish if the ability of Vpr to increase gene expression from unintegrated virus could 
be separated from the cytostatic effect. When Vpr causes cell cycle arrest, the 
decreased rate of cell division will decrease the loss of unintegrated virus genomes by 
dilution, which could phenocopy as increased gene expression. By using an S79A 
point mutant Vpr, which is known to not cause cell cycle arrest (Zhou and Ratner, 
2000), I was able to show that the Vpr phenotype for unintegrated virus is mostly 
independent  of cell cycle arrest (Figure 3.8A). Whilst the size of the Vpr-dependent 
increase of unintegrated virus expression for S79A Vpr was reduced compared to WT 
Vpr, it was importantly not completely abrogated as observed for Q65R Vpr. This may 
reflect a partial contribution of cell cycle arrest to the observed effect or a lower amount 
of delivered S79A Vpr than WT Vpr. In either case, the phenotype is not entirely 
explained by cell cycle arrest. My observation conflicts with the report by Poon et al. 
that R80A Vpr, another cell cycle arrest mutant, had no effect on gene expression from 
unintegrated virus (Poon and Chen, 2003). However, when Poon et al. chemically 
arrested cells in G1 using a thymidine block, WT Vpr still increased gene expression 
from unintegrated virus, whilst the thymidine block itself had no effect on viral gene 
expression. This data thus supports the conclusion that the ability of Vpr to increase 
unintegrated virus expression is independent of the ability to cause cell cycle arrest. It 
is also plausible that the R80A mutation not only affects cell cycle arrest but could also 
impact other Vpr functions. 
The involvement of CRL4DCAF1 in concert with my data showing a lack of phenotype 
for integrated virus further makes it unlikely that the observed phenotype is a result of 
direct transactivation of the LTR by Vpr (Wang et al., 1995). If Vpr is acting via direct 
transactivation of the LTR, then the effect on unintegrated and integrated reporters 
would likely be the same, as the same promoter elements and transcription factor 
binding sites are present in both cases. A different mechanism must be at play. Instead, 
the implication of CRL4DCAF1 suggests that Vpr-dependent increase of unintegrated 
virus expression involves degradation of a host factor. Consequently, I hypothesised 
that Vpr usurps CRL4DCAF1 to degrade a host factor which is normally repressive to 
gene expression from unintegrated HIV-1 genomes. The key question therefore 
becomes, what is this elusive Vpr target? 
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3.4: Summary 
Unintegrated lentiviral genomes have poor gene expression, indicating active 
repression by the host cell. In this chapter, I robustly replicate the previously published 
observation that the HIV-1 accessory protein Vpr can enhance gene expression from 
unintegrated virus. Using a FACS-compatible unintegrated virus reporter assay, I show 
that incoming Vpr protein packaged inside reporter virions or delivered in VLPs 
reproducibly increases gene expression from unintegrated but not integrated lentiviral 
reporters. This phenotype is shared by Vpr proteins from different pandemic clades 
and is replicated for infection with full-length virus. It does not require Vpr-induced cell 
cycle arrest but is dependent on CRL4DCAF1 E3 ligase activity. I therefore hypothesised 
that Vpr is inducing the degradation of an elusive host factor, which is normally 
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4.1: Introduction 
The experiments described in Chapter 3 revealed a dependency of Vpr on the cullin 
E3 ligase complex CRL4DCAF1 for increasing gene expression from unintegrated HIV-
1 genomes. I therefore hypothesised that Vpr mediates degradation of a repressive 
factor to antagonise restriction. The next question was clear: What is the nature of this 
host factor? Vpr has a plethora of published functions, and our own recently published 
data showed a global remodelling of the cellular proteome in the presence of Vpr 
(Greenwood et al., 2019). Taking a candidate gene approach to identifying the elusive 
Vpr target was therefore not feasible, as there were simply too many potential 
candidates. Instead, I opted to use a forward genetics approach to the problem, which 
I will describe in detail in section 4.2.1. 
Forward genetics is a collective term describing the use of unbiased methods for 
identifying genes essential for a defined biological phenotype, e.g. my observed 
unintegrated virus phenotype. The fundamental principle of a forward genetic screen 
is to introduce perturbations to gene expression in a cell population followed by 
phenotype-based isolation of a subpopulation to identify the genes responsible for the 
phenotype in question. Whilst forward genetics has been successfully exploited for 
decades in model organisms such as Saccharomyces cerevisiae (Forsburg, 2001) and 
Drosophila melanogaster (St Johnston, 2002), the application of forward genetics in 
cultured human cells was hampered by an inability to efficiently generate and recover 
bi-allelic mutants in human diploid cells. A significant breakthrough was the 
development of gene-trap retrovirus lethality screens in near-haploid KBM7 cells 
(Carette et al., 2009). Work from the Lehner group contributed to this technique by 
extending its use to fluorescence-based phenotypic selection (Duncan et al., 2012) 
with numerous subsequent successful applications from our lab (van den Boomen et 
al., 2014; Tchasovnikarova et al., 2015; Timms et al., 2013). 
Recently, forward genetics has been revolutionised by harnessing the Cas9 
endonuclease for genetic editing. In bacteria, clustered regularly interspaced short 
palindromic repeats (CRISPR) loci together with CRISPR-associated (Cas) proteins 
provide adaptive immunity against phage infections (Barrangou et al., 2007). Cas9 
from Streptococcus pyogenes (SpyCas9) is an RNA-guided DNA endonuclease which 
cleaves target DNA guided by duplexes of short CRISPR RNAs (crRNAs) and trans-
activating crRNAs (tracrRNAs) derived from the CRISPR loci (Deltcheva et al., 2011; 
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Garneau et al., 2010). Engineering of chimeric single guide RNAs (sgRNAs) allows 
reprogramming of ectopically expressed SpyCas9 to introduce blunt-ended DNA 
double strand breaks in human cells (Cong et al., 2013; Jinek et al., 2012; Mali et al., 
2013). SpyCas9 is guided by complementarity of the sgRNA sequence and target DNA 
with a downstream NGG protospacer‐adjacent motif (PAM) leading to site-specific 
cleavage of the target DNA 3 bp from the PAM sequence (Jinek et al., 2012). Ensuing 
error-prone DNA repair by non-homologous end joining (NHEJ) leads to 
insertion/deletion (indel) mutations, eventually resulting in loss of gene function. 
CRISPR-Cas9 thus provides a highly efficient means of generating bi- or even multi-
allelic gene perturbation in human cells, forming the basis for forward genetic screens. 
The development of pooled sgRNA libraries targeting all genes in the human genome 
with multiple sgRNAs per gene has allowed the use of CRISPR-Cas9 for performing 
genome-wide loss-of-function screens in human cells (Shalem et al., 2014; Wang et 
al., 2014). Phenotypic selection of rare cells within the pooled knockout population and 
subsequent identification of sgRNA sequences by next-generation sequencing (NGS) 
identifies the genetic basis for the phenotype in question. Genome-wide CRISPR-Cas9 
screens have been successfully implemented in the Lehner lab (Menzies et al., 2018; 
Tchasovnikarova et al., 2017; Timms et al., 2016) using a number of different genome-
wide sgRNA libraries including GeCKO_v2 (Sanjana et al., 2014) and the Bassik library 
(Morgens et al., 2017b) as well as an in-house constructed subgenomic ubiquitome 
library (Menzies et al., 2018). Given the expertise and available tools, I was thus 
optimally placed for using a CRISPR-Cas9 based forward genetics approach in my 
search for the host factor, which, when not targeted by HIV-1 Vpr, represses gene 
expression from unintegrated lentiviral genomes.  
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4.2: Results 
4.2.1: Designing a forward genetic approach to identifying the elusive Vpr target 
My initial data indicated the existence of an elusive Vpr target which was repressive to 
gene expression from unintegrated viral genomes. Taking a candidate gene approach 
to identifying this host factor was not feasible given the large number of putative Vpr 
targets identified in our recent proteomics study (Greenwood et al., 2019). I therefore 
opted to take a forward genetics approach to the problem. I hypothesised that if Vpr 
normally degraded a host protein that represses unintegrated virus, this could be 
phenocopied by performing CRISPR-Cas9 mediated knockout of the gene encoding 
this factor, i.e. by artificially depleting the host factor which would normally be degraded 
by Vpr. Rather than using an existing genome-wide pooled sgRNA library, I took 
advantage of our extensive knowledge of Vpr-dependent proteome changes to design 
a custom “Vpr target” sgRNA library, illustrated in Figure 4.1A. By comparing 
numerous published and unpublished proteomics datasets examining the cellular 
proteome with and without Vpr, I identified 1,217 proteins which were depleted to some 
extent by Vpr (with kind help from Dr Ed Greenwood). These formed the target basis 
for my custom Vpr library. 
Each gene was targeted by 10 independent sgRNAs to mitigate off-target effects, and 
I furthermore included 340 non-targeting control sgRNAs, yielding a total pooled library 
size of 12,510 sgRNAs. The library was split into four sub-libraries based on the Vpr 
target inclusion criteria (Figure 4.1B). Whilst the sub-library division had no practical 
importance for my subsequent CRISPR-Cas9 knockout screen, it allowed future use 
of the Vpr library for even more focused screens (e.g. only using Vpr sub-library 1) and 
furthermore provided higher cloning efficiency by reduction of the sgRNA pool sizes. 
Choosing sgRNAs with high knockout efficiency is key to construction of a high-quality 
sgRNA library. Rather than attempting my own large-scale sgRNA design, I therefore 
extracted sgRNA sequences from already published and well-validated genome-wide 
libraries (with kind help from Dr Ildar Gabaev). Most sgRNA sequences were taken 
from the Bassik Human CRISPR Knockout Library (Morgens et al., 2017b), 
supplemented with sgRNAs from the Sabatini Human CRISPR Knockout Pooled 
Library (Wang et al., 2014). 
Cloning a custom library involves large scale production of pooled lentiviral sgRNA 
expression vectors, illustrated in Figure 4.1C and described in detail in section 2.5.1. 
80
Chapter 4: A forward genetic screen implicates SLF2 in unintegrated virus restriction 
  
First, oligos containing the sgRNA sequences were designed following a previously 
published strategy (Doench et al., 2016). These adapter-flanked sgRNA sequences 
were ordered as a pooled oligo array (i), amplified by PCR (ii), and cloned into a U6 
expression vector, which also encoded BFP and a puromycin resistance gene (iii). The 
control sgRNA library pool was reused from another subgenomic library previously 
produced in the Lehner lab (Menzies et al., 2018). Finally, pooled Vpr library sgRNA 
lentivirus was produced ensuring equal representation of all sgRNAs (iv). Following 
titration of the library virus, my custom Vpr target sgRNA library was ready for use in 





Figure 4.1: Designing a custom Vpr target sgRNA library
A, Schematic of Vpr target library design rationale. 1,217 putative Vpr targets were 
identified based on Vpr-dependent depletion in multiple proteomics datasets. B, Sub-
library composition and inclusion criteria for targets in the Vpr library. C, Outline of 
library cloning process, detailed in section 4.2.1.
Identify Vpr dependent global proteome changes
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1,217 proteins depleted by Vpr
Design custom Vpr target sgRNA library
1,217 genes x 10 sgRNA/gene
 + 340 control sgRNAs    =  12,510 sgRNAs
 (i) Order pooled oligo array
(ii) PCR amplify sgRNA sub-libraries
(iii) Clone into pU6 expression vector
(iv) Package pooled lentiviral library
Library # genes Vpr target inclusion criteria Publications 
Vpr sub-library 1 105 Protein depleted at least 1 log2 (i.e. 50%) in CEM-
T4 T cells when comparing WT NL4-3 with ΔVpr 
NL4-3, or comparing Vpr VLPs with empty VLPs 
Greenwood 
et al. (2019) 
Vpr sub-library 2 261 Protein depleted at least 0.5 log2 (~30%) in CEM-
T4 T cells when comparing WT NL4-3 with ΔVpr 
NL4-3, or comparing Vpr VLPs with empty VLPs (if 
not present above) 
Greenwood 
et al. (2019) 
Vpr sub-library 3 363 Protein depleted at least 0.5 log2 (~30%) in THP-1 
cells when comparing WT YU2 with ΔVpr YU2 (if 
not present above) 
Unpublished 
dataset 
Vpr sub-library 4 488 Protein fulfilling one of the following (if not present 
above): 
A) In Greenwood et al. (2016) 'Cluster 2' following 
Vpr target depletion kinetics. 
B) Depleted by more than 0.7 log2 (~40%) in WT 
vs Mock and WT vs ΔVif dataset in Greenwood 
et al. (2016) 
C) Depleted by more than 0.7 log2 (~40%) by T/F 
or 6M CH047 strain (unpublished dataset) 
D) Annotated as Vpr target in NIH database 
Greenwood 
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4.2.2: CRISPR-Cas9 screen using custom Vpr target library  
By constructing a custom Vpr target sgRNA library, I could perform a CRISPR-Cas9 
knockout screen for factors repressing gene expression from unintegrated virus 
focusing specifically on genes that encode putative Vpr targets. The screen was 
performed following the protocol described in detail in section 2.5.2, illustrated by the 
schematic in Figure 4.2A. Briefly, Cas9-CEM-T4 T cells were transduced with “Vpr 
target library” sgRNA lentivirus (i), and sgRNA expressing cells were selected with 
puromycin, creating a pooled knockout library population. 7 days post sgRNA 
transduction, cells were co-transduced with GFP and mCherry lentiviral reporters in 
the presence of raltegravir (RAL) (ii). 3 days post infection, the top 0.5% 
GFP+/mCherry+ cells were selected by FACS to enrich for rare mutant cells in which 
we had depleted a gene that represses unintegrated virus expression (iii). To remove 
cells containing stably integrated virus which had escaped inhibition by RAL, we 
isolated the GFP-/mCherry- population by FACS (iv). Subsequently, a second round of 
GFP/mCherry reporter virus infection (v) and FACS sorting of the top 0.5% 
GFP+/mCherry+ cells (vi) was performed to achieve further enrichment. An unsorted 
pooled knockout library population was maintained for the duration of the screen (vii). 
DNA was isolated from both the FACS enriched population and the unsorted library 
population (viii) and sgRNA-containing regions sequenced (ix). 
Prior to sequencing, I wanted to confirm that my screen had successfully enriched for 
a derepressed unintegrated virus phenotype. Concurrent with the second round of 
reporter virus transduction (Figure 4.2A-v), I therefore performed an enrichment check 
by mixing BFP- WT CEM-T4 cells 1:1 with either BFP+ unsorted library cells or BFP+ 
single round enriched cells. 72 h post infection with a GFP reporter virus in the 
presence of RAL, I observed a clear increase in unintegrated virus expression for the 
FACS-enriched population when compared to WT CEM-T4 (Figure 4.2B) which was 
not seen for the unsorted library population. Following the second round of FACS 
enrichment, I therefore proceeded to isolate DNA immediately after sorting to maintain 
optimal representation of the sorted population. 
Next-generation sequencing allowed identification of sgRNA sequences by aligning 
trimmed reads to the Vpr target library with Bowtie2 followed by generation of read 
count statistics using the MAGeCK algorithm. First, I examined the coverage and 
quality of the unsorted library by making a plot of the read counts for each sgRNA in 
the Vpr target library as a fraction of the total library read counts (Figure 4.2C). The 
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plot had a flat and broad sigmoidal shape, characteristic of a high-quality library with 
even representation of sgRNAs. 96.7% of the 12,510 sgRNAs in the Vpr library were 
detected with at least 100 reads in the sequenced unsorted library population, and only 
200 sgRNAs were undetected. This confirmed successful cloning of my Vpr target 
library, which had not previously been sequenced. It also provided a high-quality 
sequenced reference library for my screen analysis. 
The MAGeCK algorithm was used to identify positive selection of sgRNAs targeting 
specific genes in the FACS enriched population when compared to the unsorted library 
population, yielding a P-value for the enrichment of each gene targeted in the library 
(Figure 4.2D). When correcting for multiple testing, one clear hit was evident above 
the significance threshold: SLF2, previously known as FAM178A (-log(P) = 4.44). SLF2 
encodes SMC5-SMC6 complex localization factor protein 2 (SLF2), a poorly 
characterised protein which has only been the subject of a single publication (Räschle 
et al., 2015). This study implicated SLF2 in DNA damage induced recruitment of the 
SMC5/6 complex to DNA lesions such as interstrand cross-links and double-strand 
breaks. However, before considering a potential link to the SMC5/6 complex, I first 
wanted to examine if SLF2 could be the Vpr target responsible for restriction of 























































Figure 4.2: Targeted CRISPR-Cas9 knockout screen implicates SMC5/6 
complex localisation factor 2 in restriction of unintegrated virus
A, Outline of CRISPR-Cas9 knockout screen, detailed in section 4.2.2. B, Enrichment 
check after 1st round of enrichment. BFP- WT CEM-T4 cells were mixed 1:1 with 
BFP+ unsorted library or pre-cleared enriched screen cells and infected with GFP 
reporter virus in the presence of RAL. Flow cytometry 3 days post infection. C, Library 
quality check. Quantification of sgRNA count in unsorted library population calculated 
as the fraction reads for each sgRNA in pooled library. D, Candidate genes essential 
for unintegrated virus silencing were identified using MAGeCK. Genes scoring above 
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4.2.3: Validation of the screen hit by CRISPR-Cas9 knockout 
I first wanted to validate a role for SLF2 in restriction of unintegrated virus expression 
in an independent cell type outside the context of the screen. I therefore established a 
Jurkat T cell line stably expressing Cas9. By transducing Cas9-Jurkat cells with a 
sgRNA expression vector, which also encoded a puromycin resistance cassette and 
expressed BFP, a mixed knockout population was enriched by puromycin selection. 
This formed the basis of my modified unintegrated virus assay (Figure 4.3A): 7 days 
post sgRNA transduction, BFP+ knockout cells were mixed 1:1 with BFP- WT Jurkat 
cells prior to infection with a GFP reporter virus in the presence of RAL, thus ensuring 
an equal MOI for comparison of the two different cell populations. Evaluating GFP 
fluorescence 72 h post infection, unintegrated virus expression was clearly increased 
following knockout of SLF2 with 3 independent sgRNAs (Figure 4.3B) but not following 
depletion of beta-2 microglobulin (β2m), an unrelated control gene (Figure 4.3C). 
Accordingly, quantification of the fold change in GFP MFI in the knockout populations 
compared to the internal WT Jurkat controls showed that knockout of SLF2 but not 
β2m significantly increased unintegrated virus expression (Figure 4.3D). I was 
therefore able to independently validate a role for SLF2 in unintegrated virus restriction 





































Figure 4.3: Validation of screen hit by CRISPR-Cas9 knockout of SLF2
A-D, CRISPR-Cas9 knockout of SLF2 increases gene expression from unintegrated 
virus. A, Unintegrated virus reporter assay. Mixed knockout population were produced 
by transduction of Cas9-Jurkat cells with an SLF2 or β2m sgRNA. 7 days post sgRNA 
transduction, BFP- WT Jurkat T cells and BFP+ mixed KO populations were mixed 1:1 
and infected with a GFP reporter virus in the presence of 1 μM RAL. Flow cytometry 
72 h post infection for KO with 3 independent SLF2 sgRNAs (B) or a β2m sgRNA 
(C). Histograms are representative example of n = 3 experiments, quantified as fold 
change GFP MFI over WT Jurkat in (D). ns, P > 0.05. *, P < 0.05. Error bars denote 
standard deviation.
SFFV-GFP
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4.2.4: Unintegrated virus expression is increased in an SLF2 knockout clone 
To more rigorously show the involvement of SLF2 in unintegrated virus restriction, I 
decided to isolate a clonal SLF2 knockout cell line. To this end, I transduced Cas9-
Jurkats with an SLF2 targeting sgRNA in the presence of raltegravir to prevent stable 
sgRNA integration, which would result in a puromycin resistant population and thus 
prevent future use of puromycin resistant constructs in this cell line. Single cell clones 
were isolated by FACS, expanded, and screened for loss of SLF2 by western blotting. 
This was a laborious task, and screening of ~100 clones yielded just one viable clone 
with no detectable SLF2 expression. The challenge was expected, as SLF2 had 
previously been identified as essential to fitness of haploid KBM7 and HAP1 cells in a 
series of unbiased insertional mutagenesis screens (Blomen et al., 2015). 
I confirmed biallelic gene disruption in my SLF2 knockout clone by Sanger sequencing 
of the SLF2 sgRNA target exon (Figure 4.4A). The exon was first amplified in a nested 
PCR reaction and TOPO cloned, which allowed sequencing of individual alleles. By 
sequencing 10 TOPO colonies, I identified two representative alleles which both 
carried frame-shift inducing insertions (marked in red) in the SLF2 sgRNA target 
region, just upstream of the protospacer adjacent motif (PAM) which enables the Cas9-
mediated cleavage. The SLF2 knockout clone had completely lost SLF2 protein 
expression as assessed by western blot (Figure 4.4B), however, this could be restored 
to wild-type levels by complementation of the SLF2 knockout clone with an untagged 
full-length SLF2 cDNA. 
I repeated my unintegrated virus reporter assay, this time mixing a previously 
established BFP+ WT Jurkat cell line with my BFP- SLF2 knockout clone with or without 
SLF2 cDNA complementation (Figure 4.5A). The SLF2 knockout clone showed a clear 
increase in unintegrated virus expression compared to WT Jurkat (Figure 4.5B), 
indicating a loss of unintegrated virus restriction, which was fully restored upon 
complementation with the SLF2 cDNA. Quantification of the fold change in GFP MFI 
over wild type Jurkat showed a highly significant increase in unintegrated virus 
expression upon SLF2 knockout (Figure 4.5C) but not after complementation of the 
knockout clone with SLF2 cDNA. Whilst this phenotype was highly reproducible for 
infection in the presence of RAL, I observed no phenotype for infection in the absence 
of RAL (Figure 4.5D). Knockout of SLF2 thus significantly increases expression from 
unintegrated, but not integrated lentiviral reporters, mirroring my previous 
characterisation of the Vpr-induced phenotype.  
88
A
Figure 4.4: Validation of SLF2 knockout clone by Sanger sequencing and 
immunoblotting
A, Sanger sequencing of SLF2 sgRNA target exon. Organisation of the human SLF2 
gene. Sequence of sgRNA target locus on exon 5 is shown with the PAM sequence 
underlined. To confirm biallelic gene disruption in the isolated clonal SLF2 knockout 
cell line, the target exon was amplified from isolated genomic DNA, TOPO cloned, and 
analysed by Sanger sequencing. Sequencing tracks representative of the two alleles 
identified among 10 sequenced TOPO clones are shown with frameshift inducing indels 
highlighted. B, Western blot confirming loss of SLF2 in knockout clone. Lysates from 
WT Jurkat, clonal SLF2 knockout cells, and clonal SLF2 knockout cells complemented 
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Figure 4.5: A clonal SLF2 knockout cell line has increased unintegrated but not 
integrated virus expression
A-C, Unintegrated virus expression is increased in an SLF2 KO clone and silencing 
restored by SLF2 cDNA complementation. A, Unintegrated virus reporter assay. BFP+ 
WT Jurkat T cells were mixed 1:1 with BFP- SLF2 KO clone cells or BFP- full-length 
SLF2 cDNA complemented SLF2 KO clone cells. Cells were infected with a GFP 
reporter virus in the presence of 1 μM RAL and analysed by flow cytometry 72 h post 
infection (B). Histograms representative example of n = 3, quantified as fold change 
in GFP MFI over WT Jurkat infection in (C). ***, P < 0.001. ns, P > 0.05. Error bars 
represent standard deviation. D, Integrated virus expression is not increased in an 
SLF2 KO clone. WT Jurkat T cells and SLF2 KO clone cells were infected with a 
GFP reporter in the presence or absence of RAL. Flow cytometry 72 h post infection. 
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4.2.5: Endogenous SLF2 is rapidly degraded by HIV-1 Vpr via CRL4DCAF1 
My forward genetic screen, which implicated SLF2 in unintegrated virus restriction, 
was focused on putative Vpr targets via my custom library design. Consequently, I next 
wanted to validate that Vpr could degrade SLF2 in a CRL4DCAF1 dependent manner. I 
therefore transduced CEM-T4 T cells with control VLPs, WT Vpr VLPs or DCAF1 
binding mutant Q65R Vpr VLPs in the presence or absence of the pan-cullin inhibitor 
MLN4924 (Figure 4.6A). 24 h post transduction, cell lysates were analysed by western 
blot (Figure 4.6B). In the presence of Vpr VLPs, SLF2 was completely depleted but 
remained unchanged in the presence of control VLPs or Q65R Vpr VLPs. Pre-
incubation with MLN4924 completely rescued SLF2 from depletion by WT Vpr VLPs. 
In concert, this shows a CRL4DCAF1-dependent depletion of SLF2 in the presence of 
HIV-1 Vpr. 
In our proteomics study defining the Vpr-dependent changes to the cellular proteome, 
we found that direct Vpr targets were already significantly depleted 6 h post addition 
of Vpr VLPs (Greenwood et al., 2019). I therefore looked at the time scale for depletion 
of SLF2 by Vpr. I transduced CEM-T4 T cells with WT Vpr VLPs in the presence or 
absence of MLN4924 and harvested cell lysates at 0, 2, 4, 6, or 8 h post transduction 
for analysis by western blot (Figure 4.6C). In the absence of MLN4924, Vpr-dependent 
depletion of SLF2 could already be observed 4 h post transduction, which gradually 
increased to a complete loss of SLF2 8 h post transduction. Again, SLF2 was rescued 
in the presence of MLN4924. Whilst the β-actin loading control was suboptimal, the 
temporal dynamics of SLF2 depletion were clear. The rapid cullin E3 ligase dependent 






Figure 4.6: HIV-1 Vpr rapidly degrades SLF2 in a CRL4DCAF1 dependent manner
A-B, SLF2 is depleted by Vpr via CRL4DCAF1. A, CEM-T4 T cells were transduced 
with control VLPs, WT Vpr VLPs or Q65R Vpr VLPs with or without 1 µM MLN4924. 
Cell lysates were harvested 24 h post transduction and analysed by western blot (B). 
Representative blot (n = 2). C, SLF2 degradation by Vpr is rapid. CEM-T4 T cells 
were transduced with WT Vpr VLPs with or without 1 µM MLN4924, and lysates were 
harvested 0, 2, 4, 6 or 8 h post transduction followed by analysis by western blot. 
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4.2.6: The ability of Vpr to degrade SLF2 is evolutionarily conserved 
The Vpr protein is found in all primate lentiviruses (Tristem et al., 1998), and some key 
Vpr functions are conserved across lineages, such as the induction of cell cycle arrest 
(Planelles et al., 1996). We previously found that whilst Vpr from HIV-1 and the closely 
related SIVcpz induced global changes to the cellular proteome, Vpr proteins from 
other lineages showed a less global set of changes (Greenwood et al., 2019). To 
establish if depletion of SLF2 was an evolutionarily conserved function of Vpr, I 
selected a diverse panel of primate lentiviral Vpr proteins. Protein sequence alignment 
of the selected Vpr proteins using Clustal Omega revealed some degree of sequence 
conservation with key residues maintained in all lineages (e.g. Q65 required for DCAF1 
interaction) (Figure 4.7A). The evolutionary relationship of the included primate 
lentiviruses was demonstrated in a neighbour joining tree based on the Vpr protein 
alignment (Figure 4.7B), e.g. reflecting the different cross-species transmission origins 
of HIV-1 (from SIVcpz) and HIV-2 (from SIVsmm) and identifying the Vpr proteins from 
SIVmus and SIVagm as more highly divergent from HIV-1 Vpr (Sharp and Hahn, 
2011). 
The packaging of Vpr protein into the virion depends on an interaction with the Gag 
precursor (Lavallée et al., 1994), and the production of Vpr VLPs from primate 
lentiviruses other than HIV-1 would therefore require their cognate Gag proteins and 
individual optimisation of VLP production. Whilst chimeric gag proteins have been 
designed for packaging of Vpr across lineages by introducing the minimal Vpr 
packaging motif from SIV gag into HIV-1 gag (Sunseri et al., 2011), these remain poor 
at packaging Vpr from most species in our hands. Therefore, I decided to examine the 
effect of de novo produced primate lentiviral Vpr on endogenous SLF2 in human cells. 
Jurkat T cells were transduced with Vpr-encoding lentiviral constructs carrying a GFP 
selection marker. 48 h post transduction, GFP+ Vpr expressing cells were isolated by 
FACS, and cell lysates analysed by western blot (Figure 4.7C). Compared to cells 
transduced with the empty control vector, SLF2 was significantly depleted for all 
included Vpr constructs. The ability of Vpr to degrade SLF2 is thus evolutionarily 
conserved within the primate lentiviral lineage, demonstrating an in vivo selective 
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Figure 4.7: The ability of Vpr to degrade SLF2 is evolutionarily conserved in 
primate lentiviruses
A-B, Primate lentiviral Vpr proteins show sequence conservation. A, Protein sequences 
of Vpr from 7 different primate lentiviruses were aligned using Clustal Omega and 
the alignment was visualised in JalView. Sequence conservation is represented by 
colour shading according to percentage identity at each position. B, Phylogenetic 
tree of primate lentiviruses based on Vpr protein sequence alignment. The tree 
was constructed using neighbour joining by BLOSUM62 in JalView. C, Vpr ability to 
degrade SLF2 is evolutionarily conserved. Jurkat T cells were transduced with a panel 
of lentiviral Vpr constructs, and Vpr expressing cells isolated by GFP+ FACS 48 h post 
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4.2.7: Knockout of SLF2 reduces the effect of HIV-1 Vpr on unintegrated virus 
Having implicated SLF2 in unintegrated virus restriction and confirmed Vpr-dependent 
depletion of SLF2, I next wanted to link the two. I hypothesised that if degradation of 
SLF2 in the presence of Vpr contributes to the ability of Vpr to increase gene 
expression from unintegrated virus, then Vpr should have a reduced effect on 
unintegrated virus expression in SLF2 knockout cells compared to wild-type cells. I 
therefore repeated my Vpr VLP unintegrated virus assay in WT and SLF2 KO Jurkat T 
cells (Figure 4.8A). Whilst Vpr VLPs readily increased gene expression from 
unintegrated virus in WT Jurkat cells, mirroring my observations in CEM-T4 T cells, the 
Vpr-induced increase of unintegrated virus expression was markedly reduced in SLF2 
knockout cells. The small remaining effect of Vpr on unintegrated virus expression in 
SLF2 knockout cells was not surprising given the multifaceted nature of Vpr function. 
Quantification of the fold change in GFP MFI in the presence of Vpr VLPs compared 
to control VLPs showed a highly significant decrease in the ability of Vpr to enhance 
expression from unintegrated virus in SLF2 knockout cells (1.84 vs. 4.26-fold increase 
compared to control VLPs). Degradation of SLF2 thus constitutes the main component 







Figure 4.8: The ability of Vpr to increase unintegrated virus gene expression is 
partially lost upon SLF2 knockout
A-C, SLF2 KO reduces Vpr-dependent increase of unintegrated virus gene expression. 
A, Unintegrated virus reporter assay. WT Jurkat or SLF2 KO clone cells were co-
transduced with GFP reporter lentivirus and either control VLPs or Vpr VLPs in the 
presence of RAL. Analysis by flow cytometry 48 h post infection (B). Grey shaded: 
Control VLPs. Red line: Vpr VLPs. Representative histogram of n = 3 experiments, 
quantified in (C) as the fold change in GFP MFI upon addition of Vpr VLPs compared 
to control VLPs. Error bars represent standard deviation. **, P < 0.01.
Vpr Vpr VLP SFFV-GFP
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4.2.8: SLF2 knockout increases gene expression from unintegrated NL4-3 virus 
Finally, I wanted to examine the effect of SLF2 knockout on infection with full-length 
lentiviral reporters to replicate my findings for the effect of Vpr deletion on gene 
expression of unintegrated reporters (Chapter 3.2.3). First, I used the NL4-3LNGFR 
reporter in which cell surface staining for LNGFR reflects nef gene expression. BFP+ 
WT Jurkat cells were mixed 1:1 with BFP- SLF2 knockout cells and infected together 
with either WT or ΔVpr VSV-G pseudotyped NL4-3LNGFR reporter virus at a low MOI in 
the presence or absence of RAL (Figure 4.9A), kindly performed by Dr Adi Naamati. 
48 h post infection, cells were stained for LNGFR and analysed by flow cytometry 
(Figure 4.9B). Focusing on the top left panel, the expression of unintegrated ΔVpr 
NL4-3LNGFR was clearly increased in the BFP- SLF2 KO cells compared to the BFP+ 
WT Jurkat T cells. Conversely, no difference was seen between WT and SLF2 KO 
cells for the infection with unintegrated WT NL4-3LNGFR (top right panel), where Vpr will 
degrade the SLF2 present in WT cells. Focusing on the lower panels, SLF2 knockout 
did not affect gene expression of integrated NL4-3LNGFR, in agreement with my 
observations for the GFP reporter viruses (Figure 4.5D). Knockout of SLF2 thus 
specifically increased gene expression of unintegrated ΔVpr NL4-3LNGFR reporters, 
acting as compensation for Vpr deletion. 
To corroborate this finding, we repeated the viral RNA (vRNA) FISH experiments using 
the NL4-3GFP reporter (kindly performed by Raven Shah). Here, WT Jurkat T cells or 
SLF2 knockout cells were infected with ΔVpr NL4-3GFP at a high MOI in the presence 
of RAL. 48 h post infection, cells were fixed, and vRNA was visualised by FISH followed 
by high-content imaging. vRNA fluorescence was quantified for 500 random cells for 
each condition, revealing a highly significant increase in the amount of vRNA detected 
per infected cell in SLF2 KO compared to WT Jurkat cells (Figure 4.10A). SLF2 
knockout thus rescued viral RNA production from ΔVpr NL4-3GFP. Next, SLF2 knockout 
cells were infected with either WT or ΔVpr NL4-3GFP, again in the presence of RAL, 
followed by vRNA FISH analysis. Here, there was no significant Vpr-dependent 
difference in detected vRNA levels, in agreement with the reduced effect of Vpr VLPs 
on unintegrated virus reporter expression (Figure 4.8A). My data supporting the 
implication of SLF2 in restriction of expression from unintegrated lentiviral reporters 
was therefore readily replicated for infection with full-length NL4-3 virus. 
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Figure 4.9: SLF2 knockout rescues gene expression from unintegrated Vpr 
deletion NL4-3 reporter viruses
A-B, SLF2 knockout increases expression from unintegrated ΔVpr NL4-3LNGFR. A, 
BFP+ WT Jurkat cells and BFP- SLF2 KO Jurkat cells were mixed 1:1 and infected 
at low MOI with WT or ΔVpr NL4-3LNGFR with or without RAL. Cells were stained with 









































































































Figure 4.10: Unintegrated Vpr deletion NL4-3 reporter viruses give rise to 
increased viral RNA levels upon knockout of SLF2
A, Unintegrated ΔVpr NL4-3GFP reporters produce more viral RNA upon SLF2 knockout. 
WT or SLF2 KO Jurkat T cells were infected with ΔVpr NL4-3GFP in presence of RAL. 
48 h post infection, vRNA was detected by FISH and quantified by automated image 
analysis. Scatter plot shows integrated vRNA fluorescence per infected cell, filtered for 
cells with signal intensity ≥2xSD above background. Data is representative example 
(n = 2). Error bars represent standard deviation. ***, P < 0.001. B, Viral RNA levels 
do not differ significantly upon Vpr deletion in SLF2 knockout cells. SLF2 KO Jurkat 
T cells were infected with WT or ΔVpr NL4-3GFP in the presence of RAL. Viral RNA 
was detected by FISH 48 h post infection and quantified as described for (A). Data is 
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4.3: Discussion          
In Chapter 3, I characterised the ability of HIV-1 Vpr to increase gene expression from 
unintegrated viral genomes via CRL4DCAF1 and proposed a role for degradation of a 
repressive factor by Vpr. Here, I uncovered the nature of this factor, SLF2, by 
performing a CRISPR-Cas9 knockout screen using a custom Vpr target sgRNA library. 
I validated the role for SLF2 in restriction of unintegrated virus gene expression outside 
the context of the screen, and I showed rapid, CRL4DCAF1-dependent degradation of 
SLF2 by Vpr. I thus present SLF2 as a novel Vpr target involved in restriction of 
unintegrated virus. The mechanism of restriction remains to be determined. 
 
4.3.1: A subgenomic sgRNA library enables identification of novel Vpr targets 
My forward genetic screen was successful in identifying the involvement of SLF2 in 
restriction of gene expression from unintegrated virus. Not only could I validate the 
SLF2 knockout phenotype, I could also link it to the effect of Vpr. Interestingly, SLF2 
is found in Vpr sub-library 1, which is composed of just 105 genes fulfilling my most 
stringent inclusion criteria for putative Vpr targets based on our own NL4-3 Vpr 
proteomics data (Figure 4.1C). I would thus have been able to perform my screen 
using only Vpr sub-library 1 alongside the control library, which could have provided 
even more powerful statistics. However, this approach would have risked excluding 
the target of interest. Of note, Vpr sub-library 1 contains the majority of published Vpr 
targets, including HLTF (Hrecka et al., 2016; Lahouassa et al., 2016), MCM10 (Romani 
et al., 2015), MUS81 (Laguette et al., 2014), TET2 (Lv et al., 2018), and ZGPAT 
(Maudet et al., 2013), thus further supporting SLF2 as a bona fide Vpr target.   
My screen was based on the hypothesis that degradation of a host target by Vpr could 
be phenocopied by CRISPR-Cas9 knockout of the same factor. Through my screen 
and subsequent validation of both the SLF2 knockout phenotype and its Vpr target 
status, I show the validity of this approach and highlight its potential application to 
similar questions. Remodelling of the host cell proteome is a common strategy for 
viruses with vastly different life cycles, and large-scale proteomics resources are 
becoming available for many viruses including human cytomegalovirus (Nightingale et 
al., 2018; Weekes et al., 2014), BK polyomavirus (Caller et al., 2019), and vaccinia 
virus (Soday et al., 2019) in addition to our own extensive HIV-1 datasets (Greenwood 
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et al., 2016, 2019; Matheson et al., 2015). Whilst these proteomics datasets are 
informative in their own right, it would be interesting to explore how subgenomic library 
construction and forward genetic screens could contribute to harnessing their full 
potential in advancing our understanding of viral life cycles.  
The use of focused, subgenomic libraries has several advantages. Firstly, it enables a 
more cost-effective screen setup where smaller amounts of reagents and cell numbers 
are needed to achieve the minimal 150-fold coverage of the total pooled library size 
(e.g. 1.8 x 106 cells for a 12,500 sgRNA focused library vs. 32.7 x 106 cells for a 
218,000 sgRNA genome-wide library). This also means that scaling up to a higher 
library coverage (e.g. >1,000-fold) is achievable without excessive costs for sorting 
and sequencing, yielding high-quality datasets. Secondly, smaller library sizes 
increase statistical power due to the reduced factor required for multiple testing 
correction, e.g. a 1/1250 vs. 1/21800 factor for Bonferroni correction of P-values in a 
Vpr target or genome-wide library screen, respectively. This is particularly 
advantageous for knockouts of genes leading to intermediate phenotypes or 
associated with reduced fitness and outgrowth issues. Although powerful, focused 
libraries are most useful when exploring a narrower hypothesis such as ‘which Vpr 
target is responsible for restriction of unintegrated virus’ (Vpr library, this thesis) or 
‘which ubiquitin ligase contributes to HMG-CoA reductase degradation in the absence 
of RNF145’ (ubiquitome library, Menzies et al., 2018). Here, in addition to the inherently 
increased statistical significance, the screens benefit from being able to focus on the 
exact gene group of interest. Formulation of such narrow hypotheses requires more 
previous knowledge of the system, contrasting with predominantly explorative screen 
designs. Focused and genome-wide sgRNA libraries therefore constitute 
complementary resources in the CRISPR-Cas9 mediated revolution of forward 
genetics. 
My Vpr library will provide an important tool for the field of HIV-1 research, as it can 
also be used to uncover the basis for other enigmatic Vpr phenotypes. One such 
example is the much debated G2/M cell cycle arrest phenotype, which has already 
been proposed to be caused by Vpr-mediated degradation of MUS81 and activation of 
the SLX4 complex by (Laguette et al., 2014), degradation of MCM10 (Romani et al., 
2015), or activation of the NF-κB pathway (Liang et al., 2015). Whilst these pathways 
may all play a role, an unbiased Vpr target library screen would provide more 
comprehensive insight into the question, provided that a suitable FACS-compatible 
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reporter system could be established. Upon publication of the manuscript based on the 
data presented in this thesis, the Vpr library will be made available to the research 
community, where it will hopefully contribute even further to enriching our 
understanding of the multifunctional nature of Vpr. 
 
4.3.2: Discrepancy between clonal and mixed population knockout phenotypes  
Whilst knockout of SLF2 readily revealed an unintegrated virus phenotype, the size of 
the phenotype differed noticeably between the mixed knockout population (1.79 fold 
increase in GFP MFI over WT; Figure 4.3D) and the clonal SLF2 knockout cell line 
(3.35 fold increase in GFP MFI over WT; Figure 4.5C). The latter corresponding more 
closely to the 3.68-fold increase I observed for addition of Vpr (Figure 3.1C) and thus 
would expect to phenocopy by SLF2 knockout. This discrepancy is not surprising, as 
the phenotype of a mixed knockout population is entirely dependent on the efficiency 
of the knockout. One component of this is the sgRNA target efficiency, which is made 
up of numerous factors including the ability of a sgRNA sequence to stimulate Cas9 
cleavage, sgRNA secondary structure, PAM sequence preference, and nucleosome 
positioning at the target site (Doench et al., 2016; Horlbeck et al., 2016; Liu et al., 
2016). As the size of the SLF2 mixed knockout phenotype is consistent between three 
independent sgRNAs, poor sgRNA efficiency is an unlikely explanation. Secondly, 
Cas9 efficiency varies between cell types, and empirical evidence from our lab 
suggests poor Cas9 efficiency in Jurkat T cells, where even our highly efficient β2m 
sgRNA only gives ~70% depletion of cell surface MHC class I, compared to ~95% in 
HeLa cells which support high Cas9 efficiency. This could potentially result from poor 
Cas9 expression in some cell types or lower expression of host factors required for 
Cas9 activity. Lastly, reduced phenotypes of mixed knockout populations can ensue if 
the knockout confers a growth disadvantage. Puromycin selection can only enrich for 
cells which have received an sgRNA, and thus the mixed knockout population is made 
up of A) cells with successful gene disruption and B) cells which carry the sgRNA yet 
have no debilitating gene disruption (e.g. carrying a 3 bp in-frame indel). The latter 
subpopulation is essentially wild type and can outgrow cells with successful knockout. 
SLF2 has been identified as essential to fitness of haploid KBM7 and HAP1 cells in an 
insertional mutagenesis screen (Blomen et al., 2015), but is currently defined as a non-
essential gene in the DepMap Consortium based on the Project Achilles genome-scale 
CRISPR screens (Dempster et al., 2019). Whilst the essentiality of SLF2 is not clear 
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in all cell types, it still supports a potential lack of fitness for SLF2 knockout cells with 
resulting outgrowth in mixed knockout populations. I routinely observed this throughout 
my project, where a mixed SLF2 knockout population would give a consistent 
phenotype if infected on day 7 post sgRNA transduction (empirically the time required 
to knockout an average gene) yet had lost the phenotype if infected on day 10, i.e. the 
knockout cells had been outgrown by WT cells by this time. As a result, the majority of 
the data presented in this thesis has been produced using my clonal SLF2 knockout 
cell line, which maintains a stable and more representative SLF2 knockout phenotype. 
It is good practice to isolate multiple clonal knockout cell lines to confirm that the 
observed phenotype is not a clonal effect. However, reflecting the potential essentiality 
discussed above, the isolation of SLF2 knockout clones was not straightforward. Whilst 
our initial screening of clonal cell lines by western blot identified four promising 
candidates, one clone did not survive expansion and another two had small residual 
levels of SLF2 revealed by long (>1 h) exposure of the western blots with extended 
duration ECL substrate. In the absence of another SLF2 clone, however, the full 
functional complementation with SLF2 cDNA makes a clonal artefact highly unlikely.  
 
4.3.3: Is SLF2 a direct Vpr target? 
A central criticism to new proposed Vpr targets is that they could be indirect effects of 
degradation of another direct Vpr target. My Vpr target library was based on the global 
remodelling of the cellular proteome that we have previously reported (Greenwood et 
al., 2019) and thus does not exclusively include validated direct Vpr targets. In our 
proteomics paper, the question of direct Vpr targets was approached by inclusion of 
stringent additional proteomics experiments including co-immunoprecipitation with 
3xHA-tagged Vpr, to show protein interaction, and a pulsed SILAC experiment, to show 
rapid protein turnover upon addition of Vpr. SLF2 was not detected in either of these 
experiments, however, nor were a number of well-validated Vpr targets including 
MCM10, TET2, and UNG. Thus, the stringent approach clearly underestimates the real 
number of direct Vpr targets. I therefore decided to mimic the pulsed SILAC experiment 
by looking at the time course of SLF2 degradation by Vpr on a western blot (Figure 
4.6C). The rapid nature of the SLF2 degradation makes an indirect effect unlikely, 
when SLF2 depletion is already visible 4 h post addition of Vpr VLPs. In the 
aforementioned pulsed SILAC experiment, only a small subset of Vpr-dependent 
changes to the proteome could be detected by 6 h, compared to the global remodelling 
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observed at 24 h, and these rapid early changes were defined as direct Vpr targets. In 
addition, my observation that the ability of Vpr to degrade SLF2 is evolutionarily 
conserved among primate lentiviruses is strong evidence in support of SLF2 being a 
direct Vpr target, as an indirect effect is unlikely to be maintained under in vivo 
selection. This observation is reflected in our proteomics study, where global proteome 
remodelling with associated numerous indirect effects was only observed for HIV-1 
and the closely related SIVcpz but not the other tested primate lentiviral Vpr proteins, 
which, in my hands, still had the ability to degrade SLF2. SLF2 is thus likely to be a 
direct Vpr target, albeit this could be more formally shown by co-immunoprecipitation 
of SLF2 with Vpr or detection of Vpr-induced ubiquitination of SLF2. 
 
4.3.4: A residual Vpr phenotype in SLF2 knockout cells 
Whilst I could confirm a role for SLF2 in unintegrated virus restriction and identify SLF2 
as a Vpr target, a key question was whether these two observations could be formally 
linked. In essence, does degradation of SLF2 by Vpr fully explain the unintegrated 
virus phenotype? The contribution of SLF2 degradation to the Vpr phenotype could be 
easily estimated by comparing the effect of Vpr on unintegrated virus expression in 
SLF2 KO cells and WT cells. If SLF2 degradation was alone responsible, Vpr should 
have no effect on unintegrated virus expression in SLF2 KO cells. Whilst the effect of 
Vpr was much reduced in SLF2 KO cells, I observed a small residual Vpr phenotype 
for my lentiviral reporters (Figure 4.8) and for full-length NL4-3LNGFR (Figure 4.9, top 
panels, compare infection of SLF2 KO with ΔVpr and WT NL4-3LNGFR, i.e. left and 
right). Whilst the MOI in the latter experiment was imperfectly matched between the 
ΔVpr and WT NL4-3LNGFR infections (28.1% vs. 37.8% LNGFR+ cells), it appeared to 
support a similar tendency. In contrast, my vRNA FISH experiment (Figure 4.10B) 
showed no significant difference between ΔVpr and WT NL4-3GFP in SLF2 KO cells. 
Thus, there appears to be a residual phenotype in SLF2 knockout cells which may not 
be reflected in vRNA levels. Although SLF2 may be responsible for the specific 
restriction of unintegrated virus, the multifunctional nature of Vpr makes it likely that 
other functions, which are not necessarily unintegrated virus specific, could also impact 
on expression, e.g. LTR transactivation or cell cycle arrest. The latter option is 
interesting in the context of my previous observation that cell cycle arrest mutant S79A 
Vpr has a reduced unintegrated virus phenotype compared to WT Vpr (Figure 3.8A), 
indicating that the unintegrated virus Vpr phenotype may consist of both a cell-cycle 
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dependent and a cell cycle independent component, which I hypothesise is mediated 
by SLF2. This could be tested by examining the effect of S79A Vpr in SLF2 KO cells. 
Additionally, the genetic basis for the SLF2-independent unintegrated virus phenotype 
could be explored by repeating the Vpr target library screen in an SLF2 knockout clone. 
Nevertheless, it is clear that SLF2 plays a central role in the specific restriction of 
unintegrated virus, which is antagonised by Vpr. 
 
4.4: Summary 
Restriction of gene expression from unintegrated virus is antagonised by HIV-1 Vpr 
through degradation of a host target protein. In this chapter, I describe a forward 
genetic approach to identifying this elusive Vpr target by cloning a custom Vpr target 
sgRNA library. Using this library in a CRISPR-Cas9 knockout screen, I implicate 
SMC5-SMC6 complex localization factor protein 2 (SLF2) in restriction of gene 
expression from unintegrated virus. I validate this by mixed population knockout of 
SLF2 and isolation of a clonal knockout cell line showing increased unintegrated but 
not integrated virus gene expression from both lentiviral reporters and full-length NL4-
3 virus. I show that incoming HIV-1 Vpr protein rapidly degrades SLF2 in a CRL4DCAF1 
dependent manner and that this is an evolutionarily conserved ability among primate 
lentiviruses. Finally, I show that degradation of SLF2 forms the main basis for the effect 
of Vpr on unintegrated virus expression, as this is significantly reduced upon SLF2 
knockout. I thus identify SLF2 as a hitherto unknown Vpr target implicated in restriction 
of unintegrated lentiviral genomes. In the following chapters, I will focus on examining 
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5.1: Introduction 
A central role for viral accessory proteins is to subvert innate restriction of the viral life 
cycle and, in turn, modulate the host cell environment to support successful production 
of progeny virions. Increasing our understanding of viral antagonism therefore provides 
important clues to the defence strategies of human cells. In Chapter 4, I described a 
forward genetics approach which identified SMC5-SMC6 complex localization factor 
protein 2 (SLF2) as a novel host target for HIV-1 Vpr, and I implicated SLF2 in 
restriction of gene expression from unintegrated lentiviral genomes. The follow-up 
questions were clear: What is the basis for this restriction, and does it involve the 
SMC5/6 complex? Before proceeding, I will therefore first provide an introduction to 
the enigmatic SMC5/6 complex and its functions in ensuring genome integrity. 
 
The shared architecture of SMC complexes. The SMC5/6 complex belongs to the 
family of structural maintenance of chromosomes (SMC) complexes, which play 
essential roles in regulating and maintaining the molecular architecture of 
chromosomes (Aragón, 2018). Three SMC complexes are conserved from yeast to 
humans: Cohesin (SMC1/3), condensin (SMC2/4), and the SMC5/6 complex. Whilst 
the importance of cohesin in sister chromatid adhesion (Michaelis et al., 1997) and of 
condensin in mitotic chromosome compaction (Hirano et al., 1997) has been widely 
recognised for decades, the SMC5/6 complex remains less well known and its roles 
enigmatic. The basic architecture is conserved from ancestral SMC complexes still 
found in bacteria and is shared between all three eukaryotic SMC complexes: A central 
trimer is formed by bridging of two SMC proteins by a kleisin protein, thus creating a 
characteristic ring-like structure (Uhlmann, 2016) (Figure 5.1A). Each SMC protein 
constitutes an “arm” in the ring consisting of an intramolecular antiparallel coiled coil 
structure formed through folding at the flexible hinge region (Melby et al., 1998) (Figure 
5.1B). This brings the N- and C-terminal globular domains within the same SMC 
protein together to form an ATP-binding cassette (ABC) type ATPase domain (Löwe 
et al., 2001) termed the “head”, and the two SMC proteins heterodimerise through 
ATP-dependent interaction at both the ATPase head and hinge regions (Haering et al., 
2002; Lammens et al., 2004). The ATPase domain enables molecular motor activity, 
meaning that the SMC protein complexes can translocate DNA in an ATP-dependent 




















Figure 5.1: The architecture of the SMC5/6 complex
A, Schematic of the three eukaryotic SMC complexes (S. pombe nomenclature). B, 
SMC protein domain structure. C, Table summarising SMC5/6 complex composition 
and nomenclature in H. sapiens, S. pombe, and S. cerevisiae. Previously used protein 
names are shown in parenthesis. The last column contains notes on protein function. 
D, Schematic of DNA damage induced recruitment of the human SMC5/6 complex as 
proposed by Räschle et al. (2015).
H. sapiens S. pombe
SMC5 Smc5 (Spr18) SMC protein, ATPase domain
SMC6 Smc6 (Rad18) SMC protein, ATPase domain
NSMCE1 Nse1 RING domain E3 ubiquitin ligase
NSMCE2 Nse2 E3 SUMO-protein ligase
NSMCE3 Nse3 Enhances NSMCE1 activity (MAGE domain)
NSMCE4 Nse4 (Rad62) Kleisin
? / SLF1 Nse5 Binds SUMO
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complex activities (addressed further in Chapter 6). The kleisins consist of two globular 
domains binding the SMC protein heads, joined by a variable linker, and are defined 
by their shared ability to bridge the SMC ring, hence deriving their name from the Greek 
word “kleisimo” meaning closure (Schleiffer et al., 2003). Additional associated non-
SMC subunits contribute essential functions specific to each complex. 
 
The yeast SMC5/6 holocomplex. The SMC5/6 complex was first discovered in 
S. pombe by affinity purification of a high-molecular-weight complex interacting with 
the orphan SMC protein Smc6 (then called Rad18) (Fousteri and Lehmann, 2000). 
Further elucidation in both S. Pombe and S. cerevisiae revealed that this was an 
octameric complex containing six non-SMC elements (Nse1-6) in addition to the 
central SMC proteins Smc5 and Smc6 (Pebernard et al., 2006; Sergeant et al., 2005; 
Zhao and Blobel, 2005). Smc5 and Smc6 interact at their hinge domains (Sergeant et 
al., 2005) and whilst they individually show a binding preference for single stranded 
DNA in vitro (Roy et al., 2011), the Smc5-Smc6 heterodimer binds preferentially to 
double stranded DNA (Roy et al., 2015), which also stimulates the ATPase activity of 
the complex (Fousteri and Lehmann, 2000). Nse4 is the kleisin, which bridges the 
Smc5 and Smc6 head domains (Hu et al., 2005; Palecek et al., 2006). Nse4 is further 
bound by Nse1 and Nse3 (Sergeant et al., 2005), which have recently been classified 
as belonging to the KITE (kleisin interacting tandem winged-helix elements) protein 
superfamily (Palecek and Gruber, 2015). Nse1 contains a RING domain (McDonald et 
al., 2003), and in vitro studies of its human homolog (NSMCE1) have shown a 
stimulating effect of interaction with the Nse3 homolog (NSMCE3) on Nse1 E3 ubiquitin 
ligase activity (Doyle et al., 2010). Nse2 is a SUMO E3 ligase (Andrews et al., 2005) 
which interacts with the coiled-coil arm of Smc5 (Duan et al., 2009). Nse2 activity 
allows the SMC5/6 complex to SUMOylate a large number of substrates, including 
auto-SUMOylation of complex subunits Smc5, Smc6, and Nse4 (Bermúdez-López et 
al., 2016). Whilst Nse1 and Nse2 both are essential to survival under basal conditions, 
their RING domains are not (Andrews et al., 2005; Pebernard et al., 2008). Finally, 
Nse5 and Nse6 form a dimeric subcomplex (Pebernard et al., 2006), which contains 
no known catalytic domains and has been proposed to associate with the core SMC5/6 
complex at either the hinge (Duan et al., 2009) or along the coiled-coil arms near the 
head domains (Palecek et al., 2006). Unlike the other core SMC5/6 complex 
components, Nse5 and Nse6 show high sequence divergence between organisms 
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(Aragón, 2018), and the subcomplex is non-essential to survival in S. pombe (Sergeant 
et al., 2005), yet essential in S. cerevisiae (Zhao and Blobel, 2005). Overall, the 
SMC5/6 complex is highly conserved from yeast to man. Still, the nomenclature varies 
significantly, and is summarised in Figure 5.1C. Human homologs have been identified 
for all SMC5/6 complex components bar Nse5 which remains uncertain. For the 
majority of this thesis I will use human SMC5/6 complex nomenclature, yet, I note that 
for the main part our understanding of the SMC5/6 complex is based on research 
performed in yeast. Just prior to the completion of this thesis, a thorough in vitro 
analysis of the human SMC5/6 complex architecture was published from the Palecek 
laboratory, which confirms a similar composition of the human as the yeast SMC5/6 
complex (Adamus et al., 2020). 
 
The role of the SMC5/6 complex in DNA repair. The implication of SMC5/6 in DNA 
repair predates the discovery of the complex itself, as the SMC6 encoding locus (then 
called rad18) was defined in a forward genetic screen for radiation sensitive mutants 
in S. pombe (Nasim and Smith, 1975). Since then, extensive evidence has emerged 
in support of a role in DNA repair, which requires all SMC5/6 complex subunits (Wu 
and Yu, 2012). Specifically, the SMC5/6 complex coordinates repair by homologous 
recombination (HR) and is recruited to DNA double strand breaks (Betts Lindroos et 
al., 2006). Here, SMC5/6 can promote HR between sister chromatids in the G2/M 
phase of the cell cycle (De Piccoli et al., 2006), potentially working in concert with 
cohesin (Potts et al., 2006). Toxic unresolved recombination intermediates accumulate 
in SMC5/6 deletion cells (Miyabe et al., 2006), and the SMC5/6 complex must therefore 
act in late stages of HR to coordinate resolution of HR structures. In support of this, 
NSMCE2 has been shown to SUMOylate known resolvases in response to DNA 
damage, thus potentially coordinating the response (Bermúdez-López et al., 2016). 
Akin to this function, SMC5/6 contributes to resolving stalled and collapsed replication 
forks (Irmisch et al., 2009) and enables translesion DNA synthesis by template 
switching (Choi et al., 2010). In human cells, recruitment of the SMC5/6 complex to 
DNA lesions (e.g. double strand breaks and DNA interstrand crosslinks) depends on 
non-catalytic activity of two poorly characterised proteins SLF1 and SLF2 (SMC5/6 
complex localisation factors 1 and 2), previously known as ANKRD32 and FAM178A 
(Räschle et al., 2015). The proposed model for recruitment involves formation of a 
ubiquitin recruitment scaffold at the DNA lesion catalysed by RNF8 and RNF168, which 
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enables binding of, in turn, RAD18, SLF1, SLF2, and finally the SMC5/6 complex 
(Figure 5.1D). The authors furthermore propose SLF2 as a distant human homolog of 
S. pombe Nse6. Of note, this is to date the only publication concerned with SLF2 
function – the protein I showed to be targeted by HIV-Vpr. In the recent publication on 
human SMC5/6 complex structure by the Palecek lab (Adamus et al., 2020), binding 
of SLF2 to the human SMC5/6 protein coiled coil arms was confirmed by yeast two-
hybrid (Y2H) screening. In this publication, SLF1 was furthermore examined as the 
human Nse5 homolog based on the publication by Räschle et al., yet, whilst the binding 
of SLF1 to SLF2 could be reproduced in the Y2H assay, no interaction was observed 
between SLF1 and SMC5/6. It is unclear whether SLF1 could be an Nse5 homolog or 
whether the human homolog remains to be found, as will be discussed below (section 
5.2.5). 
 
The SMC5/6 complex - beyond DNA repair. Outside genotoxic stress conditions, the 
SMC5/6 complex contributes to maintenance and correct mitotic segregation of 
repetitive chromosome regions such as telomeres and ribosomal DNA (rDNA) (Torres-
Rosell et al., 2005). Due to their repetitive sequence, these regions are at a risk of 
erosion via aberrant HR, and both replication and repair must be tightly controlled to 
avoid genome instability and premature cell senescence (Warmerdam and Wolthuis, 
2019). The SMC5/6 complex further contributes to subtelomeric heterochromatin 
formation by regulating binding of the Sir4 silencing factor in S. cerevisiae (Moradi-
Fard et al., 2016), and this function was found to be separate from its role in regulating 
HR of the telomeric repeats (Moradi-Fard et al., 2020). Finally, the SMC5/6 complex 
contributes to releasing topological stress resulting from overwinding of DNA during 
replication (Kegel et al., 2011) and resolution of sister chromatid intertwinings (SCIs) 
(Jeppsson et al., 2014). Supporting this, temporal degradation of SMC5/6 complex 
subunits using inducible degrons in human cells reveal mitotic aberrations upon 
SMC5/6 degradation in G1 but not in late G2 phase of the cell cycle (Venegas et al., 
2020). 
Of particular interest to me, the SMC5/6 complex has recently been proposed as a 
restriction factor for hepatitis B virus (HBV) (Decorsière et al., 2016), which, like 
unintegrated HIV-1 genomes, is extrachromosomal in its nature. Rather than 
integrating into the host genome, HBV is maintained as a covalently closed circular 
DNA (cccDNA) molecule, and these DNA species are similarly restricted by the host 
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cell. Gene expression from cccDNA was found to be stimulated by the HBV accessory 
protein HBx via a mechanism involving the cullin–RING E3 ubiquitin ligase adapter 
protein DDB1 (van Breugel et al., 2012). HBx did not affect gene expression from 
integrated reporters, indicating specific antagonism of a restriction mechanism acting 
on extrachromosomal viral DNA (van Breugel et al., 2012) – a clear parallel to my 
observations for Vpr and unintegrated HIV-1 genomes. The Strubin lab followed up 
their initial observation of a role for HBx by identifying cellular interaction partners of 
HBx, which included members of the SMC5/6 complex, thereby implicating it in 
restriction of HBV cccDNA (Decorsière et al., 2016). In the absence of HBx, the 
SMC5/6 complex binds to HBV cccDNA and reduces viral gene expression. HBx 
degrades SMC5/6 via CRL4 ubiquitin ligase activity and thus antagonises restriction. 
This ability was later found to be an evolutionarily conserved function of mammalian 
hepadnavirus HBx proteins (Abdul et al., 2018). 
The mechanism of cccDNA restriction by the SMC5/6 complex remains unclear. A 
follow-up study showed that it did not involve induction of an innate immune response 
and proposed an involvement of localisation to Nuclear Domain 10 (ND10) bodies (Niu 
et al., 2017). Others propose that SMC5/6 complex restriction of HBV and Herpes 
Simplex virus 1 (HSV-1) involves topoisomerase activity and interaction with the RING 
E3 ubiquitin ligase PJA1 (Wu et al., 2018). Finally, the SMC5/6 complex has been 
implicated in genome maintenance but not transcriptional activation of human 
papillomavirus (HPV) via the viral E2 protein (Bentley et al., 2018). Consequently, there 
exists an intriguing connection between the SMC5/6 complex and a number of 
extrachromosomal viruses, thus providing further impetus to my question regarding the 
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5.2: Results 
5.2.1: IP-MS confirms interaction of SLF2 with the SMC5/6 complex 
Given that SLF2 had only been subject of a single previous publication (Räschle et al., 
2015), I first wanted to validate the interaction between SLF2 and the SMC5/6 complex 
in Jurkat T cells. In order not to bias my analysis, I decided to use mass spectrometry 
for identification of endogenous SLF2 interaction partners in immunoprecipitated 
material (Figure 5.2A). I isolated the nuclear fraction from either WT Jurkat or clonal 
SLF2 knockout cells and performed immunoprecipitation (IP) using an SLF2 antibody. 
The immunoprecipitated material was subjected to proteolytic digestion and analysis 
by mass spectrometry (kindly performed by Dr James Williamson). When applying 
stringent inclusion criteria, 16 high-confidence SLF2-interacting proteins were 
identified in the IP (Figure 5.2B). These included all 6 known components of the 
SMC5/6 complex (SMC5, SMC6, NSMCE1, NSCME2, NSCME3, and NSMCE4) and 
the 3 upstream recruitment pathway components (RAD18, SLF1, and SLF2 itself), 
indicated in blue on the histogram and on the SMC5/6 complex schematic (Figure 
5.2C). It is therefore clear that the SMC5/6 complex is connected to the SLF2-






Figure 5.2: SLF2 co-immunoprecipitates with the SMC5/6 complex
A-C, IP-MS identifies SMC5/6 complex components as SLF2-interactors. A, 
Immunoprecipitated material from endogenous SLF2 IP in SLF2 KO and WT Jurkat 
cells was analysed by mass spectrometry. Interactors displayed in (B) satisfy inclusion 
criteria of being undetected in IP from SLF2 KO cells and detected with ≥ 3 peptides in 
IP from WT cells, ordered in descending order by number of unique peptides identified. 
Representative data set (n = 2). Blue bars represent SLF2 and SMC6 interactors 
identified by quantitative BAC–GFP interactomics (QUBIC) by Räschle et al. (2015), 
labelled on SMC5/6 complex schematic in (C).
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5.2.2: The SMC5/6 complex restricts expression from unintegrated virus  
Having validated the interaction between SLF2 and the SMC5/6 complex in Jurkat T 
cells, I therefore set out to examine the potential involvement of the SMC5/6 complex 
in restricting gene expression of unintegrated lentiviral genomes. To this end, I 
generated mixed knockout populations by transduction of Cas9-Jurkat cells with a 
panel of sgRNA expression vectors followed by puromycin selection. 7 days post 
sgRNA transduction, I set up my unintegrated virus reporter assay, mixing BFP+ mixed 
knockout populations with BFP- WT Jurkat cells. Whilst knockout of the β2m control 
gene had no effect, knockout of SLF2 and all the core components of the SMC5/6 
complex (SMC5, SMC6, NSCME1, NSMCE2, NSMCE3, and NSMCE4A) increased 
unintegrated virus gene expression (Figure 5.3A). Surprisingly, no phenotype was 
observed for knockout of components from the ubiquitin signalling arm (SLF1, 
RNF168, RNF8, and RAD18), which had been implicated in DNA-damage induced 
recruitment of the SMC5/6 complex via SLF2 (Räschle et al., 2015). To mitigate effects 
of poor sgRNA efficiency or off target effects, knockout was performed using 
3 independent sgRNAs per gene, summarised in (Figure 5.3B) via quantification of 
fold change in GFP MFI over WT for each individual sgRNA. Whilst some variation 
between sgRNAs were seen for most genes, the phenotypes shown by a 
representative sgRNA for each gene in (Figure 5.3A) were consistently replicated 
across all 3 sgRNAs, highlighted by colour coding on the histogram and on the SMC5/6 
complex schematic in (Figure 5.3C). The implications were clear: Whilst my data 
supported an involvement of the core SMC5/6 complex components in restriction of 






Figure 5.3: Unintegrated virus expression is restricted by the SMC5/6 complex
A-C, CRISPR-Cas9 knockout of SMC5/6 complex increases expression from 
unintegrated virus. Mixed knockout populations were produced by transduction of Cas9-
Jurkat cells with 3 independent sgRNAs per gene. 7 days post sgRNA transduction, 
BFP- WT Jurkat cells and BFP+ KO populations were mixed 1:1 and infected with a 
GFP reporter virus in the presence of 1 μM RAL. Flow cytometry 72 h post infection 
(A). Representative histograms for sgRNAs targeting each gene shown. Quantification 
summarises data for all 3 sgRNAs/gene in (B) as the fold change in GFP MFI over 
WT. Error bars show standard deviation. Bar colours reflect if a phenotype is present 




































































































































































































































































β2m SLF2 SMC5 SMC6
NSMCE1 NSMCE2 NSMCE3 NSMCE4A




Chapter 5: Unintegrated virus is restricted by the SMC5/6 complex 
  
5.2.3: Unintegrated virus expression is unchanged in an SLF1 knockout clone 
To confirm the lack of SLF1-dependence for unintegrated virus restriction, I decided to 
isolate a clonal SLF1 knockout cell line. To do this, I transduced Cas9-Jurkat cells with 
an SLF1 targeting sgRNA in the presence of RAL to prevent stable sgRNA construct 
integration. Following transient puromycin selection, cells were single cell cloned by 
FACS, expanded, and screened for loss of SLF1 expression by western blot. Whilst I 
struggled to obtain a good SLF1 antibody, I managed to get a sufficiently specific signal 
to be able to identify candidate clones with no residual SLF1 expression using 
extended duration ECL substrates. As for my isolation of an SLF2 knockout clone, this 
was a laborious task, where screening of >50 clones yielded just one promising 
candidate clone. Correspondingly, SLF1 has a high dependency score in the DepMap 
Consortium (Dempster et al., 2019), indicating that the gene is essential to the fitness 
of the cell. The SLF1 knockout clone had no detectable SLF1 protein expression 
(Figure 5.4A), contrary to WT Jurkat cells. Given the poor quality of my SLF1 antibody, 
genetic confirmation of the SLF1 knockout was essential. To confirm biallelic gene 
disruption, I PCR amplified and TOPO cloned the SLF1 sgRNA target exon from the 
SLF1 knockout clone. Sanger sequencing of 10 TOPO colonies identified two 
represented alleles (Figure 5.4B), which both carried frame-shift inducing indels in the 
sgRNA target region (marked in red). I had thus successfully isolated an SLF1 
knockout clone. 
To examine the dependency on SLF1 for unintegrated virus restriction, I repeated my 
unintegrated reporter assay (Figure 5.5A). Here, I mixed BFP+ WT Jurkat cells 1:1 
with BFP- SLF1 knockout clone or SLF2 knockout clone cells prior to infection with a 
GFP reporter virus in the presence of RAL and performed analysis by flow cytometry 
(Figure 5.5B). Replicating my observation for mixed knockout populations, 
unintegrated virus expression was unchanged in the SLF1 knockout clone, contrasting 
with the clear phenotype for the SLF2 knockout clone. Quantification of the fold change 
in GFP MFI over WT Jurkat showed a highly significant increase in unintegrated virus 
expression upon SLF2 knockout (4.47-fold) but not SLF1 knockout (0.72-fold), which 
rather revealed a slight reduction (Figure 5.5C). Restriction of unintegrated virus is 





Figure 5.4: Validation of SLF1 knockout clone by immunoblotting and Sanger 
sequencing
A, Western blot confirming loss of SLF1 in knockout clone. Lysates from WT Jurkat 
and clonal SLF1 knockout cells were analysed by western blot. B, Sanger sequencing 
of SLF1 sgRNA target exon. Organisation of the human SLF1 gene. Sequence of 
sgRNA target locus on exon 11 is shown with the PAM sequence underlined. To confirm 
biallelic gene disruption in the isolated clonal SLF1 knockout cell line, the target exon 
was amplified from isolated genomic DNA, TOPO cloned, and analysed by Sanger 
sequencing. Sequencing tracks representative of the two alleles identified among 10 
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Figure 5.5: SLF1 knockout does not affect unintegrated virus expression
A-C, Unintegrated virus expression is unchanged in an SLF1 KO clone. A, Unintegrated 
virus reporter assay. BFP+ WT Jurkat T cells were mixed 1:1 with BFP- SLF1 KO clone 
cells or BFP- SLF2 KO clone cells. Cells were infected with a GFP reporter virus in 
the presence of 1 μM RAL and analysed by flow cytometry 48 h post infection (B). 
Histograms representative example of n = 3, quantified as fold change in GFP MFI 
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5.2.4: The SLF2 N-terminus is dispensable for unintegrated virus restriction 
Having identified an SLF1-independent function for SLF2, I next asked if these 
functions could be separated by a truncation analysis of SLF2. As the majority of 
research on the SMC5/6 complex has been performed in yeast, which has no direct 
SLF1 homolog (Räschle et al., 2015), I performed a homology search for human SLF2 
against the S. pombe proteome using the remote protein homology detection tool 
HHpred (Zimmermann et al., 2018) to inform my truncation analysis. This 
unambiguously confirmed SLF2 as a homolog of S. pombe Nse6 (Figure 5.6A), as 
previously proposed (Räschle et al., 2015). The yeast Nse6 protein is much shorter 
than the human SLF2 protein (522 vs 1,173 amino acids, respectively), and Nse6 
aligned almost in its entirety to the C-terminus of SLF2, suggesting that the N-terminal 
section of SLF2 is a more recent acquisition. It was thus possible that the C-terminal 
part of SLF2 alone could perform the evolutionarily conserved roles of the protein. 
In parallel, I ran a protein disorder prediction on human SLF2 to identify possible 
domain structures using GeneSilico metadisorderMD2 (Kozlowski and Bujnicki, 2012) 
(Figure 5.6B). This predicted the entire N-terminal of SLF2 to be intrinsically 
disordered with only the region comprising amino acids 710-1173 having a predicted 
ordered structure. Informed by these in silico analyses, I cloned two truncated human 
SLF2 cDNAs: SLF2(590-1173) (corresponding to the region of identified homology to 
S. pombe Nse6) and SLF2(710-1173) (corresponding to the region with predicted 
ordered structure), indicated on (Figure 5.6B). This removed my SLF2 antibody 
epitope and potentially the nuclear localisation signal (NLS), and I therefore appended 
an N-terminal 3xHA-tag and an SV40 NLS. 
I used these truncated cDNAs alongside the full-length SLF2 cDNA for 
complementation of the SLF2 knockout clone and repeated my unintegrated virus 
reporter assay (Figure 5.6C). Whilst 3xHA-SLF2(710-1173) did not restore restriction, 
3xHA-SLF2(590-1173) not only restored restriction in the SLF2 knockout clone but 
silenced even more potently than full-length SLF2. The N-terminal 589 amino acids of 








Figure 5.6: A minimal SLF2 fully restores unintegrated virus restriction in an 
SLF2 knockout clone
A, Nse6 is the S. pombe homolog of human SLF2. A HHPred homology search was 
performed with human SLF2 (Q8IX21) against the S. pombe proteome using default 
parameters. Results are summarised for hits with >75% confidence. B, The SLF2 
N-terminal is predicted to be disordered. The human SLF2 protein sequence (Q8IX21) 
was analysed using GeneSilico MetadisorderMD2. Plot shows predicted disorder 
tendency for each position (disordered regions have scores > 0.5). Truncated SLF2 
cDNAs were cloned based on the Nse6 homology and disorder predictions as illustrated. 
C, SLF2 knockout cells are fully complemented by minimal SLF2. Unintegrated virus 
reporter assay in SLF2 knockout cells or knockout cells complemented with either 
full-length SLF2(1-1173 aa), 3xHA-SLF2(590-1173 aa), or 3xHA-SLF2(710-1173). 
Analysis by flow cytometry 72 h post infection. Data representative example of n = 3.
HHPred homology search for SLF2_human (Q8IX21)
Query proteome: Schizosaccharomyces pombe  
Hit ID Hit name E-valueHit length Aligned cols Identities
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To further corroborate this finding, I repeated my immunoprecipitation and mass 
spectrometry analysis, looking for interactors of 3xHA-SLF2(590-1173) (Figure 5.7A) 
and 3xHA-SLF2(710-1173) (Figure 5.7B). SLF2(590-1173) co-immunoprecipitated 
with all core components of the SMC5/6 complex (Figure 5.7C) as well as RAD18 and 
SLF1. Whilst NSMCE3 was also identified in the IP, this was only covered by 2 
peptides and did not satisfy the very stringent inclusion criteria which I chose to apply. 
Despite the extensive N-terminal truncation, SLF2(590-1173) was fully capable of 
interacting with the SMC5/6 complex, in agreement with its ability to restore 
unintegrated virus restriction in the SLF2 KO clone. Whilst not as clean, my IP data 
obtained with the SLF2(590-1173) truncation was almost identical to the full length 
SLF2 IP (Figure 5.2B), confirming the lack of requirement for amino acids 1-589, which 
had been revealed by my functional complementation studies. Conversely, SLF2(710-
1173) co-immunoprecipitated with RAD18 and SLF1 (Figure 5.7D), but no core 
SMC5/6 complex components. This mirrors its inability to complement the SLF2 KO 
clone for restriction and shows an absolute requirement of amino acids 590-710 for 
recruitment of the SMC5/6 complex. In agreement with this, the recent study of human 
SMC5/6 complex architecture by the Palecek lab reported binding of the SLF2 C-
terminus (aa 635-1173) alone to SMC5/6 and SLF1, which was not seen for two N-
terminal sections (aa 1-310 or aa 330-660) (Adamus et al., 2020). 
Seen in concert, my truncation analysis data therefore shows that the ability of SLF2 
to interact with the SMC5/6 complex is absolutely essential for restriction of 
unintegrated virus, and that the evolutionarily conserved SLF2 C-terminus alone can 






































Figure 5.7: Minimal SLF2 co-immunoprecipitates with the SMC5/6 complex
A-D, IP-MS identifies SMC5/6 complex as an interactor of SLF2(590-1173). A, 
Immunoprecipitated material from HA antibody IP in SLF2 KO cells and SLF2 KO cells 
complemented with 3xHA-SLF2(590-1173) or 3xHA-SLF2(710-1173) was analysed by 
mass spectrometry. Interactors satisfy inclusion criteria of being undetected in IP from 
SLF2 KO cells and detected with (A) ≥ 3 peptides in IP from 3xHA-SLF2(590-1173) 
complemented cells, or (B) ≥ 5 peptides in IP from 3xHA-SLF2(710-1173) complemented 
cells. Interactors represented as bars showing signal intensity, ordered in descending 
order by number of unique peptides identified (n = 1). Blue bars represent SLF2 and 
SMC6 interactors identified by Räschle et al. (2015), indicated on SMC5/6 complex 
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5.2.5: SIMC1 restricts unintegrated virus and is a putative Nse5 homolog 
When comparing my various IP-MS datasets, I noticed an interesting consistency: The 
protein SIMC1 was detected with high abundance in both replicates of my extremely 
clean endogenous SLF2 immunoprecipitation, in the 3xHA-SLF2(590-1173) IP, and 
even in the 3xHA-SLF2(710-1173) IP. SIMC1 thus appeared to be a strong specific 
interactor of SLF2, which had not been previously characterised. In order to examine 
the potential involvement of SIMC1 in restriction of unintegrated virus, I transduced 
Cas9-Jurkat cells with 3 independent SIMC1-targeting sgRNAs or the β2m control 
sgRNA. 6 days post sgRNA transduction, I set up my unintegrated virus reporter assay 
by mixing BFP- WT Jurkat cells with BFP+ mixed knockout populations. Whilst 
knockout of β2m had no effect, expression of the unintegrated viral reporter was 
consistently increased for knockout of SIMC1 with all 3 sgRNAs (Figure 5.8A). Not 
only was SIMC1 an interactor of SLF2, I could also implicate it in restriction of 
unintegrated virus. 
SUMO interacting motifs containing 1 (SIMC1, previously known as C5orf25) is a 
poorly characterised protein, which was named in a bioinformatics study searching for 
proteins containing clusters of SUMO-interacting motifs (SIMs) (Sun and Hunter, 
2012). Whilst SUMOylation provided a putative link to the SMC5/6 complex, I also 
considered whether a yeast homology search could provide further insight, as I had 
seen for SLF2. I therefore performed another distant homology search against the 
S. pombe proteome in HHPred for human SIMC1 (Figure 5.8B). Surprisingly, a top hit 
was Nse5, the close interactor of yeast Nse6. Correspondingly, different isoforms of 
human SIMC1 were the only hits obtained for a HHPred search for S. pombe Nse5 
against the human proteome (Figure 5.8C). The identity of human Nse5 is surrounded 
by uncertainty. Whilst SLF1 was assumed to be the human Nse5 in the recent study 
of human SMC5/6 complex architecture (Adamus et al., 2020), this was based solely 
on the interaction with SLF2 (human Nse6) identified by Räschle et al. and not 
supported by neither functional nor structural data. Whilst more evidence will clearly 
be needed to support this observation, my data strongly suggests a link between the 
SLF2, the SMC5/6 complex, and SIMC1, which I propose as a putative distant human 






Figure 5.8: Unintegrated virus is restricted by SIMC1 - a putative Nse5 homolog
A, Knockout of SIMC1 increases unintegrated virus expression. Mixed knockout 
populations were produced by transducing Cas9-Jurkat cells with a β2m or SIMC1 
sgRNA. 6 days post sgRNA transduction, BFP- WT Jurkat cells and BFP+ mixed KO 
populations were mixed 1:1 and infected with a GFP reporter virus in the presence of 
RAL. Flow cytometry 72 h post infection for KO with 3 independent SIMC1 sgRNAs. B-C, 
SIMC1 is a putative human homolog of S. pombe Nse5. B, A HHPred homology search 
was performed with human SIMC1 (Q8NDZ2) against the S. pombe proteome using 
default parameters. Results are summarised for unique hits with >75% confidence. C, 
A HHPred homology search was performed with S. pombe Nse5 (O94668) against the 
















































































HHPred homology search for SIMC1_human (Q8NDZ2)
Query proteome: Schizosaccharomyces pombe  
Hit ID Hit name E-valueHit length Aligned cols Identities






NP_595508.1 Nse5 388 aa 241 22.1% 93.3%22
3H0G_A RNA pol II 1752 aa 249 25.1% 84.2%220
1TWF_A
3H0G_A
HHPred homology search for Nse5_SCHPO (O94668)
Query proteome: Homo sapiens  
Hit ID Hit name E-valueHit length Aligned cols Identities







NP_001295124.1 SIMC1 (A) 891 aa 244 20.1% 85.7%260
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5.2.6: HIV-1 Vpr specifically degrades SLF2 but not the core SMC5/6 complex 
Whilst my screen suggested SLF2 as the central Vpr target, and I could confirm 
depletion of SLF2 by Vpr by western blot (Figure 4.6), I decided to revisit the subject 
in the light of the implication of the SMC5/6 complex in restriction of unintegrated virus. 
The aim was to establish if protein levels of the core SMC5/6 complex were also 
affected by Vpr. I therefore transduced CEM-T4 T cells with control VLPs, WT Vpr 
VLPs or DCAF1 binding mutant Q65R Vpr VLPs in the presence or absence of the 
pan-cullin inhibitor MLN4924 (Figure 5.9A). 24 h post transduction, cell lysates were 
analysed by western blot (Figure 5.9B). Whilst CRL4DCAF1-dependent degradation of 
SLF2 was evident, Vpr had no effect on SMC6 and NSCME1, two core components of 
the SMC5/6 complex. Vpr thus specifically degrades the SMC5/6 complex localisation 





Figure 5.9: HIV-1 Vpr degrades SLF2 but not other SMC5/6 complex members
A-B, SLF2, but not SMC6 or NSMCE1, is depleted by Vpr via CRL4DCAF1. A, CEM-T4 
T cells were transduced with control VLPs, WT Vpr VLPs or Q65R Vpr VLPs with 
or without 1 µM MLN4924. Cell lysates were harvested 24 h post transduction and 
analysed by western blot (B).
Vpr
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5.2.7: Hepatitis B virus HBx can antagonise restriction of unintegrated HIV-1 
The implication of Vpr-induced degradation of SLF2, but not SMC6, in antagonism of 
restriction by the SMC5/6 complex was interesting in the context of the previously 
proposed role of hepatitis B virus (HBV) protein HBx in antagonising the same complex 
via degradation of SMC6 (Decorsière et al., 2016). The two viruses appeared to have 
developed different mechanisms of antagonising the same complex, and I therefore 
hypothesised that the means of antagonism for one virus might be able to substitute 
for the other. In essence, HBV HBx should be able to rescue gene expression from 
unintegrated HIV-1 genomes. To test this hypothesis, I cloned a 3xHA-tagged HBx 
expression construct with a puromycin resistance cassette, which allowed for ectopic 
expression of HBx in the HIV-1 target cells prior to infection. First, I confirmed 
successful expression of 3xHA-HBx in Jurkat T cells, which led to depletion of SMC6 
in both WT and SLF2 KO cells, whilst SLF2 levels were unaffected (Figure 5.10A). 
Next, I set up an unintegrated HIV-1 reporter assay to assay the influence of HBx 
(Figure 5.10B). BFP+ WT Jurkat cells were mixed 1:1 with BFP- 3xHA-HBx expressing 
WT Jurkat cells prior to infection with lentiviral GFP reporters in the presence of RAL. 
Just as I had observed for HIV-1 Vpr, ectopically expressed HBx increased gene 
expression from unintegrated HIV-1 genomes (Figure 5.10C), thus successfully 
antagonising restriction of genomes from a completely unrelated virus. A parallel assay 
was performed in SLF2 KO cells. Here, HBx only had a marginal effect on unintegrated 
reporter expression (Figure 5.10C), which was significantly reduced compared to the 
effect in WT cells (Figure 5.10D). These results suggest that when SMC5/6 complex 
restriction was removed by knockout of SLF2, HBx had only a marginal effect, 
highlighting how SLF2 degradation by Vpr and SMC6 degradation by HBx antagonise 






Figure 5.10: Hepatitis B virus HBx rescues gene expression from unintegrated 
HIV-1 genomes
A, HBV protein HBx degrades SMC6 but not SLF2. WT or SLF2 KO Jurkat cells were 
transduced with 3xHA-HBx, puromycin selected, and lysates analysed 96 h post 
transduction by western blot. Representative blot (n = 3). B-D, HBV HBx can antagonise 
restriction of unintegrated lentiviral reporters. B, Unintegrated virus reporter assay with 
HBx. 96 h post 3xHA-HBx transduction, BFP- WT/SLF2 KO Jurkat cells transduced with 
3xHA-HBx were mixed 1:1 with BFP+ WT/SLF2 KO Jurkat cells. Cells were infected 
with a GFP reporter virus in the presence of 1 μM RAL and analysed by flow cytometry 
72 h post infection (C). Grey shaded: Without HBx. Red line: With HBx. Histograms 
representative example of n = 3, quantified as fold change in GFP MFI over WT Jurkat 
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5.3: Discussion          
The expression of unintegrated HIV-1 genomes is markedly restricted by the host cell 
in the absence of antagonism by the accessory protein Vpr. In Chapter 4, I identified 
SMC5/6 localisation factor 2 (SLF2) as a novel Vpr target implicated in restriction of 
unintegrated virus. Consequently, I next sought to examine the basis for this restriction 
mechanism by evaluating the potential involvement of the SMC5/6 complex, which has 
previously been proposed as a restriction factor for hepatitis B virus. In this chapter, I 
provide evidence that unintegrated HIV-1 is restricted by the SMC5/6 complex, and 
that this restriction is SLF2-dependent but SLF1-independent, suggesting a DNA-
damage independent role for SLF2. I identify the poorly characterised protein SIMC1 
as a novel interactor of SLF2, and, based on in silico homology analysis, propose that 
SIMC1 may be a distant human homolog of yeast Nse5. Finally, I provide proof-of-
principle that HIV-1 Vpr and Hepatitis B virus HBx are interchangeable for antagonism 
of SMC5/6 complex restriction. 
 
5.3.1: The SMC5/6 complex restricts unintegrated virus independent of SLF1 
The central finding of this chapter is that gene expression from unintegrated virus is 
restricted by the SMC5/6 complex in an SLF1-independent manner. By generating 
mixed knockout populations, I show that knockout of each individual core SMC5/6 
complex component leads to increased expression of an unintegrated lentiviral 
reporter (Figure 5.3). Whilst consistently reproduced, the size of the KO phenotypes 
varied. As discussed in the context of SLF2 (section 4.3.2), phenotypes obtained for 
mixed knockout populations are highly dependent on sgRNA target efficiency and 
decreased fitness of knockout cells. This is reflected in the large variance between KO 
with the 3 different sgRNAs for each gene, summarised in Figure 5.3B. All core 
SMC5/6 complex subunits are defined as essential genes across a large spectrum of 
cell lines tested in the DepMap consortium (Dempster et al., 2019). Lethality will thus 
have influenced the observed phenotypes. Correspondingly, my attempts to isolate 
clonal SMC6 and NSMCE2 knockout cell lines all failed. 
Whilst it is tempting to extrapolate that all enzymatic functions of the SMC5/6 complex 
must be required for restriction, the interdependency for structural integrity invalidates 
this conclusion. SMC5, SMC6, NSMCE1, NSMCE3, and NSMCE4 are all required for 
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stability of the human SMC5/6 complex (Taylor et al., 2008). siRNA mediated depletion 
of either of these subunits led to depletion of the other subunits, whereas they were 
unaffected by siRNA mediated depletion of NSMCE2 (Taylor et al., 2008). 
Consequently, my observed phenotype for knockout of NSCME2 provides the only 
clear indication of functional importance of a single subunit. To more formally test this, 
one could remove the SUMO ligase activity whilst maintaining the presence of 
NSMCE2, e.g. by point mutation of the Zn-coordinating residues of the RING domain 
(C185S/H187A) or deletion of the entire C-terminal domain (Andrews et al., 2005), 
which would enable a global characterisation of human NSMCE2 target proteins as 
has been performed for yeast (Bermúdez-López et al., 2016). This would, however, 
require either isolation of a knockout clone for complementation or knock-in into the 
endogenous locus. 
The connection between SLF2 and the SMC5/6 complex was first identified by Räschle 
et al. in the context of DNA-damage induced recruitment to DNA interstrand crosslinks 
(Räschle et al., 2015). However, much to our surprise, mixed population knockout of 
components of the ubiquitin-mediated SMC5/6 recruitment pathway (SLF1, RAD18, 
RNF8, and RNF168) had no effect on unintegrated virus expression (Figure 5.3), and 
this was confirmed in a clonal SLF1 knockout cell line (Figure 5.5.). Importantly, 
recruitment of the SMC5/6 complex thus appears to occur via an SLF1-independent 
mechanism, which differs from the DNA-damage recruitment pathway. Akin to the 
known functions of the SMC5/6 complex outside DNA damage, there likely exists other 
SLF2-dependent mechanisms of recruitment in human cells. Additionally, in S. pombe, 
the BRCT-domain containing protein Brc1 performs a function analogous to SLF1 in 
recruiting the SMC5/6 complex to sites of genotoxic stress. However, deletion of Brc1 
only leads to loss of SMC5/6 complex occupancy at a subset of target sites, compared 
to the extensive loss of occupancy upon knockout of Nse6 (the SLF2 homolog) 
(Oravcová et al., 2018), indicating a more global importance for Nse6.  
The lack of SLF1 involvement further raises the question of how SLF2 and the SMC5/6 
complex is recruited to viral DNA independently of DNA damage ubiquitin scaffold 
formation. The individual components of the complex are in themselves directly DNA 
binding, including SMC5 (Roy et al., 2011), SMC6 (Roy and D’Amours, 2011), and 
NSMCE3 (Zabrady et al., 2016), and the SUMO ligase activity of NSMCE2 is 
stimulated by binding of SMC5 to DNA (Varejão et al., 2018). It is thus clear that the 
SMC5/6 complex can bind to DNA independently of ubiquitin-dependent recruitment. 
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However, the basis of the specificity for this binding to extrachromosomal viral DNA is 
not straightforward and may depend on topological structure and subcellular location 
rather than the existence of a target recognition motif. 
 
5.3.2: SLF2 interacts with the SMC5/6 complex independent of its N-terminus 
In addition to providing genetic evidence for a shared function of SLF2 and the SMC5/6 
complex, I replicated the previously proposed interactions between SLF2 and the 
SMC5/6 complex and SLF1/RAD18, respectively (Räschle et al., 2015), which have 
since been independently verified in the extensive interactome work from the Gygi lab 
(Huttlin et al., 2020). My own datasets represent a number of advances over the reports 
which Räschle et al. published previously. Firstly, they did not study endogenous 
protein interactions, but instead used quantitative BAC-green fluorescent protein 
interactomics (QUBIC) (Hubner et al., 2010) in which GFP-tagged bait proteins were 
expressed from bacterial artificial chromosomes (BAC) in a wild type HeLa cell 
background. Whilst the cognate promoters for all baits were included in the BACs, 
expression from outside the natural genetic context could still lead to differential 
regulation and potentially altered protein levels. My IP of endogenous SLF2 with a 
knockout clone for non-specific background subtraction should thus yield a more 
physiologically relevant result. Secondly, whilst Räschle et al. identified SLF2, SLF1, 
RAD18, and all 6 SMC5/6 complex core components with an SMC6-GFP bait, only 
RAD18, SLF1, SMC5, and NSMCE4 were identified with an SLF2-GFP bait, contrary 
to my successful identification of the entire complex in the endogenous SLF2 IP. 
In addition to confirming the interaction of endogenous SLF2 with the SMC5/6 
complex, I provide further insight via the SLF2 truncations. The N-terminal 589 amino 
acids of SLF2 were dispensable for both unintegrated virus silencing (Figure 5.6C) 
and interaction with the SMC5/6 complex (Figure 5.7A), whereas both abilities were 
lost with the more extensive SLF2(710-1173) truncation (Figure 5.6C and 5.7B), which 
only retained binding to RAD18 and SLF1. The implications of this are twofold. First, 
part of the 590-710 amino acid region must be required for formation of the binding 
interface between SLF2 and the core SMC5/6 complex, whereas the SLF1 interaction 
site is separate. Second, it demonstrates the functional link between the SMC5/6 
complex and SLF2, as the loss of SMC5/6 complex binding capacity for truncated 
SLF2(710-1173) coincides with loss of unintegrated virus restriction. This hypothesis 
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could be examined by knocking out SMC6 in an SLF2 knockout clone, which should 
have no effect if the two proteins act in the same pathway. I have, however, struggled 
to obtain any noticeable Cas9 activity in SLF2 knockout cells. One may speculate that 
this could result from an involvement of SLF2 and the SMC5/6 complex in DNA repair 
upon DNA cleavage by Cas9. Also, given that both SLF2 and SMC6 are essential 
genes, a double knockout cell line would almost certainly not be viable. 
Lastly, my in silico analysis predicted the N-terminal tail of SLF2 to be disordered. The 
presence of intrinsically disordered tails of different lengths is more common for DNA 
binding proteins (~70%) than for non-DNA binding proteins (~50%) (Vuzman et al., 
2010), and they may contribute to fine-tuning of protein-DNA interaction affinity and 
facilitate DNA searching (Vuzman and Levy, 2012). The N-terminal tail of SLF2 may 
thus perform a similar role in DNA topology surveillance by the SMC5/6 complex, 
although it is dispensable for unintegrated virus restriction. 
 
5.3.3: SIMC1 and SLF2: The human homolog of the yeast Nse5-Nse6 dimer?  
In addition to replicating the previously proposed interaction between SLF2 and the 
SMC5/6 complex, I propose a novel interaction between SLF2 and SIMC1 (Figure 
5.2B). SIMC1 was not identified by Räschle et al., but has been detected in affinity 
purifications from both SLF2 and several SMC5/6 complex components in the Gygi lab 
Bioplex 3.0 interactome (Huttlin et al., 2020). Knockout of SIMC1 lead to a consistent 
increase in unintegrated virus expression (Figure 5.8A), and I therefore hypothesise 
that SIMC1 plays a role in the SLF2-dependent restriction of unintegrated virus by the 
SMC5/6 complex. Unfortunately, I have not been able to obtain a specific SIMC1 
antibody nor managed to clone the SIMC1 cDNA prior to the completion of this thesis, 
and I can therefore not, at present, provide further experimental evidence for this 
putative role for SIMC1 in unintegrated virus restriction 
The sparse literature on SIMC1 focuses on the presence of clustered SUMO-
interacting motifs (SIMs) (Sun and Hunter, 2012) and the ability to bind di-SUMO 
chains in vitro (Kost and Mootz, 2018). Only one functional study exists, which provides 
a tenuous link between SIMC1 and modulation of calpain cleavage in muscle cells 
(Ono et al., 2013), which is not of immediate relevance to SLF2 or the SMC5/6 
complex. However, my distant homology search of human SIMC1 against the 
S. pombe proteome identified the SMC5/6 complex associated factor Nse5 among the 
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top hits (Figure 5.8B). Other top hits were RNA polymerase II subunits, but a closer 
examination of the alignment reveals a number of features characteristic of a false 
positive hit. Firstly, the aligned columns only comprise a small proportion of the total 
hit length (228/1733 amino acids). Secondly, the alignment is dominated by repeats 
containing SPxx-type motifs found in the RNA polymerase C-terminal domain (CTD), 
which may contribute to DNA binding  (Suzuki, 1989) and which are also targets for 
proline-directed protein kinases, well-known for phosphorylating the RNA polymerase 
II CTD (Harlen and Churchman, 2017). The N-terminal region of SIMC1 may thus 
share these characteristics without being related to RNA polymerase II. A reverse 
search for human homologs of S. pombe Nse5 unanimously proposed SIMC1 isoforms 
(Figure 5.8C), supporting my initial interpretation. 
The identity of the human homolog of Nse5 is uncertain. Whilst Räschle et al. 
implicated both SLF2 and SLF1 in recruitment of the SMC5/6 complex to DNA lesions 
in human cells, they only proposed homology of SLF2 to Nse6 (Räschle et al., 2015). 
Yet, in the recent analysis of human SMC5/6 complex architecture by the Palecek 
laboratory, SLF1 was included as the human Nse5, quoting Räschle et al. (Adamus et 
al., 2020). Presumably, the authors have assumed functional equivalence based on 
the binding of SLF1 to SLF2 (akin to the Nse5-Nse6 dimer) in the light of the missing 
identity of human Nse5. However, no interaction between SLF1 and SMC5/6 could be 
shown by yeast two-hybrid analysis, contrasting with the previous analysis of the yeast 
SMC5/6 complex architecture which showed direct interaction of Nse5 with SMC5/6 
(Palecek et al., 2006). Consequently, more work will be needed to elucidate the true 
identity of human Nse5, including considering my observations regarding SIMC1. 
Yeast Nse5, like SIMC1, interacts with SUMO itself whilst also binding enzymes of the 
SUMO conjugation pathway (Bustard et al., 2012, 2016), potentially forming a 
SUMOylation hub together with the Nse2 E3 SUMO ligase. 
In yeast, Nse5 and Nse6 form a dimeric subcomplex within the SMC5/6 holocomplex 
(Pebernard et al., 2006). The precise activity of the Nse5-Nse6 dimer is unclear, yet it 
is essential to SMC5/6 complex functions in DNA repair in response to genotoxic stress 
(Pebernard et al., 2006), replication stress  (Bustard et al., 2012), and resolution of 
holiday junctions in meiosis (Wehrkamp-Richter et al., 2012). A prevailing model 
suggests a role for Nse5-Nse6 in loading of the SMC5/6 complex onto DNA (Oravcová 
and Boddy, 2019). This is supported by ChIP-PCR data showing 5-10 fold reduced 
occupancy of the SMC5/6 complex at known target sites including centromeres, 
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telomeres, and transfer DNAs in Nse5 and Nse6 deletion strains of S. pombe 
(Oravcová et al., 2018). The idea of a dimeric DNA loading complex for SMC5/6 is 
interesting in the context of the better understood SMC protein complexes cohesin and 
condensin. Here, dimeric loading complexes regulate binding of the core SMC 
complexes onto DNA (Wells et al., 2017), e.g. Scc2/Scc4 for cohesin (Ciosk et al., 
2000). It is thus tempting to speculate whether an SLF2-SIMC1 dimer might enable 
loading of the human SMC5/6 complex onto DNA.  
 
5.3.4: An example of convergent evolution: HIV-1 and HBV both antagonise 
restriction by the SMC5/6 complex 
By implicating the SMC5/6 complex in restriction of unintegrated HIV-1 genomes, I 
established a parallel to the already known role of SMC5/6 in restriction of gene 
expression from hepatitis B virus (HBV) cccDNA (Decorsière et al., 2016). 
Interestingly, HBV and HIV-1 have developed independent strategies for antagonising 
restriction by the SMC5/6 complex, as HBV HBx degrades SMC6 itself, whereas HIV-
1 Vpr degrades SLF2 (Figure 5.10A). This provided the foundation for a proof-of-
principle experiment in which I showed a functional equivalence of HBx and Vpr for 
SMC5/6 complex antagonism. By ectopically expressing HBx in Jurkat T cells, I could 
significantly increase gene expression from unintegrated HIV-1 genomes in WT but 
not in SLF2 KO Jurkat cells (Figure 5.10C). 
Not only is this evidence that the two unrelated viral accessory proteins confer similar 
functions, it also provides support to my model in which SLF2 and SMC5/6 function in 
the same restriction pathway. Were the two mechanisms independent, then HBx 
should have still increased gene expression from unintegrated virus in the SLF2 
knockout clone. Secondly, the different strategies of antagonism employed by HBV 
and HIV-1, to degrade the same complex, support an in vivo importance of viral 
restriction by the SMC5/6 complex. The two evolutionarily distinct viruses are unlikely 
to both develop means of antagonising the same complex, unless this confers a 
significant selective advantage. As an example of this, well-established restriction 
factors of HIV-1 such as APOBEC3G (Sheehy et al., 2002) and tetherin (Neil et al., 
2008) are also antagonised by HBx (Chen et al., 2017; Lv et al., 2015). It is interesting 
to hypothesise that HBV and unintegrated HIV-1 may be restricted by the SMC5/6 
complex via the same mechanism, and that the ability to antagonise restriction by the 
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SMC5/6 complex could be a prerequisite for successful gene expression from all 
extrachromosomal DNA viruses. Consequently, the implications of furthering our 
mechanistic understanding of restriction by the SMC5/6 complex extend far beyond an 
importance for HIV biology. 
 
5.4: Summary 
How does SLF2 induce restriction of unintegrated virus? In this chapter, I implicate the 
SMC5/6 complex and confirm its interaction with SLF2 by IP-MS. I show that individual 
gene knockout of SLF2 and all core SMC5/6 complex components lead to increased 
unintegrated virus expression, whereas knockout of the SLF1-RAD18-RNF8-RNF168 
recruitment arm has no effect. Restriction by the SMC5/6 complex is thus SLF2-
dependent but SLF1-independent. Furthermore, I implicate SIMC1, a novel SLF2 
interactor, and propose that SIMC1 could be the hitherto unknown human homolog of 
Nse5, which in yeast forms a dimer with Nse6, the yeast homolog of SLF2. Lastly, I 
show that the HBx protein from HBV can substitute for Vpr to increase gene expression 
from unintegrated virus. Whilst HIV-1 Vpr degrades SLF2, HBx degrades SMC6 itself. 
The two evolutionarily distinct viruses, HBV and HIV-1, have thus developed 
independent mechanisms of antagonising restriction by the SMC5/6 complex, 
highlighting the in vivo importance of this complex and providing a good example of 
convergent evolution. Clearly, furthering our mechanistic understanding of this 
restriction will be of great importance to understanding the impact of SLF2 and SMC5/6 










The SMC5/6 complex induces a 





Chapter 6: The SMC5/6 complex induces a repressive unintegrated virus chromatin structure 
  
6.1: Introduction 
Genetic material in eukaryotes is organised in a tightly regulated but dynamic 
chromatin structure. Posttranslational histone tail modifications, nucleosome 
occupancy, and chromatin compaction all regulate the accessibility of genomic DNA, 
which forms the basis for epigenetic regulation of gene expression (Swygert and 
Peterson, 2014). This is governed by numerous chromatin regulatory proteins, 
including the SMC proteins, which play an essential role in maintaining and regulating 
the structural integrity of chromatin (Uhlmann, 2016). In Chapter 5, I established a role 
for the SMC5/6 complex in the regulation of gene expression from unintegrated HIV-1 
genomes, thus suggesting the existence of a novel pathway for HIV-1 restriction acting 
selectively on extrachromosomal DNA. I therefore asked: What is the mechanistic 
basis for unintegrated virus restriction by the SMC5/6 complex? 
Unintegrated HIV-1 DNA species are rapidly chromatinised by the host cell (Geis and 
Goff, 2019), thus becoming subject to the same tight epigenetic regulation as genomic 
chromatin. Given the intimate relationship of the SMC5/6 complex with chromatin, it is 
important to consider the mechanistic basis for restriction of unintegrated virus in the 
context of chromatin. Previous work by the Goff lab has shown the presence of both 
core and linker histones on 2-LTR circles as early as 12 hours after infection (Geis and 
Goff, 2019). This coincided with high levels of the silencing histone mark H3K9me3, 
consistent with a repressive chromatin structure. The Goff lab has previously 
implicated NP220-dependent recruitment of the HUSH complex for silencing of gene 
expression from unintegrated MLV retroviral DNAs, yet, in the context of unintegrated 
HIV-1 genomes, the authors reported an involvement of NP220 whereas knockout of 
HUSH complex components had little or no effect (Zhu et al., 2018). Whilst the role of 
NP220 remains an open question, the HUSH complex is unlikely to be involved in the 
SMC5/6 complex-mediated molecular mechanism for restriction of unintegrated HIV-1 
gene expression, which I will explore in this chapter. 
It is interesting to consider whether the physical association of the SMC5/6 complex 
with unintegrated viral DNA could directly generate a repressive chromatin structure, 
without the need for recruitment of additional repressive factors. All SMC protein 
complexes bind DNA and, as illustrated in Figure 6.1A, are able to either topologically 
or pseudotopologically entrap one or two DNA molecules via their ring structure 
(Cuylen et al., 2011; Haering et al., 2008; Kanno et al., 2015). 
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A
Figure 6.1: SMC proteins, DNA topology and loop extrusion
A, SMC proteins regulate DNA topology. Pseudotopological entrapment: The DNA 
molecule forms a loop but is not topologically entrapped in the SMC ring. Topological 
entrapment: One or two DNA molecules enter the SMC ring. B, Loop extrusion and 
topological entrapment of DNA forms the basis of well-studied SMC protein complex 
functions. The schematic illustrates three examples: (i) Cohesin mediating DNA looping 
for promoter-enhancer contact. (ii) Cohesin mediating adhesion of sister chromatids. 
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The SMC protein ATPase domain enables molecular motor activity in which SMC 
protein complexes can translocate DNA in an ATP-dependent manner (Hassler et al., 
2018). In the case of cohesin and condensin, this has been linked to DNA loop 
extrusion (Kim et al., 2019b; Terakawa et al., 2017), enabling both chromosomal 
communication and chromatin compaction (Figure 6.1B). Whilst loop extrusion has 
not been demonstrated for the SMC5/6 complex, it is plausible in light of the high 
structural similarity between the different SMC protein complexes, and thus the 
SMC5/6 complex may share the ability to compact DNA. Alternatively, topological 
association of the complex with DNA could provide a roadblock to transcribing 
polymerases, essentially leading to silencing of gene expression. In this chapter, I 
explore the hypothesis that the SMC5/6 complex physically associates with 
unintegrated viral genomes in an SLF2-dependent manner and induces a repressive 
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6.2: Results 
6.2.1: The HUSH complex, NP220, and PJA1 do not restrict unintegrated virus 
During my thesis work, a high profile paper from the Goff lab suggested a critical role 
for the HUSH complex in silencing of the retrovirus moloney leukemia virus (MLV), 
proposing a model where the HUSH complex was recruited to unintegrated MLV 
genomes via the DNA binding protein NP220 (Zhu et al., 2018). In the wake of our 
lab’s discovery of the HUSH complex via its role in position-dependent silencing of 
integrated HIV-1 genomes (Tchasovnikarova et al., 2015), we had already previously 
investigated the HUSH complex in the context of silencing unintegrated HIV-1 
genomes and did not find a role for any of the complex components (TASOR, MPP8 
and PPHLN1). In agreement with this, the Goff lab also did not find conclusive 
evidence for a role of the HUSH complex in silencing of unintegrated HIV-1 genomes 
(Zhu et al., 2018), contrary to their observations for MLV. They did, however, report a 
role for NP220. Unpublished data from our lab had previously identified NP220 as a 
dominant interactor of TASOR, however, we had no functional role for NP220. I 
therefore decided to revisit the question of the involvement of both the HUSH complex 
and NP220 in silencing unintegrated HIV-1 in my reporter system. 
First, I took advantage of a previously established clonal TASOR knockout Jurkat cell 
line to compare the effect of HUSH knockout with that of my SLF2 knockout clone. I 
set up my unintegrated virus reporter assay mixing BFP+ WT Jurkat cells with BFP- 
TASOR or SLF2 knockout clone cells (Figure 6.2A). Whilst my SLF2 knockout clone 
showed a clear phenotype, knockout of TASOR had no effect on unintegrated virus 
expression (Figure 6.2B), indicating that the HUSH complex did not play a role in 
silencing of unintegrated HIV-1 genomes. To examine this more rigorously, I extended 
my focus to include all HUSH complex components as well as NP220 in comparison 
to the SMC5/6 complex (Figure 6.2C). I established mixed knockout populations by 
transducing Cas9-Jurkat cells with a panel of sgRNA expression vectors followed by 
puromycin selection. 7 days post sgRNA transduction, I repeated my unintegrated 
virus reporter assay, this time mixing BFP+ mixed knockout populations with BFP- WT 
Jurkat cells (Figure 6.2D). Knockout of the HUSH complex components or NP220 with 
3 independent sgRNAs per gene consistently showed no phenotype for unintegrated 
virus expression when compared to WT Jurkat cells, in contrast to the increased 
expression observed for knockout of SLF2 or the core SMC5/6 complex (Figure 6.2E).   
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I could thus not replicate the observation from the Goff lab that NP220 is involved in 
restriction of unintegrated HIV-1 genomes (Zhu et al., 2018). I furthermore included 
sgRNAs targeting the ubiquitin ligase PJA1, which had been suggested to replace 
NSMCE1 in the SMC5/6 complex for restriction of hepatitis B virus (HBV) and herpes 
simplex virus 1 (HSV-1) (Wu et al., 2018). Likewise, I did not observe any effect on 
unintegrated HIV-1 reporter expression upon knockout of PJA1 (Figure 6.2E). Whilst 
my experiments confirmed the importance of the SMC5/6 complex for restriction of 
unintegrated HIV-1, my data did not support a role for NP220, the HUSH complex or 


























Figure 6.2: Unintegrated virus restriction is independent of HUSH and PJA1
A-B, Unintegrated virus expression is unchanged in a TASOR KO clone. A, BFP+ 
WT Jurkat T cells were mixed 1:1 with BFP- clonal TASOR KO or SLF2 KO cells and 
infected with a GFP reporter virus in the presence of 1 μM RAL. Analysis by flow 
cytometry 72 h post infection (B). Representative example (n=2). C-E, Knockout of 
HUSH complex components or PJA1 does not affect unintegrated virus expression. C, 
Schematic of HUSH complex and SMC5/6 complex components. D, Unintegrated virus 
assay. 7 days post sgRNA transduction, BFP+ mixed knockout populations were mixed 
1:1 with BFP- WT Jurkat cells and infected with a GFP reporter virus in the presence 
of 1 μM RAL. Flow cytometry 72 h post infection. Quantification summarises data for 3 
independent sgRNAs/gene in (E) as the fold change in GFP MFI over WT. Error bars 
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6.2.2: Activating histone marks are depleted on unintegrated viral genomes 
I commenced my characterisation of unintegrated virus restriction at the chromatin 
level by examining histone tail modifications on unintegrated viral genomes in the 
presence and absence of SLF2. Posttranslational modifications of histone tails 
constitute the histone code, which together guide recruitment of chromatin modifying 
enzymes and consequently define the chromatin state (Strahl and Allis, 2000). Whilst 
acknowledging the complexity of the histone code, I decided to focus my work on three 
well-characterised modifications of histone H3: Trimethylation of lysine 9 (H3K9me3) 
and trimethylation of lysine 27 (H3K27me3), which are repressive histone marks 
characteristic of heterochromatin (Saksouk et al., 2015), and trimethylation of lysine 4 
(H3K4me3), which is an activating histone mark characteristic of regions of active gene 
transcription (Howe et al., 2017). I chose to use chromatin immunoprecipitation (ChIP) 
to examine the presence of modified histones on unintegrated HIV-1 genomes. By 
inducing protein-DNA crosslinks followed by chromatin fragmentation, DNA regions 
bound by the protein of interest (e.g. total H3) can be immunoprecipitated and DNA 
regions of interest (e.g. a lentiviral reporter gene) can be quantified by qPCR (Figure 
6.3A). Whilst ChIP as a technique has been exploited widely for chromatin studies for 
decades, resulting in numerous available protocols, getting this technique to work on 
small, unintegrated viral genomes, as opposed to integrated or cellular loci, was 
technically difficult. Only the Goff lab had successfully performed ChIP on unintegrated 
retroviral genomes when I commenced this work, and I consequently first had to 
optimise our own ChIP protocol for studying unintegrated viral DNA. This proved a 
non-trivial and time-consuming task, as the conditions used by the Goff for ChIP of 
retroviral genomes in HeLa cells were not directly transferable to my setup in Jurkat 
cells. I first attempted to optimise a sonication-based fragmentation protocol, however, 
the conditions proved non-reproducible. After later switching to a micrococcal nuclease 
(MNase) fragmentation protocol and changing from a GFP to an iRFP reporter virus to 
avoid PCR contamination issues, I was finally able to properly optimise my conditions. 
To set up my experiments, I infected WT Jurkat, SLF2 knockout clone and full-length 
SLF2 complemented knockout cells with an iRFP reporter virus in the presence of 
raltegravir (RAL) and performed ChIP 48 h post infection. First, I performed ChIP using 
an antibody which recognises the total population of H3 histones. This showed 
consistent binding of core histones to unintegrated viral genomes in the absence and 
presence of SLF2 (Figure 6.3B), forming the basis for further studies of H3 histone tail 
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modifications. I next focused on the classical repressive histone modifications. 
However, I observed no significant change in the levels of H3K9me3 (Figure 6.3C) or 
H3K27me3 (Figure 6.3D) in the presence or absence of SLF2. Restriction of 
unintegrated virus by the SMC5/6 complex thus did not appear to involve recruitment 
of the most well-studied chromatin writers associated with heterochromatin formation. 
When I instead focused on the activating histone mark H3K4me3 (Figure 6.3E), I 
observed a significant increase in H3K4me3 on unintegrated viral genomes upon SLF2 
knockout, which was restored to wild-type levels upon complementation with a full-
length SLF2 cDNA. The presence of SLF2 and, by inference, the SMC5/6 complex 
thus lead to a depletion of activating histone marks on unintegrated virus, indicating 
that the complex was somehow able to induce a repressive chromatin environment. 
This could be through deposition of a repressive histone mark, perhaps of unknown 
identity, active depletion of activating histone marks, or otherwise creating a chromatin 





Figure 6.3: Activating histone marks on unintegrated viral genomes are 
reduced in the presence of SLF2
A, Diagram of chromatin immunoprecipitation (ChIP). See section 2.7.1 for detailed 
method. WT Jurkat, SLF2 KO clone cells, and full-length SLF2 complemented SLF2 
KO cells were infected with an iRFP reporter virus at MOI = 2.5 in the presence of 1 μM 
RAL. 48 h post infection, cells were harvested and ChIP performed using antibodies 
specific for total H3 (B), H3K9me3 (C), H3K27me3 (D), and H3K4me3 (E). Data was 
analysed using the percentage input method. Each graph summarises data for two or 











































































































Chapter 6: The SMC5/6 complex induces a repressive unintegrated virus chromatin structure 
  
6.2.3: The SMC5/6 complex binds unintegrated viral genomes via SLF2 
Having established that the presence of SLF2, and by inference the SMC5/6 complex, 
lead to a significant loss of activating histone marks on unintegrated viral genomes, I 
next asked whether the SMC5/6 complex is actively recruited to unintegrated viral 
chromatin. I chose to use ChIP to examine complex binding to an unintegrated iRFP 
reporter virus using my previously developed MNase-based protocol. Optimising ChIP 
of DNA-binding proteins with less intimate and stable DNA association patterns than 
histones is a further challenge, which is particularly dependent on choosing the right 
fixation method and antibody. I chose to keep my fixation protocol and MNase digest 
constant but vary the SMC5/6 complex component I was targeting with my IP. My initial 
attempts at optimising the protocol for ChIP of SLF2 using an endogenous SLF2 
antibody or N-terminally truncated 3xHA-SLF2(590-1173) using anti-HA magnetic 
beads were not successful. I therefore decided to express a core SMC5/6 complex 
component, NSMCE2, with an N-terminal 3xHA-tag in both wild-type and SLF2 
knockout cells along with a puromycin resistance cassette for selection of 3xHA-
NSMCE2 expression cells, which proved a suitable system. To set up my experiments, 
I infected WT cells with or without 3xHA-NSMCE2 with my iRFP reporter virus in the 
presence of RAL and performed ChIP using anti-HA magnetic beads 48 h post 
infection (Figure 6.4A). A parallel experiment was performed in clonal SLF2 knockout 
cells with or without 3xHA-NSMCE2. The matched HA-negative cell lines could thereby 
control for unspecific background IP. These experiments showed a highly significant 
enrichment of unintegrated viral genomes in the 3xHA-NSMCE2 ChIP over 
background in wild type Jurkat cells (Figure 6.4B), which was completely lost upon 
SLF2 knockout. This suggests that NSMCE2, and by inference the rest of the core 





























Figure 6.4: The SMC5/6 complex binds unintegrated viral genomes in an SLF2-
dependent manner
A, Experimental setup for 3xHA-NSMCE2 ChIP. 14 days post 3xHA-NSMCE2 
transduction, wild type Jurkat T cells with or without 3xHA-NSMCE2 were infected with 
an iRFP reporter virus at MOI = 2.5 in the presence of 1 μM RAL. A parallel experiment 
was performed for clonal SLF2 knockout cells with or without 3xHA-NSMCE2. 48 h 
post infection, cells were harvested and ChIP performed using anti-HA magnetic beads 
(B). Data was analysed using the percentage input method, calculating the fold change 
over background in relation to the matched cell lines not expressing 3xHA-NSMCE2. 
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6.2.4: Unintegrated viral chromatin is less accessible in the presence of SLF2 
My data showing SLF2-dependent binding of the SMC5/6 complex to unintegrated viral 
genomes opened the possibility that the physical association of the complex might 
directly impact viral chromatin structure. Specifically, I hypothesised that the SMC5/6 
complex, like cohesin and condensin, could compact chromatin. By compacting 
unintegrated viral genomes, the SMC5/6 complex would make them inaccessible for 
transcription factor binding and, as a result, silence gene expression. To test this, I 
decided to use ATAC-seq (Assay for Transposase-Accessible Chromatin using 
sequencing) which is an unbiased method for probing accessibility of native chromatin 
and thereby chromatin compaction at the genome-wide level (Buenrostro et al., 2013). 
ATAC-seq exploits a hyperactive Tn5 transposase preloaded with adaptor sequences 
to identify “open” regions of chromatin through a process termed tagmentation (Figure 
6.5A). If a chromatin region is accessible, Tn5 will fragment the genome in that location 
and further tag the fragment with the pre-loaded adaptor sequences, which allows for 
PCR amplification of the released chromatin fragments. Steric hindrance makes 
“closed” chromatin inaccessible for Tn5, meaning that tagged chromatin fragments will 
only be released from “open” accessible chromatin regions. Next-generation 
sequencing (NGS) of released fragments thereby enables mapping of chromatin 
accessibility for both cellular and viral chromatin. 
To perform my experiments, I infected WT or SLF2 knockout Jurkat T cells with a GFP 
reporter virus in the presence of RAL and performed ATAC-seq 48 hours post infection. 
All ATAC-seq data analysis was kindly performed by Dr Sergio Martinez Cuesta 
(Balasubramanian group, CRUK Cambridge). Trimmed reads were aligned to the 
human and viral (1-LTR circle) genomes using BWA-MEM followed by generation of 
bigWig files for alignment visualisation (see section 2.7.3 for detailed data analysis). A 
high-quality ATAC-seq dataset should exhibit a characteristic “nucleosome ladder” 
fragment length profile in which the intensity of fragments sizes periodically repeats 
reflecting sub-nucleosomal, mono-nucleosomal, di-nucleosomal, etc. fragments. A 
representative example from my data sets is shown in (Figure 6.5B), confirming high 
quality data. Additionally, a key issue with early ATAC-seq protocols was a 
disadvantageous overrepresentation of reads mapping to mitochondrial DNA 
(Buenrostro et al., 2015). Whilst mitochondrial DNA makes up just 1% of total cellular 
DNA, early ATAC-seq protocols yielded up to 75% of all reads mapping to 
mitochondrial DNA in some cell lines – something which had caused previous 
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problems in our lab. I therefore chose to use a protocol optimised to minimise 
mitochondrial contamination in K562 cells (Karabacak Calviello et al., 2019). Across 
all my analysed samples, I achieved a low level of mitochondrial contamination (4.2 – 
8.4%), again confirming the data set quality. 
The next step was to visualise the aligned data in a genome browser. As the main 
focus of this thesis is on the effect of the SMC5/6 complex on viral extrachromosomal 
DNA, I here focus my ATAC-seq data analysis on the viral genome alignment. 
Comparing the normalised read densities across the viral genome, I observed an 
increase in viral read density for SLF2 knockout cells compared to WT Jurkat cells 
(Figure 6.5C). The largest increase was observed across the SFFV-GFP and WPRE 
expression cassette, whereas the highest general read density was observed at the 
viral LTR, likely reflecting reads derived from linear unintegrated virus and/or 2-LTR 
circles which contain two copies of the LTR. The average fold change across the viral 
genome was 1.34, revealing a subtle yet consistent increase in viral chromatin 
accessibility in SLF2 knockout cells compared to WT Jurkat cells. This data provided 
a first indication that the presence of SLF2 and the SMC5/6 complex could induce 





Figure 6.5: Unintegrated virus chromatin accessibility is increased by SLF2 KO
A, Diagram of ATAC-seq. See section 2.7.2 for detailed method description. WT Jurkat 
and SLF2 KO clone cells were infected with a GFP reporter virus at MOI = 2.5 in 
the presence of 1 μM RAL. 48 h post infection, cells were harvested and ATAC-seq 
performed. Data analysis followed method described in section 2.7.3. B, Sequenced 
fragments display a nucleosome ladder length distribution. Representative example 
of fragment size plot. Insert shows untransformed fragment size data on a logarithmic 
scale. Reads were aligned to the human genome and a 1-LTR unintegrated virus 
reference genome. Normalised read density for the viral genome is displayed in (C). 
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6.2.5: Viral proteins Vpr and HBx increase accessibility of unintegrated HIV-1 
Next, I wanted to examine the effect of viral antagonism of the SMC5/6 complex on 
unintegrated HIV-1 chromatin accessibility. I therefore first repeated my ATAC-seq 
experiments in the presence of HIV-1 Vpr. To set up this experiment, I co-transduced 
WT Jurkat cells with a GFP reporter virus and either no VLPs, control VLPs or Vpr 
VLPs in the presence of RAL and performed ATAC-seq 48 hours post infection. 
Comparing the normalised read densities across the viral genome, I observed a very 
clear increase in viral read density in the presence of Vpr VLPs compared to control 
VLPs (average 1.89 fold change) (Figure 6.6A). The read density in the presence of 
control VLPs was indistinguishable from WT Jurkat cells with no VLPs (average 1.07 
fold change). Delivery of Vpr protein and resulting SLF2 depletion thus significantly 
increased unintegrated virus chromatin accessibility, providing further support to the 
role for viral chromatin compaction in silencing of unintegrated HIV-1 genomes. 
The HBV protein HBx antagonises SMC5/6 complex silencing of HBV cccDNA by 
degrading SMC6 (Decorsière et al., 2016). I previously showed that ectopically 
expressed HBx can rescue gene expression from unintegrated HIV-1 genomes. I 
therefore asked whether HBx could also increase chromatin accessibility of 
unintegrated HIV-1 reporters, as I had observed for HIV-1 Vpr. HBx protein cannot be 
actively packaged into VLPs using lentiviral packaging vectors. I therefore cloned 
3xHA-tagged HBx into an MLV-based retroviral expression construct alongside a 
puromycin resistance cassette. By using a retroviral vector, I ensured that reads could 
still be uniquely mapped to my unintegrated lentiviral reporter, bar a few similarities 
between the MLV LTR and the SFFV promoter of my reporter. To set up the 
experiment, I transduced WT Jurkat cells with the 3xHA-HBx construct. 24 hours post 
transduction, I applied puromycin selection to the HBx expressing cells and infected 
these alongside WT Jurkat cells with my GFP reporter virus in the presence of RAL. I 
then performed ATAC-seq 48 hours later. HBx extensively increased the chromatin 
accessibility across the HIV-1 genome compared to WT Jurkat cells (Figure 6.6B) to 
an even larger degree (average 9.45 fold change) than what I observed for HIV-1 Vpr. 
HBx could thus not only increase gene expression from unintegrated HIV-1, but also 
shared the ability to increase viral chromatin accessibility. This likely – at least in part 
– reflects the ability of HBx to antagonise the SMC5/6 complex. In concert, this data 
thus supports a model in which the SMC5/6 complex induces chromatin compaction 
of unintegrated HIV-1 genomes, thereby silencing gene expression. 
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Figure 6.6: HIV-1 Vpr and HBV HBx proteins increase chromatin accessibility of 
unintegrated HIV-1 genomes
A, VLP-delivered HIV-1 Vpr protein increases accessibility of unintegrated HIV-
1 chromatin. WT Jurkat cells were infected with a GFP reporter virus at MOI = 2.5 
alongside control or WT Vpr containing VLPs in the presence of 1 μM RAL. 48 h post 
infection, cells were harvested and ATAC-seq performed. Data analysis followed the 
method described in section 2.7.3. Plot shows normalised read density for alignment 
to a 1-LTR circle reference genome. B, Ectopically expressed HBV HBx protein 
increases chromatin accessibility of unintegrated HIV-1 genomes. WT Jurkat cells and 
WT Jurkat cells expressing 3xHA-HBx were infected with a GFP reporter virus at MOI 
= 2.5 in the presence of 1 μM RAL. 48 h post infection, cells were harvested and ATAC-
seq performed. Plot shows normalised read density for alignment to a 1-LTR circle 
reference genome.
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6.2.6: Viral genomes are most significantly affected by SMC5/6 depletion 
Given the unbiased nature of ATAC-seq, the generated datasets not only provide 
information about the HIV-1 genome but should also reveal the effects of SLF2 deletion 
and viral accessory proteins on cellular chromatin. This therefore allowed me to 
examine the significance of the unintegrated viral genome decompaction within the 
context of all changes to the cellular genome. Does depletion of SLF2 and the SMC5/6 
complex lead to a global increase in cellular accessibility, or is the effect we observe 
specific to the unintegrated viral genome? In order to obtain an overview of the global 
effect on the cellular genome and compare this to the viral genome, we designed a 
differential analysis algorithm that would allow a suitable comparison (Figure 6.7A). 
First, we divided the human genome into 100,000 random regions in silico, which were 
all mappable by ATAC-seq (i.e. did not contain repeat regions) and which were each 
the same size as the viral 1-LTR circle reference genome (3,825 bp). We then counted 
the number of mapped ATAC-seq reads across each of these regions and performed 
pairwise comparisons of the read counts for each region in different conditions using 
Fisher’s tests. This produced a fold change in read counts and a statistical significance 
for this change for each region within the comparison. The data was visualised as 
volcano plots with each data point representing one of the 100,000 regions (black dots) 
or the viral genome (red dot). 
First, we compared the SLF2 knockout and WT Jurkat ATAC-seq datasets (Figure 
6.7B). Whilst the majority of the 100,000 cellular regions showed no change, the 
increase in chromatin accessibility across the viral genome (red dot) was highly 
significant. A small subset of cellular targets likewise showed increased chromatin 
accessibility, albeit to a lesser extent. A similar effect was seen for Vpr protein delivery 
in VLPs (Figure 6.7C). Expression of HBx had the most dramatic effect on not only 
viral but also cellular chromatin accessibility (Figure 6.7D) with numerous cellular 
regions showing large changes. For all three comparisons tested, the viral genome 
showed the most significant change, highlighting the importance of SLF2 and the 
SMC5/6 complex for regulating the chromatin accessibility unintegrated virus. At the 
point of writing up my thesis, the analysis of the cellular ATAC-seq data sets is only in 
its early phase, yet it is clear from the global overview provided by these volcano plots 








































































SLF2 KO vs WT Jurkat
A
Figure 6.7: Global analysis of effect on viral and cellular chromatin accessibility
A, Schematic of differential analysis strategy. ATAC-seq read count statistics for 
100,000 in silico defined regions of the cellular genome (black dots) and the HIV-1 
1-LTR reference genome (red dot) were generated by pairwise comparisons using 
Fisher’s tests. P-values were adjusted by false discovery rate (FDR) to control for 
multiple testing. B-C, SLF2 depletion by knockout or delivery of Vpr protein has 
significant viral but limited cellular effect. Volcano plots show results of differential 
analysis for all analysed genome regions when comparing SLF2 KO and WT Jurkat 
cells (B) or Con VLP and Vpr VLPs (C). D, HBV HBx induces a global increase in 
cellular chromatin accessibility. Volcano plot generated as described above.
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6.3: Discussion          
Unintegrated HIV-1 genomes are rapidly chromatinised by the host cell, forming the 
basis for epigenetic regulation. In the light of the intimate relation of the SMC protein 
family with chromatin, focusing on viral chromatin could hold the key to understanding 
the molecular mechanism for SMC5/6 complex restriction of unintegrated virus. First, 
I examined the potential involvement of NP220 and the HUSH epigenetic repressor 
complex, which is reported to silence unintegrated MLV retrovirus genomes. However, 
I saw no role in my system for NP220, confirming that HUSH does not play a role in 
regulating unintegrated HIV-1 genomes in line with previous experiments from our lab. 
Next, I focused on histone tail modifications on unintegrated viral genomes. Whilst the 
two classical silencing marks H3K9me3 and H3K27me3 were unchanged upon SLF2 
knockout, I observed a marked increase in the activating histone mark H3K4me3. 
Furthermore, I showed that the SMC5/6 complex core component NSMCE2 and by 
inference the SMC5/6 complex binds unintegrated viral genomes in an SLF2-
dependent manner. Finally, I used ATAC-seq to probe chromatin accessibility, which 
revealed an increase in viral chromatin accessibility upon SLF2 knockout and in 
particular in the presence of viral accessory proteins HIV-1 Vpr and HBV HBx. I 
therefore hypothesise that restriction of gene expression from unintegrated viral 
genomes by SLF2 and the SMC5/6 complex involves compaction of viral chromatin. 
 
6.3.1: Addressing the discrepancy of NP220 and unintegrated HIV-1 silencing 
We had previously examined the HUSH complex in the context of unintegrated HIV-1 
silencing but did not find any role. However, I decided to revisit the topic when the Goff 
lab published a high profile paper reporting a role for the HUSH complex in silencing 
unintegrated MLV retrovirus genomes (Zhu et al., 2018). In this publication, the authors 
observed a clear effect on unintegrated MLV expression when knocking out HUSH 
complex components, which they could not replicate for unintegrated HIV-1 genomes. 
This is consistent with my own data, which show no effect on unintegrated lentiviral 
reporter expression when knocking out TASOR, MPP8, or PPHLN1 (Figure 6.2E). It 
suggests a difference in the restriction mechanisms of different extrachromosomal 
viruses, even between viruses with very similar lifestyles such as HIV-1 and MLV. This 
clearly needs to be confirmed but could reflect differences in the presence of DNA 
sequences required for the recruitment of sequence specific DNA binding proteins 
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such as NP220. In the Goff lab paper, knockout of NP220 still increased gene 
expression of unintegrated HIV-1 reporters (Zhu et al., 2018). This implies the possible 
existence of a HUSH-independent but NP220-dependent mechanism, which is, 
however, not supported by my data, as I have been unable to show increased 
unintegrated HIV-1 gene expression upon knocking out NP220 in my reporter system 
(Figure 6.2E). The possibility remains that this reflects a difference in experimental 
setup. First, there is a cell type difference as the Goff lab primarily uses HeLa cells, 
whereas I use Jurkat T cells – a more relevant model cell line for HIV-1 infections. 
Second, the Goff lab uses a luciferase reporter system, which as discussed previously 
(section 3.3.1) allows for amplification of smaller differences. Last, and most important, 
the Goff lab uses a pNL4.3-Luc reporter, in which luciferase expression is driven from 
the WT HIV-1 LTR, whereas I use a pHRSIN GFP reporter, in which GFP expression 
is driven from an internal SFFV promoter. NP220 preferably binds to cytidine clusters 
in target DNA with the consensus sequence CCCCC(G/C) (Inagaki et al., 1996). 
According to analyses from the Goff lab, putative NP220 binding sites are found in the 
U3 region of the HIV-1 LTR (Zhu et al., 2018), which are not found in my pHRSIN 
reporter that carries an inactivating U3 region deletion. The putative NP220 binding 
sites proposed by the Goff lab overlap with essential transcription factor binding sites 
in the HIV-1 LTR U3 region making it hard to assess their importance by deletion 
studies. Still, the potential importance of the U3 region for NP220-mediated restriction 
suggests that my pHRSIN-based reporter system may not allow for proper testing. In 
either case, my data show that the novel SMC5/6 complex dependent restriction 
mechanism, which I have identified in this thesis, is independent of any NP220 or 
HUSH complex activity. 
 
6.3.2: Unintegrated viral chromatin: Is H3K4me3 the only relevant histone mark? 
I started my studies of viral chromatin by focusing on histone tail modifications, which 
form the basis for a multitude of known silencing mechanisms, e.g. the position-
dependent silencing of integrated HIV-1 through H3K9me3 deposition by the HUSH 
complex, which was previously discovered in our lab (Tchasovnikarova et al., 2015). 
My first thought was therefore to identify the silencing histone mark responsible for my 
phenotype, focussing on the two classical silencing marks H3K9me3 and H3K27me3. 
Whilst I could detect both marks on unintegrated HIV-1 reporters (Figure 6.3C-D), their 
levels were unchanged upon SLF2 knockout and thus they did not explain my 
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phenotype. The histone marks of unintegrated HIV-1 genomes have only recently been 
addressed by the Goff lab (Geis and Goff, 2019). The authors show high levels of 
H3K9me3 and low levels of gene expression from unintegrated HIV-1 genomes, 
however, no evidence is provided for a functional connection between the two 
observations. H3K9me3 and H3K27me3 have previously been studied in the context 
of HBV cccDNA silencing and HBx-dependent antagonism, however, H3K9me3 and 
to a lesser degree H3K27me3 levels on viral chromatin were increased for HBx 
deletion viruses (Rivière et al., 2015). It is possible that this reflects HBx antagonism 
of an SMC5/6 complex-independent silencing mechanism. Another study examining 
histone modifications on HBV chromatin from liver biopsies of chronically infected 
patients found virtually no H3K27me3 on viral chromatin, whilst H3K9me3 levels 
showed a large variation between individuals which did not correlate with the levels of 
viral transcripts detected in patient tissue (Flecken et al., 2019). It is thus unclear how 
H3K9me3 deposition relates to silencing of both unintegrated HIV-1 and HBV cccDNA 
and whether this has any connection to the SMC5/6 complex. 
Alongside my search for a silencing mark, I examined activating histone marks, 
focusing on H3K4me3 in particular. Here, I observed a marked increase in H3K4me3 
levels on unintegrated viral genomes in SLF2 knockout cells (Figure 6.3E). Upon 
complementation of the SLF2 knockout clone with a full-length SLF2 cDNA, the 
H3K4me3 level was returned to the same level as in wild type cells, in agreement with 
restored silencing. The increased H3K4me3 upon SLF2 knockout was therefore not 
due to a clonal effect. This indicates that the presence of SLF2 and the consequential 
recruitment of the SMC5/6 complex leads to a less active viral chromatin landscape. 
H3K4me3 has not previously been studied on unintegrated HIV-1 genomes, however, 
studies of the HBV cccDNA show high levels of H3K4me3 for full-length viruses across 
different model systems and patient samples (Flecken et al., 2019; Tropberger et al., 
2015). Additionally, H3K4me3 levels are significantly increased on HBV cccDNA in WT 
compared to HBx deletion viruses (Rivière et al., 2015) – which cannot degrade SMC6. 
It is thus possible that lack of H3K4me3 deposition is either involved in or, more likely, 
is a result of, restriction of extrachromosomal DNA virus gene expression by the 
SMC5/6 complex. The connection between H3K4me3 and active transcription is well-
established, yet there is disagreement within the field of epigenetics with regards to its 
causal or derivative relation to transcription (Howe et al., 2017). Some favour an active 
role of H3K4me3 in transcription initiation through recruitment of general transcription 
initiation factors (Lauberth et al., 2013), whilst others report H3K4me3 deposition as a 
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consequence of transcription providing an epigenetic memory of recent transcriptional 
activity (Ng et al., 2003). It would be interesting to examine a wider panel of both 
activating (e.g. H3K9ac, H3K27ac) and silencing (e.g. H2AK119ub, H4K20me3) 
histone marks to more thoroughly characterise the unintegrated HIV-1 landscape. 
My studies were limited by the multitudinous challenges I encountered in optimising a 
ChIP protocol for studying unintegrated HIV-1 genomes, which affected the feasibility 
of examining large panels of histone modifications. Since the completion of these 
datasets, the Goff lab has published a study which contains ChIP analysis of 
unintegrated HIV-1 genomes (Geis and Goff, 2019), in which they highlight that rabbit 
IgG displays high background levels for ChIP of unintegrated HIV-1 but not MLV 
genomes, and that this can affect the reproducibility of the technique. In hindsight, I 
would therefore not have opted to perform ChIP using rabbit antibodies, as this could 
have spared significant problems with optimising my protocol for achieving 
reproducible datasets. In agreement with this, I experienced problems with using my 
rabbit anti-SLF2 endogenous antibody for ChIP, yet, had success with using magnetic 
anti-HA magnetic beads which are coated with mouse anti-HA antibodies for HA-
NSMCE2 ChIP. Additionally, ChIP as a method is highly dependent on achieving an 
optimal cross-linking protocol, which can in itself affect chromatin structure and 
potentially mask some protein associations with chromatin. New techniques are 
emerging allowing probing of native chromatin in intact nuclei, such as CUT&RUN, 
which we are currently exploring in the lab (Skene and Henikoff, 2017). With further 
optimisation, these may prove more amenable in the context of extrachromosomal 
DNA than ChIP has been in my hands. 
 
6.3.3: The SMC5/6 complex and viral chromatin compaction 
The increase in H3K4me3 levels on unintegrated viral chromatin supported an effect 
of the SMC5/6 complex on unintegrated virus gene expression on the chromatin level. 
Concordantly, I showed binding of the SMC5/6 complex core component NSCME2 to 
unintegrated viral DNA in WT but not SLF2 knockout Jurkat cells (Figure 6.4B). This 
suggests that the SMC5/6 complex is recruited to DNA via SLF2, in agreement with a 
role as a DNA loading factor, which has been hypothesised for the yeast SLF2-
homolog Nse6 (Oravcová and Boddy, 2019). This places the SMC5/6 complex at a 
point of intimate connection with viral chromatin that could allow a direct physical effect 
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on chromatin structure. The key characteristic of all SMC protein activity is their ability 
to affect DNA topology and to translocate DNA (Hassler et al., 2018). For cohesin and 
condensin this has been linked to chromatin compaction through DNA loop extrusion 
(Kim et al., 2019b; Terakawa et al., 2017), and compaction is widely studied, 
particularly in the context of converting interphase chromatin into mitotic chromosomes 
allowing faithful sister chromatid segregation (Kakui and Uhlmann, 2018). Whilst ATP-
dependent molecular motor activity has been identified for the SMC5/6 complex 
(Kanno et al., 2015) this has not been addressed in the context of loop extrusion or 
chromatin compaction. Yet, given the high structural similarity within the SMC protein 
family it seems likely that the SMC5/6 complex will also share the ability to compact 
DNA – something which could form the basis for the unintegrated virus silencing which 
I observe. The basis for a connection between chromatin compaction and silencing of 
gene expression is clear: if the chromatin is compacted, the DNA will be less accessible 
for transcription factors and RNA polymerases due to steric hindrance, and silencing 
does not require the presence of an additional repressive histone mark. For example, 
chromatin compaction by condensin forms the basis for gene silencing in cellular 
quiescence such as that of naïve T cells in mice (Rawlings et al., 2011), something 
which has recently been demonstrated at the molecular level in S. cerevisiae model 
systems (Swygert et al., 2019). In the context of extrachromosomal DNA, oncogenes 
amplified on cellular extrachromosomal DNAs in cancers exhibit higher levels of gene 
expression and lower levels of chromatin compaction (Wu et al., 2019). 
To address my hypothesis that the SMC5/6 complex induces compaction of 
unintegrated HIV-1 genomes, I performed ATAC-seq in cells infected with GFP 
reporter lentivirus in the presence of RAL. This revealed an increased viral chromatin 
accessibility upon SLF2 knockout compared to WT Jurkat cells (Figure 6.5C). The 
increase was observed across the entire viral genome but was most pronounced 
around the SFFV-GFP expression cassette. Given that all SMC5/6 complex subunits 
(including SLF2) are essential genes, it is possible that this unique clone harbours 
some compensatory mechanisms, which prevent loss of genome integrity in the 
absence of SLF2, explaining the smaller chromatin compaction phenotype. 
Furthermore, it is important to note that the ATAC-seq data analysis assumes an 
identical number of viral genomes per cell for the two conditions in the comparison. 
However, a difference in viral genome input cannot give rise to the observed increase 
in normalised read counts for the SLF2 knockout condition compared to WT Jurkats, 
as the fold-change is not constant across the viral genome. A difference originating 
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from differences in viral copy numbers would instead shift the curve upwards by the 
same fraction at all positions. 
Further support for my hypothesis was provided by the subsequent experiments 
performed in the presence of the viral proteins Vpr and HBx. Both are capable of 
antagonising the SMC5/6 complex and both mediated a clear increase in unintegrated 
virus chromatin accessibility (Figure 6.6A-B). As to why the magnitude of the change 
in viral chromatin compaction differed between Vpr and HBx, there are several 
potential explanations. A key difference between the two experiments is that HBx was 
de novo expressed from a retroviral construct throughout the experiment and HBx 
expressing cells were puromycin selected whereas Vpr VLPs only deliver incoming 
Vpr protein. The Vpr VLP setup is thus more physiologically relevant than the more 
artificial HBx overexpression setup. It would be interesting to repeat the HBx 
experiment using a HBV-based system delivering HBx at more relevant levels. Another 
possibility is that the scale of the cellular effect is larger upon depletion of SMC6 directly 
(i.e. by HBx) rather than depletion of the recruitment factor SLF2 (i.e. by Vpr).  
Based on this data, I propose a model in which chromatin compaction of unintegrated 
HIV-1 genomes via SMC5/6 complex activity leads to decreased viral gene expression. 
This opens the question of the molecular mechanism for how viral chromatin 
compaction is achieved. Interestingly, the rapid chromatinisation of unintegrated HIV-
1 genomes has been shown to include loading of H1 linker histones (Geis and Goff, 
2019). Linker histones are involved in the formation of higher order chromatin 
structures and are required for chromatin compaction (Hergeth and Schneider, 2015). 
The molecular basis for chromatin compaction is thus present at unintegrated HIV-1 
genomes, and the H1 linker histones along with the SMC5/6 complex could form the 
basis for transcriptional silencing. 
 
6.3.4: Does the SMC5/6 complex affect cellular chromatin accessibility? 
At the point of completing this thesis, the analysis of my ATAC-seq data in the context 
of the cellular genome was still in its very early phase. Our initial volcano plot analysis 
indicated that whilst depletion of SLF2 by knockout or delivery of Vpr in VLPs did not 
have a global effect on cellular chromatin accessibility (Figure 6.7B-C), it did appear 
to increase accessibility of a minor subset of regions of cellular chromatin. This 
tendency was even more pronounced for overexpression of HBV HBx (Figure 6.7D). 
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To better understand this observed effect, it would be interesting to compare the 
identified decompacted genome regions in each dataset, i.e. are the same cellular 
genome regions affected by loss of SLF2 via knockout or acute depletion by Vpr, and 
are these regions similarly affected by HBx expression? This could identify novel 
cellular regions regulated by the SMC5/6 complex. The majority of our knowledge of 
SMC5/6 complex function relates to its role under DNA damage conditions and in the 
maintenance of integrity of repeat regions such as rDNA and telomeric DNA (Aragón, 
2018). Unfortunately, our ATAC-seq data sets do not at present allow us to determine 
the effect of SLF2 and SMC5/6 complex depletion on the chromatin accessibility in 
repetitive genome regions, as our data analysis pipeline relies on the ability to uniquely 
map sequencing reads to a single cellular genome region. The highly repetitive nature 
of the known SMC5/6 complex binding sites makes unique read mapping impossible, 
meaning that these regions were excluded from our analysis. We may therefore be 
underestimating the effect of SMC5/6 complex depletion on cellular chromatin 
accessibility. It would be interesting to develop a targeted data analysis pipeline to 
potentially look at pooled read counts for regions containing repetitive region motifs. 
The discrepancy in the number of cellular regions affected by Vpr and HBx (Figure 
6.7C-D) suggests that SMC6 depletion alone may not be solely responsible for the 
global effect of HBx on cellular chromatin accessibility. ChIP-seq studies of HBx have 
shown binding to a large repertoire of cellular genes and non-coding regions, some of 
which were shown to correlate with increased expression (Guerrieri et al., 2017). It 
would be informative to examine the overlap between my ATAC-seq data sets and the 
published HBx ChIP-seq datasets. Perhaps binding of HBx has a more direct effect on 
the cellular genome. Clearly, having the ability to affect cellular chromatin would be 
advantageous for viral remodelling of the host cell – akin to the global remodelling of 
the cellular proteome which we have reported for HIV-Vpr (Greenwood et al., 2019). 
A much more detailed analysis of the cellular ATAC-seq data sets will be needed to 
uncover their full potential, yet, for the purpose of this thesis, I have used the power of 
the ATAC-seq method to demonstrate a clear effect of SLF2 and SMC5/6 complex 
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6.4: Summary 
What is the molecular mechanism for restriction of gene expression from unintegrated 
HIV-1 genomes by SLF2 and the SMC5/6 complex? In this chapter, I examine the 
effect of the SMC5/6 complex in the viral chromatin context. Contrary to the silencing 
mechanism acting on unintegrated MLV genomes, I find no role for the HUSH complex 
in restricting unintegrated HIV-1. The abundance of classical silencing histone marks 
H3K9me3 and H3K27me3 on unintegrated HIV-1 genomes is unchanged upon SLF2 
knockout, yet I observe a significant increase in the activating histone mark H3K4me3, 
consistent with a loss of silencing. I show that the SMC5/6 complex core component 
NSMCE2 associates with unintegrated viral genomes in an SLF2-dependent manner, 
allowing the complex to act directly on viral chromatin. By using ATAC-seq, I reveal a 
consistent increase in the accessibility of unintegrated viral genomes upon SLF2 
knockout, and in the presence of the viral accessory proteins Vpr and HBx. Viral 
antagonism of the SMC5/6 complex leads to decompaction of unintegrated virus 
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7.1: Summary and model for silencing by the SMC5/6 complex 
Unintegrated viral DNA species are highly abundant in HIV-1 infection and are 
competent for gene expression, suggesting that they play an underappreciated active 
role in the HIV life cycle. It has long been known that unintegrated HIV-1 genomes 
have poor gene expression compared to integrated proviruses (Wiskerchen and 
Muesing, 1995) and that this can be increased by the HIV-1 accessory protein Vpr 
(Poon and Chen, 2003). This indicates the existence of a hitherto unknown mechanism 
of host restriction which acts on extrachromosomal viral DNA and which is antagonised 
by Vpr. The major aim of my thesis was therefore to uncover the molecular basis for 
silencing of gene expression from unintegrated HIV-1 genomes. 
First, I characterised the effect of HIV-1 Vpr on unintegrated virus gene expression and 
identified a dependency on CRL4DCAF1 activity. I consequently hypothesised that Vpr 
induces degradation of a host factor, which is normally repressive to gene expression 
from unintegrated viral genomes, thereby antagonising restriction. By taking 
advantage of our existing large proteomics datasets, I designed a custom Vpr target 
sgRNA library, which allowed me to take a forward genetics approach to identifying 
SMC5-SMC6 complex localization factor 2 (SLF2) as the implicated Vpr target. SLF2 
is a poorly characterised protein, which had only previously been described in a single 
publication as a recruitment factor for the SMC5/6 complex in the context of DNA repair 
(Räschle et al., 2015). I confirmed this interaction between SLF2 and the entire known 
SMC5/6 complex through mass spectrometry analysis of immunoprecipitated material 
and obtained strong functional evidence for a role of both SLF2 and the SMC5/6 
complex in restriction of unintegrated virus gene expression by performing individual 
gene knockout using CRISPR-Cas9. This restriction was independent of the RNF8-
RNF168-RAD18-SLF1 ubiquitin signalling axis but required the interaction of SLF2 
with the SMC5/6 complex. I further identified a novel interaction of SLF2 with the poorly 
characterised protein SIMC1 and obtained functional evidence for a role for SIMC1 in 
unintegrated virus silencing, which warrants further research. 
Focusing on viral antagonism, I showed that HIV-1 Vpr specifically depletes SLF2 but 
not core SMC5/6 complex components in a CRL4DCAF1-dependent manner. Likewise, 
Vpr proteins from other primate lentiviruses could degrade human SLF2, showing 
evolutionary conservation of this Vpr function within the lentiviral lineage. The SMC5/6 
complex has previously been implicated in restriction of another extrachromosomal 
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DNA virus, hepatitis B virus (HBV), which utilises its HBx protein to degrade SMC6 
itself (Decorsière et al., 2016). I showed that whilst HBV HBx does not affect SLF2, it 
can substitute for Vpr to antagonise silencing of gene expression from unintegrated 
HIV-1 genomes. This example of convergent evolution between different viruses 
highlights the in vivo importance of restriction of extrachromosomal viruses by the 
SMC5/6 complex. 
Finally, I addressed the molecular mechanism for restriction of gene expression by the 
SMC5/6 complex in the context of viral chromatin. I showed that the SMC5/6 complex 
binds unintegrated HIV-1 genomes in an SLF2-dependent manner, and this correlates 
with a depletion of the activating histone mark H3K4me3. Using ATAC-seq to study 
chromatin accessibility, I observed an increased accessibility of unintegrated viral 
chromatin when the SMC5/6 complex was removed by knockout of SLF2 or via the 
viral accessory proteins Vpr and HBx. Together, my data support a model in which the 
SMC5/6 complex is recruited directly to unintegrated HIV-1 genomes in an SLF2-
dependent manner (Figure 7.1). This leads to viral chromatin compaction and 
depletion of activating histone marks, in concert creating a repressive chromatin 
environment with resulting silencing of viral gene expression. This host restriction 
mechanism is actively antagonised by extrachromosomal DNA viruses to ensure viral 
gene expression, i.e. by depletion of SLF2 by HIV-1 Vpr and depletion of SMC6 by 
HBV HBx, respectively. 
Whilst the model which I present in this thesis lays the foundation for understanding 
unintegrated HIV-1 restriction by the SMC5/6 complex, it also opens up questions 
about the detailed molecular mechanism. First, my model implicates a new function of 
the SMC5/6 complex in DNA compaction. This is inferred from the known function of 
the two other SMC protein complexes, cohesin and condensin (Kim et al., 2019b; 
Terakawa et al., 2017), which have been shown to compact DNA. Single-molecule 
approaches (e.g. electron microscopy of purified complexes) will be required to 
formally demonstrate DNA compaction and chromatin loop extrusion by the SMC5/6 
complex, akin to the studies performed on cohesin and condensin. This will further 
address whether compaction uniquely affects circular or also linear DNAs, whether it 
requires histones (e.g. is there a role for linker histone H1?), and whether the DNA is 
topologically or pseudotopologically trapped within the SMC5/6 ring. 
Second, the question arises of how dynamic the association of the SMC5/6 complex 
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Figure 7.1: Model for silencing of unintegrated HIV-1 by the SMC5/6 complex 
(i) In the absence of antagonism by Vpr, the SMC5/6 complex is recruited to unintegrated 
HIV-1 genomes in an SLF2-dependent manner. (ii) This leads to compaction of viral 
chromatin by either (a) topological, or (b) pseudotopological entrapment of DNA. A 
repressive chromatin environment is created, and viral gene expression is silenced. 
(iii) HIV-Vpr degrades SLF2 to antagonise restriction by the SMC5/6 complex, thereby 
rescuing gene expression from unintegrated viral genomes.
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associated with unintegrated viral genomes, or is it a more dynamic association-
dissociation process? I show that recruitment of the SMC5/6 complex to unintegrated 
viral DNA is SLF2-dependent, and I propose that SFL2 acts as a DNA loading factor 
for the core SMC5/6 complex, yet it remains to be shown whether SLF2 itself is 
continuously bound to unintegrated viral DNA. My observation that Vpr VLPs added 
24 h post infection can still antagonise restriction supports a continued requirement for 
SLF2 (Figure 3.7A), but more evidence is needed. A related question is the role of 
SIMC1, which I propose as a putative homolog of yeast Nse5 (Figure 5.8). Is SIMC1 
required for SMC5/6 complex loading, and if yes, does SLF2 and SIMC1 act as a 
dimeric loading factor, or are their actions sequential? 
It will be important to understand the molecular basis for recognition of 
extrachromosomal viral DNAs. We know that two entirely different viruses, HIV-1 and 
HBV, are restricted by the complex. A sequence-based recognition method therefore 
seems unlikely. Alternative means of recognition could be based on nuclear 
localisation (e.g. recruitment to PML bodies), DNA topology (HBV cccDNA is 
supercoiled but there is no evidence of unintegrated HIV-1 supercoiling), or, perhaps 
most likely, simply the defining feature of being extrachromosomal chromatin. 
Common to these three options is that they would not be unique to HIV-1 and HBV but 
could account for an effect of the SMC5/6 complex on a wide variety of 
extrachromosomal DNA viruses and even cellular extrachromosomal DNAs – 
something which I will discuss in detail below. The implications of the work presented 
in this thesis thus extend far beyond the field of HIV biology as it forms the basis for 
studies of novel roles of the SMC5/6 complex – both at the fundamental level defining 
SMC5/6 complex molecular activities and in the context of silencing other viruses and 
cellular extrachromosomal DNA in health and disease. 
 
 
7.2: Is SLF2 a restriction factor? 
Throughout this thesis I have been referring to the silencing of unintegrated viral 
genomes as restriction of gene expression by SLF2 and the SMC5/6 complex. A key 
question arises: Is SLF2 (and the SMC5/6 complex) a bona fide restriction factor? In 
its most basal definition, a restriction factor is a cell-intrinsic factor which suppresses 
168
Chapter 7: Summary and general discussion 
  
viral replication (Wolf and Goff, 2008). Whilst I have not addressed the effect of the 
SLF2 and the SMC5/6 complex on a wild-type spreading HIV-1 infection, I have 
provided clear evidence for suppression of an isolated aspect of the viral life cycle, i.e. 
gene expression from unintegrated viral genomes. Reduced gene expression is likely 
to impact viral replication, and so if we apply a more lenient definition of “suppresses 
viral replication”, SLF2 is a restriction factor. In the more stringent definition, which I 
introduced in section 1.2.1, a restriction factor has to fulfil a number of shared hallmarks 
(Malim and Bieniasz, 2012). First, restriction factors are germline encoded antiviral 
proteins, which act in a cell autonomous manner; both of which are true for SLF2 and 
the SMC5/6 complex. Second, restriction factors are constitutively expressed but can 
be interferon (IFN) inducible in some cell types. According to the Interferome 
annotation of IFN-stimulated genes, neither SLF2 nor the SMC5/6 complex are 
upregulated in response to IFN treatment (Rusinova et al., 2013), however they fulfil 
the criteria of being constitutively expressed. Third, restriction factors are frequently 
downregulated or suppressed by viral accessory proteins, which means that they are 
essentially inactive against wild type viruses replicating in their natural host. This is 
perhaps the most important criteria in the context of the SMC5/6 complex, as I 
demonstrate depletion of SLF2 by HIV-1 Vpr in this thesis, and SMC6 is depleted by 
the HBV HBx protein (Decorsière et al., 2016). The convergent evolution of viral 
proteins for SMC5/6 complex antagonism supports the in vivo importance of restriction. 
With respect to the activity of the SMC5/6 complex against wild type viruses, I observed 
no significant difference in gene expression when comparing Vpr-proficient NL4-3 
reporters in WT and SLF2 KO Jurkat cells (Figure 4.9A). The SMC5/6 complex is 
essentially inactive against a wildtype HIV-1 infection in the face of efficient viral 
antagonism. Last, restriction factors display hallmarks of positive genetic selection, 
which results from the evolutionary arms race between host and pathogen. Due to its 
essential role in DNA repair, the SMC5/6 complex shows a high degree of evolutionary 
conservation with a low rate of nonsynonymous substitutions (dN/dS ratio) (Abdul et 
al., 2018), contrary to the evolutionary arms race observed for classical restriction 
factors like tetherin (Gupta et al., 2009). This further suggests that the SMC5/6 
complex does not pose a significant barrier to cross-species transmission as 
highlighted by the ability of a wide variety of primate lentiviral Vpr proteins to deplete 
human SLF2 (Figure 4.7C) and of hepadnaviral HBx proteins to deplete human SMC6 
(Abdul et al., 2018). 
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SLF2 and the SMC5/6 complex thus fall short of a number of the classical hallmarks 
of restriction factors. Should we then refrain from referring to SLF2 as a restriction 
factor? Interestingly, the aforementioned shortcomings are shared with another group 
of recognised restriction factors: The SERINCs. Neither SERINC3 nor SERINC5 is IFN 
sensitive (Rusinova et al., 2013), and they do not contain sites subject to detectable 
positive selection, meaning there is no evidence for an evolutionary arms race (Murrell 
et al., 2016). Like SLF2 and the SMC5/6 complex, the SERINCs are not solely 
dedicated to antiviral restriction but perform an essential cellular function in amino acid 
metabolism (Inuzuka et al., 2005). Consequently, it appears that a novel class of 
restriction factors with essential cellular functions are starting to emerge, and perhaps 
our criteria for classifying restriction factors should be updated accordingly. These 
restriction factors could not have been identified in heterokaryon experiments due to 
their ubiquitous expression, yet further discoveries will be enabled by advances in 
proteomic and forward genetic techniques, as we have seen for the SERINCs (Usami 
et al., 2015) and now SLF2 and the SMC5/6 complex. It would seem plausible that 
these factors have not evolved to restrict viruses, but rather that their cellular function 
indirectly leads to an advantageous additional function in pathogen restriction. For 
example, the SMC5/6 complex coordinates cellular extrachromosomal DNA 
(discussed further in section 7.4) and therefore also has an effect on unintegrated HIV-
1 DNA species. Discovering more members of this new group of restriction factors 
gives us important insight into both viral life cycles and host cell function. 
 
 
7.3: Restriction by the SMC5/6 complex: More than just HIV-1?  
With this thesis, I provide strong evidence for a role of SLF2 and the SMC5/6 complex 
in restricting gene expression from unintegrated HIV-1 genomes. As discussed in 
section 1.4.1, unintegrated virus DNA species are abundantly produced in the early 
stages of the HIV-1 lifecycle, and they are particularly long-lived in key target cell 
populations such as resting memory T cells and macrophages (Sloan and Wainberg, 
2011). Consequently, they are very likely to contribute vital gene products to ensure 
successful viral replication, particularly in the early stages of infection, although it is 
difficult to gather experimental support for this model given the identity of unintegrated 
viral genomes to the integrated provirus sequence. The observation that the accessory 
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protein Vpr has an evolutionarily conserved ability to deplete host SLF2 and thus 
incapacitate unintegrated virus restriction by the SMC5/6 complex provides indirect 
evidence for the importance of gene expression from unintegrated HIV-1 DNA species, 
a topic which is severely underrepresented in HIV research. 
As the SMC5/6 complex has now been implicated in restriction of both HBV 
(Decorsière et al., 2016), HSV-1 (Wu et al., 2018), and unintegrated HIV-1, it is 
interesting to hypothesise whether it might confer ubiquitous restriction of all nuclear 
DNA viruses. My proposed model of restriction requires no sequence specificity but is 
rather based on the presence of extrachromosomal viral DNA, which is consequently 
compacted by the host cell to prevent expression. Still, a number of features may affect 
whether a DNA virus is restricted by the SMC5/6 complex, and further research will be 
needed to properly uncover the basis for restriction. So far, all viruses reported to be 
restricted produce circular double-stranded DNA (dsDNA) species in the host cell 
nucleus. It will be interesting to examine if linear dsDNA viruses (e.g. adenoviruses) or 
single-stranded DNA (ssDNA) viruses (e.g. parvoviruses) could also be subject to 
restriction. Additionally, HBV, HSV-1, and HIV-1 are all enveloped viruses and thus 
share similarities in the way the viral genome enters the nucleus. Non-enveloped 
viruses like polyomaviruses and papillomaviruses enter the nucleus via different 
pathways which may influence the potential of restriction. 
Drawing from our experience with SMC5/6 complex restriction in the context of HIV-1 
and HBV, we predict that these other viruses have also developed means of 
antagonising the restriction, potentially through protein degradation. A good entry point 
for studying the SMC5/6 complex in the context of these different viruses would 
therefore be to look for signs of antagonism in existing proteomics datasets, akin to 
our own proteomics dataset for HIV-1 Vpr. If the complex is actively antagonised as 
for HIV-1 and HBV, studying the replication of a wildtype virus is unlikely to unmask 
any potential restriction. When considering viral antagonism, it will furthermore be 
important to consider whether some viruses might intentionally regulate antagonism in 
a temporal fashion to support their lifestyle. In section 1.3.1 I introduced the concept 
of herpesvirus latency focusing on human cytomegalovirus (HCMV). A body of 
evidence is emerging suggesting that a failure to counteract host cell restriction 
actually aids the establishment of a latent infection. Perhaps the SMC5/6 complex 
could play a role in this model? In incompletely differentiated cells which support latent 
infections (e.g. CD34+ hematopoietic progenitor cells), a large proportion of the viral 
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accessory proteins collectively termed the tegument fail to translocate to the nucleus 
in the early stages of infection (Lee and Kalejta, 2019). One of these tegument 
proteins, pp71, would otherwise induce proteasomal degradation of the antiviral 
silencing factor Daxx in the nucleus, contributing to the establishment of an active viral 
chromatin environment, which is a prerequisite for a lytic infection (Saffert and Kalejta, 
2006). It would be interesting to examine if the SMC5/6 complex is similarly 
antagonised by a HCMV tegument protein and whether this antagonism fails in cell 
types that support latency, thus contributing to establishing the characteristic 
repressive latent HCMV chromatin structure. It is clear that we are only just beginning 
to uncover the effect of the SMC5/6 complex.  
 
 
7.4: The SMC5/6 complex and cellular extrachromosomal DNA  
Studies of cellular extrachromosomal DNA have been hampered by an inability to 
distinguish genomic DNA copies from extrachromosomal DNA copies within an intact 
cellular context. Only recently, technological advances in next-generation sequencing 
have started to shed light on this large group of cellular DNAs. However, this cannot 
compensate for the lack of good model systems, and our studies of unintegrated HIV-
1 reporters may thus help provide insight into the regulation of other extrachromosomal 
DNAs. 
As I discussed in section 1.5.1, the formation of extrachromosomal DNA species 
(ecDNA) in normal cellular function generally results from aberrant recombination of 
repetitive DNA regions leading to genomic instability, which is particularly pertinent for 
ribosomal DNA (rDNA) and telomeric DNA (tDNA) due to their highly repetitive 
sequences (Cohen and Segal, 2009). Consequently, DNA repair and replication of 
rDNA and tDNA is subject to tight regulation, a central part of which is mediated by the 
SMC5/6 complex (Torres-Rosell et al., 2005). In the light of the work presented in this 
thesis, it is interesting to consider whether the SMC5/6 complex might also silence 
cellular extrachromosomal DNAs through compaction. One can imagine a scenario 
where the SMC5/6 complex would act in DNA repair of a repetitive locus (e.g. rDNA), 
yet at the same time be optimally positioned to silence any resulting extrachromosomal 
DNA species and direct them for degradation through an unknown pathway. It has 
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been recently proposed that accumulation of ecDNA might contribute to cellular 
senescence in the context of the central nervous system (CNS) due to acting as a 
damage-associated molecular pattern (DAMP) which could initiate an inflammatory 
response (Ain et al., 2020). The SMC5/6 complex activity may thus contribute to 
preventing cellular senescence both by controlling telomere stability and by regulating 
extrachromosomal DNA. In agreement with this, conditional depletion of the SMC5/6 
complex subunit NSMCE2 led to premature aging in adult mice (Jacome et al., 2015). 
Examining the potential involvement of the SMC5/6 complex in regulating and perhaps 
silencing cellular ecDNA would thus be an interesting further research avenue. 
Another rapidly developing topic in the field of cellular extrachromosomal DNA is the 
high prevalence of ecDNA in human cancers (Paulsen et al., 2018). One study which 
employed automated metaphase chromosome spread analysis could identify ecDNA 
species in almost half of the included 72 cancer cell lines (Turner et al., 2017), and this 
coincided with a high prevalence of oncogene amplification. By amplifying oncogenes 
on ecDNA, the cancer cells could achieve higher oncogene copy numbers and thereby 
massively increase oncogene expression (Wu et al., 2019). Follow-up studies found 
evidence of ecDNA in 436 of 1,695 examined patient tumour samples, and samples 
containing extrachromosomal oncogene amplification were more prevalent among 
aggressive tumour types (Kim et al., 2019a). Surprisingly, ATAC-seq revealed a more 
accessible chromatin structure of these cancer ecDNAs than the corresponding 
genomic oncogene encoding (Wu et al., 2019). This challenges my model of 
generalised ecDNA restriction and compaction by the SMC5/6 complex, as I would 
predict a lower expression of oncogenes from restricted extrachromosomal DNAs. One 
explanation could be that the SMC5/6 complex is not able to efficiently suppress the 
>1 Mbp large oncogene carrying ecDNAs but has rather evolved to silence small 
cellular ecDNAs derived from rDNA/tDNA loci. Alternatively, it would be interesting to 
examine if SMC5/6 complex mutations are more prevalent in cancers which rely on 
ecDNA oncogene amplification. Perhaps loss of SMC5/6 complex control both in 
relation to DNA repair and ecDNA restriction could play a role in oncogenesis. A 
putative link between the SMC5/6 complex and cancer exists in vivo, as NSMCE2 
heterozygous mice exhibited a reduced lifespan with a higher incidence of tumours 
(Jacome et al., 2015). The growing body of evidence for a role of ecDNA in 
oncogenesis and my proposed link between the SMC5/6 complex and restriction of 
extrachromosomal DNAs warrants further examination of the SMC5/6 complex in the 
context of cancer. 
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In conclusion, I have identified a novel mechanism for restriction of unintegrated HIV-
1 DNA, which provides the molecular basis for the long-standing observation that 
unintegrated virus is poorly expressed yet can be rescued by the HIV-1 accessory 
protein Vpr. The SMC5/6 complex associates with unintegrated HIV-1 genomes in an 
SLF2-dependent manner and induces a repressive chromatin structure through 
physical compaction of the viral DNA, thereby silencing gene expression. HIV-1 Vpr 
degrades SLF2 via the host CRL4DCAF1 E3 ligase complex, thereby antagonising 
restriction. Given the high prevalence of other viral and cellular extrachromosomal 
DNAs, the impact of this silencing mechanisms is likely to extend far beyond the realm 
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Appendix 1: Primer sequences 




















Sequencing primer  CTTGTGGAAAGGACGAAACACCG  
  
 
Genetic validation of clonal knockout cell lines 
SLF1_exon 11_outer_f GCAGTTCCAGGAACAATTTGGA 
SLF1_exon 11_outer_r AACACTTCGGGGCATTGATG 
SLF1_exon 11_inner_f TCTTTGCTGTGGTTAACATGGT 
SLF1_exon 11_inner_r GCCAAGACTTCAAACACATGAC 
SLF2_exon 5_outer_f TGTTTGTTTTAGGGAGTGGCA 
SLF2_exon 5_outer_r GCACAACTTCCAAAGCAGCA 
SLF2_exon 5_inner_f TGGAATGAAAATGAGCATTTGTCA 















Appendix 2: sgRNA sequences 
sg1_SLF2 GAACTGGAATTTAGCTCCCAG 
sg2_SLF2 GAACCGAGTGATGAAACTGA 
sg3_SLF2 GCCTCCAAATATTTAGCCAA 
sg1_SMC5 GCCAACGATCATATTCAAGTG 
sg2_SMC5 GCAGCCTTAAATATTCAAGT 
sg3_SMC5 GCTTGAAGCAAAAAGGCCAT 
sg1_SMC6 GAATAGCCTAATTGACATGAG 
sg2_SMC6 GTTTCTTATAACTAGGCTCCG 
sg3_SMC6 GTTCCTCTTTCTCTACACAC 
sg1_NSMCE1 GTCCTCCAACTTATCTACGG 
sg2_NSMCE1 GATGACCCATGGCGTGCTAG 
sg3_NSMCE1 GTGGGAGACCCATTTATGCGT 
sg1_NSMCE2 GTCCATACCAGAGTTGATAC 
sg2_NSMCE2 GCAACTAAACCATTATGTAA 
sg3_NSMCE2 GAGTGAGTAGTGAATATAGTA 
sg1_NSMCE3 GTATACCCGAAGACGTACTGG 
sg2_NSMCE3 GATCATCAGGAGGCCCGTAG 
sg3_NSMCE3 GAGCCATAGCGGAAACCCCG 
sg1_NSMCE4A GTGCCGGTGACAAATTAACAG 
sg2_NSMCE4A GATCTCGTCCCCGGAATCCGA 
sg3_NSMCE4A GAATCAGGACTATCTTCATCA 
sg1_SLF1 GCATGGCTATTAAGACAGATG 
sg2_SLF1 GCATGAAGAACGCATACAGG 
sg3_SLF1 GCTTATCAGTTCTAACAAGG 
sg1_RAD18 GAGTGGATTGTCCTGTTTGCG 
sg2_RAD18 GTCCAGACAGTCTTTAAAGCA 
sg3_RAD18 GTTACCAGTTCATCTAATATG 
sg1_RNF168 GAAGAAATTCTCTCGTCAACG 
sg2_RNF168 GCACCACAGGCACATAACCA 
sg3_RNF168 GTTGAAGAACAATTTCTGTG 
sg1_RNF8 GTGAGCCAAGTAAGACCACAG 
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sg2_RNF8 GCAGGGAGACTACATCCAACT 
sg3_RNF8 GTGGTTTCGAGAAATCATCA 
sg1_SIMC1 GGGTCTGAACGACATAACGC 
sg2_SIMC1 GGAAAGCACCATGTTTGCAA 
sg3_SIMC1 GACGTTTGATTTCCATTTGG 
sg1_NP220 GTCTTATAACTGAATTACCAG 
sg2_NP220 GCATTGGGCTTCGAGACCGA 
sg3_NP220 GATGCTTTCACAATACCAAA 
sg1_MPP8 GCAGGTTGCGGAGGGAGCAA 
sg2_MPP8 GGGGGTATGTGGAGGGGCCC 
sg3_MPP8 TTTGGCGTTTGGGCAGATAC 
sg1_PPHLN1 GAGACGATCATTCTGCAAGC 
sg2_PPHLN1 CTTCCCATTATGCGAGAGAG 
sg3_PPHLN1 AGACCGCTCTCTCGCATAAT 
sg1_TASOR ACATACTTAGGTCCAAATGA 
sg2_TASOR TTGCAGCCTTTATGAAGTTG 
sg3_TASOR GTTTCCTTATAAAACAGTGC 
sg1_PJA1 GTGCGTCCAGAAGTCAGGGT 
sg2_PJA1 GAGTAGTGGAAAATGGCGAT 
sg3_PJA1 GCCACCACCACAAATACTCAC 
sg1_β2M GGCCGAGATGTCTCGCTCCG 
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